@article{TraubOttoSelletal.2022,
  author    = {Traub, Jan and Otto, Markus and Sell, Roxane and Homola, Gy{\"o}rgy A. and Steinacker, Petra and Oeckl, Patrick and Morbach, Caroline and Frantz, Stefan and Pham, Mirko and St{\"o}rk, Stefan and Stoll, Guido and Frey, Anna},
  title     = {Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure},
  series = {ESC Heart Failure},
  volume    = {9},
  journal   = {ESC Heart Failure},
  number    = {4},
  doi       = {10.1002/ehf2.13986},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-312736},
  pages     = {2626-2634},
  year      = {2022},
  abstract  = {Aims Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF. Methods and results Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1\% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = -4.7; P < 0.001), alanine aminotransferase (T = -2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = -3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025). Conclusions Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF.},
  language  = {en}
}
@phdthesis{Schramm2002,
  author    = {Schramm, Axel},
  title     = {Sensomotorische Integration bei zervikalen Dystonien},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-4722},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2002},
  abstract  = {Zervikale Dystonien geh{\"o}ren zu den h{\"a}ufigsten Formen fokaler Dystonien. Diese sind durch anhaltende, unwillk{\"u}rliche Muskelkontraktionen gekennzeichnet, welche zu verdrehenden oder repetitiven Bewegungen oder abnormalen Haltungen des Kopfes f{\"u}hren. Ein seit {\"u}ber 100 Jahren beobachtetes Ph{\"a}nomen stellt hierbei die M{\"o}glichkeit dar, mittels sogenannter "sensibler Trickman{\"o}ver", welche meistens in einer leichten Ber{\"u}hrung von Arealen im Kopfbereich bestehen, die pathologische Muskelaktivit{\"a}t zu reduzieren und damit die Kopfposition zu normalisieren. Ziel der vorliegenden Arbeit war es, eine breite und vor allem erstmalig quantitative Charakterisierung von wirksamen Trickman{\"o}vern vorzunehmen und so verschiedene Einflußgr{\"o}ßen auf die Wirksamkeit solcher Tricks zu untersuchen. Hierzu wurden die Muskelaktivit{\"a}ten der vier wichtigsten den Kopf drehenden Muskeln mittels Oberfl{\"a}chen-EMG abgeleitet und die Ver{\"a}nderungen bei Trickapplikation unterschiedlicher Lokalisation, Modalit{\"a}t und bei verschiedenen Ausgangspositionen ermittelt. 1) Hinsichtlich der Lokalisation ergaben sich {\"u}ber alle Patienten gemittelt keine signifikante Seitendifferenz, und auch bei individuellem Vergleich zeigten sich bei rund 50\% der Patienten keine signifikanten Unterschiede zwischen kontralateraler und ipsilateraler Trickapplikation. Unter den getesteten Applikationsorten grenzte sich das Areal "Wange" mit durchschnittlich 33\%iger Reduktion der gesamten EMG-Aktivit{\"a}t signifikant gegen die Areale "Kinn" (-23\%) und "Hals" (-23\%) ab und war bei 79\% der Patienten am besten wirksam. 2) Bei weiterer Untersuchung verschiedener Trickmodalit{\"a}ten auf dem f{\"u}r jeden Patienten individuell wirksamsten Areal waren neben dem klassischen Trickman{\"o}ver (-42\%) auch die Verwendung eines Plastikstabes durch den Patienten (-43\%) oder Untersucher (-32\%), sowie nicht-sensible Man{\"o}ver wie das Heben des Armes ohne eigentliche Ber{\"u}hrung (-18\%) und die bloße Vorstellung einer Trickapplikation (-20\%) hochsignifikant wirksam. Allerdings korrelierten sensible und (wie die beiden letztgenannten) nicht-sensible Tricks nicht miteinander, was auf einen prinzipiell unterschiedlichen Wirkmechanismus hinweisen k{\"o}nnte. Visuelle R{\"u}ckkopplung {\"u}ber einen Spiegel hatte im Gegensatz dazu keine Wirkung. 3) Bez{\"u}glich der Bedeutung der Kopfposition f{\"u}r Muskelaktivit{\"a}t und Trickwirksamkeit zeigte sich bereits bei willk{\"u}rlicher Einnahme einer Neutralposition ohne Trickanwendung eine signifikante Reduktion agonistischer Muskelaktivit{\"a}t (-30\%), die allerdings von einer leichten antagonistischen Aktivierung begleitet war (+2,4\%). {\"U}berraschenderweise war die Applikation eines Tricks um so wirksamer, je weiter der Kopf zu Beginn auf die zur dystonen Drehrichtung kontralateralen Seite gedreht war. Demgegen{\"u}ber ließ sich bei Trickapplikation in dystoner Maximalposition kaum mehr eine Wirkung nachweisen (-12\%). Die vorliegenden Ergebnisse sprechen aufgrund der unspezifischen Wirkung verschiedenster Trickman{\"o}ver (2) und Lokalisationen (1) f{\"u}r die Einbeziehung h{\"o}herer sensomotorischer Integrationszentren wie z. B. des Parietalcortex in den Wirkmechanismus. Sensible Trickman{\"o}ver k{\"o}nnten bei auf die pathologische Kopfposition adaptierten sensiblen Afferenzen Zusatzinformationen {\"u}ber die Kopfposition im Vergleich zum Rumpf liefern. M{\"o}glicherweise sind diese umso wirksamer, je weiter sich der Kopf noch auf der kontralateralen Seite befindet (3), da in dieser Situation die dystone Muskelaktivit{\"a}t noch gering und das sensible Mismatch, {\"u}ber welches sensible Stimuli modulierend einwirken k{\"o}nnten, maximal ist. Nach den vorgelegten Ergebnissen l{\"a}ßt sich erstmals ein zweiphasiger Ablauf der Trickwirkung postulieren: Der in einer ersten Phase teils willk{\"u}rlich in eine g{\"u}nstige Ausgangsposition gebrachte Kopf kann durch die Anwendung sensibler Stimuli oder Imagination in einer zweiten Phase mit geringerer Anstrengung und unter Ausnutzung kortikaler sensomotorischer Servomechanismen stabilisiert werden. Im Rahmen der vorgelegten Studie konnte das Verst{\"a}ndnis f{\"u}r therapeutisch nutzbare sensible Trickman{\"o}ver verbessert und somit Patienten unterschiedliche Trickstrategien an die Hand gegeben werden. Die Identifikation der zentralen Rolle h{\"o}herer integrativer Zentren wie dem Parietalcortex im Rahmen des Wirkmechanismus, k{\"o}nnte dabei Ausgangspunkt f{\"u}r neue Therapieans{\"a}tze in Form einer gezielten Beeinflussung solcher Areale sein.},
  language  = {de}
}
@phdthesis{Nehring2003,
  author    = {Nehring, Claudia},
  title     = {Sensitivit{\"a}t elektrophysiologischer Parameter bei der chronischen inflammatorischen demyelinisierenden Polyneuropathie (CIDP) in der Beurteilung des Langzeitverlaufes},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-7659},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {Die Chronische Inflammatorische Demyelinisierende Polyneuropathie (CIDP) ist eine seltene autoimmune Erkrankung des peripheren Nervensystems. In der vorliegenden Dissertation wurden die Akten von 23 CIDP - Patienten der Neurologischen Klinik der Universit{\"a}t W{\"u}rzburg aus dem Zeitraum von 1990 bis 1999 ausgewertet und die elektrophysiologischen Parameter sowohl mit den klinischen Befunden als auch mit den Biopsiebefunden in Beziehung gestellt. Folgende Schlussfolgerungen konnten gezogen werden : - In dem untersuchten Patientenkollektiv war die sensomotorische Form der CIDP mit {\"u}berwiegend motorischen Symptomen die h{\"a}ufigste Auspr{\"a}gungsform. Hingegen treten rein motorische und rein sensible Formen sehr selten auf. - Die Krankheit manifestierte sich {\"u}berwiegend an den distalen Extremit{\"a}ten. - Die oberen Extremit{\"a}ten waren selten und in keinem Fall isoliert betroffen. - Die systematische Auswertung des klinischen Schwergrades erfolgte anhand des Modifizierten Rankin Scores, der sowohl motorische als auch sensible Symptome ber{\"u}cksichtigt. Zus{\"a}tzlich erfolgte der Entwurf eines sensiblen Scores, bei dem die sensiblen Symptome der Patienten in Zahlenwerten ausgedr{\"u}ckt sind. - Der Vergleich des klinischen Schweregrades mit den neurophysiologischen Befunden ergab vier unterschiedliche Korrelationstypen, die von sehr enger Korrelation bis hin zu nur geringen {\"U}bereinstimmungen reichten. - Der Schwergrad der Beeintr{\"a}chtigung der Patienten war im Langzeitverlauf mit dem axonalen Verlust korreliert. Es fand sich eine gute Korrelation der Muskelsummenaktionspotentiale (CMAP) des Nervus medianus und des Nervus tibialis sowie der sensiblen Nervenaktionspotentiale (SNAP) des Nervus suralis mit dem Score. - Es ergab sich ein signifikanter Zusammenhang zwischen der Amplitude des Nervus suralis NAP`s und dem Ausmaß des Axonverlustes, wohingegen zwischen der Nervenleitungsgeschwindigkeit des Nervus suralis und dem Axonverlust nur eine geringe Abh{\"a}ngigkeit besteht. - Der Grad der Demyelinisierung korrelierte mit der Anzahl der endoneuralen Makrophagen. - Zwischen der Nervenleitgeschwindigkeit des Nervus suralis und dem Grad der Demyelinisierung im Biopsat konnte keine eindeutige Abh{\"a}ngigkeit nachgewiesen werden. - Es besteht ein Zusammenhang zwischen der Spontanaktivit{\"a}t im EMG und im Verlauf abnehmenden Nervenleitgeschwindigkeiten des Nervus medianus, der aber statistisch nicht signifikant ist. - Insbesondere ist die NLG- Abnahme in den ersten Wochen ein prognostisch ung{\"u}nstiges Zeichen. - Eine Analogie zwischen einer durch das EMG nachgewiesenen Spontanaktivit{\"a}t und der Amplitude des Nervus suralis besteht. - Zwischen den Amplituden der motorischen Summenaktionspotentiale des Nervus tibialis oder den Amplituden der sensiblen Nervenaktionspotentiale des Nervus suralis auf der einen Seite und dem Ausmaß der Spontanaktivit{\"a}t im EMG auf der anderen Seite bestehen erkennbare Korrelationen.},
  language  = {de}
}
@article{MaggRieglerWiedmannetal.2015,
  author    = {Magg, Barbara and Riegler, Christoph and Wiedmann, Silke and Heuschmann, Peter and Sommer, Claudia and {\"U}{\c{c}}eyler, Nurcan},
  title     = {Self-administered version of the Fabry-associated pain questionnaire for adult patients},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {10},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {113},
  doi       = {10.1186/s13023-015-0325-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-145294},
  year      = {2015},
  abstract  = {Background Fabry-associated pain may be the first symptom of Fabry disease (FD) and presents with a unique phenotype including mostly acral burning triggerable pain attacks, evoked pain, pain crises, and permanent pain. We recently developed and validated the first Fabry Pain Questionnaire (FPQ) for adult patients. Here we report on the validation of the self-administered version of the FPQ that no longer requires a face-to-face interview but can be filled in by the patients themselves allowing more flexible data collection. Methods At our W{\"u}rzburg Fabry Center for Interdisciplinary Treatment, Germany, we have developed the self-administered version of the FPQ by adapting the questionnaire to a self-report version. To do this, consecutive Fabry patients with current or past pain history (n = 56) were first interviewed face-to-face. Two weeks later patients' self-reported questionnaire results were collected by mail (n = 55). We validated the self-administered version of the FPQ by assessing the inter-rater reliability agreement of scores obtained by supervised administration and self-administration of the FPQ. Results The FPQ contains 15 questions on the different pain phenotypes, on pain development during life with and without therapy, and on impairment due to pain. Statistical analysis showed that the majority of questions were answered in high agreement in both sessions with a mean AC1-statistic of 0.857 for 55 nominal-scaled items and a mean ICC of 0.587 for 9 scores. Conclusions This self-administered version of the first pain questionnaire for adult Fabry patients is a useful tool to assess Fabry-associated pain without a time-consuming face-to-face interview but via a self-reporting survey allowing more flexible usage.},
  language  = {en}
}
@article{BenKraiemSauerNorwigetal.2021,
  author    = {Ben-Kraiem, Adel and Sauer, Reine-Solange and Norwig, Carla and Popp, Maria and Bettenhausen, Anna-Lena and Atalla, Mariam Sobhy and Brack, Alexander and Blum, Robert and Doppler, Kathrin and Rittner, Heike Lydia},
  title     = {Selective blood-nerve barrier leakiness with claudin-1 and vessel-associated macrophage loss in diabetic polyneuropathy},
  series = {Journal of Molecular Medicine},
  volume    = {99},
  journal   = {Journal of Molecular Medicine},
  number    = {9},
  doi       = {10.1007/s00109-021-02091-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265237},
  pages     = {1237-1250},
  year      = {2021},
  abstract  = {Diabetic polyneuropathy (DPN) is the most common complication in diabetes and can be painful in up to 26\% of all diabetic patients. Peripheral nerves are shielded by the blood-nerve barrier (BNB) consisting of the perineurium and endoneurial vessels. So far, there are conflicting results regarding the role and function of the BNB in the pathophysiology of DPN. In this study, we analyzed the spatiotemporal tight junction protein profile, barrier permeability, and vessel-associated macrophages in Wistar rats with streptozotocin-induced DPN. In these rats, mechanical hypersensitivity developed after 2 weeks and loss of motor function after 8 weeks, while the BNB and the blood-DRG barrier were leakier for small, but not for large molecules after 8 weeks only. The blood-spinal cord barrier remained sealed throughout the observation period. No gross changes in tight junction protein or cytokine expression were observed in all barriers to blood. However, expression of Cldn1 mRNA in perineurium was specifically downregulated in conjunction with weaker vessel-associated macrophage shielding of the BNB. Our results underline the role of specific tight junction proteins and BNB breakdown in DPN maintenance and differentiate DPN from traumatic nerve injury. Targeting claudins and sealing the BNB could stabilize pain and prevent further nerve damage.},
  language  = {en}
}
@article{VolkmannAlbaneseAntoninietal.2013,
  author    = {Volkmann, Jens and Albanese, Alberto and Antonini, Angelo and Chaudhuri, K. Ray and Clarke, Karl E. and de Bie, Rob M. A. and Deuschl, G{\"u}nther and Eggert, Karla and Houeto, Jean-Luc and Kulisevsky, Jaime and Nyholm, Dag and Odin, Per and Ostergaard, Karen and Poewe, Werner and Pollak, Pierre and Rabey, Jose Martin and Rascol, Olivier and Ruzicka, Evzen and Samuel, Michael and Speelman, Hans and Sydow, Olof and Valldeoriola, Francesc and van der Linden, Chris and Oertel, Wolfgang},
  title     = {Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review},
  series = {Journal of Neurology},
  volume    = {260},
  journal   = {Journal of Neurology},
  doi       = {10.1007/s00415-012-6798-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-132373},
  pages     = {2701-2714},
  year      = {2013},
  abstract  = {Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.},
  language  = {en}
}
@article{SamperAgreloSchiraHeinenBeyeretal.2020,
  author    = {Samper Agrelo, Iria and Schira-Heinen, Jessica and Beyer, Felix and Groh, Janos and B{\"u}termann, Christine and Estrada, Veronica and Poschmann, Gereon and Bribian, Ana and Jadasz, Janusz J. and Lopez-Mascaraque, Laura and Kremer, David and Martini, Rudolf and M{\"u}ller, Hans Werner and Hartung, Hans Peter and Adjaye, James and St{\"u}hler, Kai and K{\"u}ry, Patrick},
  title     = {Secretome analysis of mesenchymal stem cell factors fostering oligodendroglial differentiation of neural stem cells in vivo},
  series = {International Journal of Molecular Sciences},
  volume    = {21},
  journal   = {International Journal of Molecular Sciences},
  number    = {12},
  issn      = {1422-0067},
  doi       = {10.3390/ijms21124350},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-285465},
  year      = {2020},
  abstract  = {Mesenchymal stem cell (MSC)-secreted factors have been shown to significantly promote oligodendrogenesis from cultured primary adult neural stem cells (aNSCs) and oligodendroglial precursor cells (OPCs). Revealing underlying mechanisms of how aNSCs can be fostered to differentiate into a specific cell lineage could provide important insights for the establishment of novel neuroregenerative treatment approaches aiming at myelin repair. However, the nature of MSC-derived differentiation and maturation factors acting on the oligodendroglial lineage has not been identified thus far. In addition to missing information on active ingredients, the degree to which MSC-dependent lineage instruction is functional in vivo also remains to be established. We here demonstrate that MSC-derived factors can indeed stimulate oligodendrogenesis and myelin sheath generation of aNSCs transplanted into different rodent central nervous system (CNS) regions, and furthermore, we provide insights into the underlying mechanism on the basis of a comparative mass spectrometry secretome analysis. We identified a number of secreted proteins known to act on oligodendroglia lineage differentiation. Among them, the tissue inhibitor of metalloproteinase type 1 (TIMP-1) was revealed to be an active component of the MSC-conditioned medium, thus validating our chosen secretome approach.},
  language  = {en}
}
@article{RauschenbergerKnorrPisanietal.2021,
  author    = {Rauschenberger, Lisa and Knorr, Susanne and Pisani, Antonio and Hallett, Mark and Volkmann, Jens and Ip, Chi Wang},
  title     = {Second hit hypothesis in dystonia: Dysfunctional cross talk between neuroplasticity and environment?},
  series = {Neurobiology of Disease},
  volume    = {159},
  journal   = {Neurobiology of Disease},
  doi       = {10.1016/j.nbd.2021.105511},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265028},
  year      = {2021},
  abstract  = {One of the great mysteries in dystonia pathophysiology is the role of environmental factors in disease onset and development. Progress has been made in defining the genetic components of dystonic syndromes, still the mechanisms behind the discrepant relationship between dystonic genotype and phenotype remain largely unclear. Within this review, the preclinical and clinical evidence for environmental stressors as disease modifiers in dystonia pathogenesis are summarized and critically evaluated. The potential role of extragenetic factors is discussed in monogenic as well as adult-onset isolated dystonia. The available clinical evidence for a "second hit" is analyzed in light of the reduced penetrance of monogenic dystonic syndromes and put into context with evidence from animal and cellular models. The contradictory studies on adult-onset dystonia are discussed in detail and backed up by evidence from animal models. Taken together, there is clear evidence of a gene-environment interaction in dystonia, which should be considered in the continued quest to unravel dystonia pathophysiology.},
  language  = {en}
}
@phdthesis{Teuteberg2003,
  author    = {Teuteberg, Philipp Wilhelm Friedemann},
  title     = {Schmerzhafte Mononeuropathie an C57BL/6 M{\"a}usen: Studien mit neutralisierenden Antik{\"o}rpern gegen Tumor-Nekrose-Faktor Alpha an zwei verschiedenen L{\"a}sionsmodellen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-5346},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {Die vorliegende Arbeit befaßt sich mit zwei Modellen einer schmerzhaften Mononeuropathie an der C57BL/6-Maus sowie deren Beeinflussung durch neutralisierende AK gegen TNF. Daf{\"u}r wurden die Nn. ischiadici der M{\"a}use operativ manipuliert, zum einen in Form der CCI durch drei den Nerven einschn{\"u}rende Ligaturen und zum anderen in Form der PST durch Heraustrennen eines Drittels des Nervendurchmessers. Beide Operationsmodelle l{\"o}sten bei den M{\"a}usen eine schmerzhafte Neuropathie aus. Es wurde untersucht, inwieweit zum Zeitpunkt der jeweiligen Operation oder am 4. postoperativen Tag applizierte TNF-AK das Schmerz-assoziierte Verhalten beeinflussen konnten und ob diese Behandlung einen Einfluß auf die Zytokinexpression im Endoneurium, auf den Makrophageneinstrom und auf die Nervenregeneration hatte. Hierzu wurden Verhaltenstests sowie immunhistochemische und morphometrische Methoden verwendet. Aus den vorliegenden Ergebnissen kann geschlossen werden, daß der bei CCI vermutete Einfluß der epineuralen Entz{\"u}ndung auf das Schmerz-assoziierte Verhalten kleiner ist als urspr{\"u}nglich angenommen. Die Tatsache, daß zumindest auf einen Parameter (Hitzehyperalgesie) nicht nur die pr{\"a}ventive sondern auch die therapeutische TNF-Hemmung wirksam war, l{\"a}ßt auf einen Einsatz von TNF-Hemmern bei bestimmten Formen des neuropathischen Schmerzes zur Therapieerg{\"a}nzung hoffen. Obwohl die TNF-Hemmung in den hier verwendeten Dosen und Applikationsweisen keinen Einfluß auf die endoneurale Zytokinexpression, Makrophagendichte und Regeneration hatte, sollten zuk{\"u}nftige Studien diese Parameter unter variierten Applikationsbedingungen genauer untersuchen.},
  language  = {de}
}
@phdthesis{Papagianni2018,
  author    = {Papagianni, Aikaterini},
  title     = {Schmerz-assoziierte elektrisch evozierte Potentiale (PREP) bei Patienten mit neuropathischen Schmerzsyndromen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-159728},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {In der vorliegenden Studie wurden 32 Patienten (19 Frauen, 13 M{\"a}nner, medianes Alter 50 Jahren, Spanne: 26-83 Jahre) mit einem klinisch akralen neuropathischen Schmerzsyndrom unterschiedlicher Genese mittels QST, PREP und Hautbiopsie untersucht. Unser Patientenkollektiv bestand aus drei Subgruppen: sechsen Patienten erf{\"u}llten die Kriterien einer SFN, acht Patienten hatten eine Neuropathie der großkalibrigen Nervenfasern mit zus{\"a}tzlicher Beeintr{\"a}chtigung der kleinkalibrigen Nervenfasern und weitere acht Patienten hatten ein akrales Schmerzsyndrom mit neuropathischen Charakteristika, ohne vorbekannte Diagnose einer Neuropathie der groß- oder kleinkalibrigen Nervenfasern. Die Patienten wurden mittels klinischer neurologischer Untersuchung, elektrophysiologischer Tests, QST, PREP und Hautbiopsie untersucht. Die Patientendaten wurden jeweils mit Daten großer Kontrollgruppen verglichen, die wir in unserer Klinik unter Angeh{\"o}rigen und Freunden unserer Patienten mit deren Einwilligung rekrutiert hatten. QST und die Hautbiopsie waren bei Patienten mit SFN und PNP jeweils auff{\"a}llig, bei akralem Schmerzsyndrom unklarer {\"A}tiologie hingegen unauff{\"a}llig. Nach elektrischer kutaner Stimulation aller drei K{\"o}rperregionen zeigte sich eine Amplitudenminderung der PREP-Reizantwort in allen Patientensubgruppen (7,5 µV in der SFN-Gruppe, 3,8 µV in der PNP-Gruppe, und 11,3 µV bei den Patienten mit akralem Schmerzsyndrom). Somit konnten wir zeigen, dass eine Kleinfaserpathologie in der Studienpopulation von Patienten mit neuropathischem Schmerzsyndrom besteht. Nur die Amplitudenminderung der PREP bildet diese Pathologie ab. Diese Daten erlauben uns die eingangs aufgestellte Hypothese, dass PREP zur Diagnostik bei Frage nach Kleinfaserbeteiligung geeignet ist, positiv zu belegen. PREP ist eine nicht-invasive Methode f{\"u}r die Evaluation der Funktion v.a. der Aδ-Faser mit standardisiertem Ablaufprotokoll zur Erhebung von reproduzierbaren Daten. Sie kann bei Patienten mit der Anamnese eines akralen neuropathischen Schmerzsyndroms einen objektiven Hinweis auf eine Dysfunktion der kleinkalibrigen Nervenfasern, auch wenn bereits etablierte Methoden (QST und Hautbiopsie) unauff{\"a}llig bleiben, erbringen. Entsprechend k{\"o}nnen die PREP eine wertvolle Erg{\"a}nzung der klinischen Untersuchungsbatterie f{\"u}r die Evaluation der Funktion der kleinkalibrigen Nervenfasern sein.},
  subject      = {PREP},
  language  = {de}
}
@phdthesis{Auchter2021,
  author    = {Auchter, Antonia},
  title     = {Schlafassoziierte Ver{\"a}nderung der lokalen Feldpotential Aktivit{\"a}t im Nucleus subthalamicus bei Patienten mit Morbus Parkinson},
  doi       = {10.25972/OPUS-23782},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-237822},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Die tiefe Hirnstimulation ist eine etablierte und hocheffiziente operative Behandlungsmethode f{\"u}r Patienten mit idiopathischem Parkinson- Syndrom (IPS). Als Zielgebiet dient in den meisten F{\"a}llen der Nucleus subthalamicus. Die Indikationen zur Implantation einer tiefen Hirnstimulation (THS) sind medikament{\"o}s nicht behandelbare motorische Fluktuationen und Dyskinesien oder ein medikament{\"o}s nicht kontrollierbarer Tremor. Bislang erfolgt eine kontinuierliche Stimulation. Little et al. konnten jedoch bereits in ihrer 2013 ver{\"o}ffentlichen Studie zeigen, dass eine adaptive Stimulation, gemessen am UPDRS, um 27 \% effektiver war und entsprechend die Stimulationszeit um 56 \% gesenkt werden konnte. Voraussetzung f{\"u}r die Anwendbarkeit einer adaptiven Stimulation im klinischen Alltag ist der Nachweis eines oder mehrerer Physiomarker, welche als R{\"u}ckkopplungssignal f{\"u}r den Stimulationsbeginn dienen. Diese Marker m{\"u}ssen verl{\"a}sslich mit dem Auftreten und der Auspr{\"a}gung der Bewegungsst{\"o}rungen korrelieren. Die Systeme m{\"u}ssen die Signale auslesen und entsprechend darauf reagieren k{\"o}nnen, damit ein sogenanntes Closed- loop- Verfahren entstehen kann. Bei diesen Markern handelt es sich um sogenannte lokale Feldpotenzialaktivit{\"a}ten, das heißt niederfrequente Potential{\"a}nderungen von Zellen in subkortikalen Arealen des Gehirns, welche {\"u}ber Elektroden der THS abgeleitet werden k{\"o}nnen. Der Stimulator Activa PC+S (Medtronic) erm{\"o}glicht es erstmalig Aufzeichnungen von LFP- Daten, außerhalb eines experimentellen Laboraufbaus, mittels dauerhaft implantiertem Ger{\"a}t vorzunehmen und damit auch Langzeitanalysen durchzuf{\"u}hren. Erkenntnisse vergangener Studien ergaben, dass die synchronisierte, pathologisch gesteigerte oszillatorische Aktivit{\"a}t im Beta-Frequenzband (13- 35 Hz) eine bedeutende Rolle im Bezug auf die Pathophysiologie des IPS spielt und als krankheitsspezifische Aktivit{\"a}t gilt. Es konnte bereits belegt werden, dass die Verbesserung der motorischen Symptome (Bradykinese und Rigor) mit dem Ausmaß der Suppression der Betaband- Aktivit{\"a}t korreliert. Die Betabandaktivit{\"a}t als lokale Feldpotentialaktivit{\"a}t kann als Physiomarker einer adaptiven Stimulation dienen. Unser Hauptaugenmerk galt daher der Analyse der Betabandaktivit{\"a}t oder anderer Frequenzbereiche w{\"a}hrend des Schlafes um hier die THS bedarfsgerecht einzusetzen. Hierf{\"u}r wurden n{\"a}chtliche subkortikale LFP- Aufzeichnungen parallel zur Schlaf- Polysomnographie durchgef{\"u}hrt. Zudem erfolgte in der vorliegenden Arbeit sowohl in unserem Vorversuch als auch in unserem Hauptversuch die Anwendung des UPDRS Teil III zur Erfassung der motorischen Symptome, sowie die Durchf{\"u}hrung von Frageb{\"o}gen zur Erfassung der nicht- motorischen Symptome, insbesondere des Schlafes vor und nach Implantation der tiefen Hirnstimulation. Wir konnten belegen, dass es nach Implantation der THS zu einer Erh{\"o}hung der Schlafeffizienz und zu einer Erh{\"o}hung des Anteils der Schlafstadien II und III und damit einhergehend zu einer Steigerung der Schlafqualit{\"a}t kommt. {\"U}bereinstimmend mit anderen Studien konnten wir zeigen, dass sich die Motorik unter Stimulation deutlich verbessert. Im Vorversuch reduzierte sich der mittlere pr{\"a}operative MDS- UPDRS III im MedsOFF verglichen mit dem mittleren postoperativ MDS- UPDRS III im MedsOFF/StimON um 37 \%. In der PC+S- Studie imponierte eine Reduktion um 67\%. Zudem zeigte sich eine Reduktion der nicht- motorischen Symptome durch die THS, insbesondere in der Kategorie Schlaf. Die Ergebnisse der vorliegenden Arbeit ergaben außerdem, dass die Betabandaktivität im Schlafstadium II und vor allem im Schlafstadium III am geringsten ist. Im Schlafstadium I und REM ist die Betabandaktivit{\"a}t höher als im Schlafstadium II und III. Hierbei war entscheidend, dass die Patienten eine klar abgrenzbare Betabandaktivit{\"a}t im Wachstadium aufwiesen und die Elektrodenkontakte im dorsolateralen Kerngebiet des STN lokalisiert waren. Gegenl{\"a}ufig dazu verh{\"a}lt sich die Deltaaktivität. Sie ist im Schlafstadium II und besonders im Stadium III am h{\"o}chsten. Stadium I ist mit durchschnittlich um 7,3 \% niedriger als im Wachstadium. Am geringsten ist sie jedoch im REM-Schlafstadium. Indem wir mit der Betabandaktivit{\"a}t und Deltaaktivit{\"a}t in den einzelnen Schlafstadien einen stabilen und reproduzierbaren Physiomarker finden konnten, sind wir unserem Ziel der adaptiven THS ein St{\"u}ck n{\"a}her gekommen.},
  subject      = {Parkinson},
  language  = {de}
}
@article{SteinhardtCejkaChenetal.2024,
  author    = {Steinhardt, Maximilian J. and Cejka, Vladimir and Chen, Mengmeng and B{\"a}uerlein, Sabrina and Sch{\"a}fer, Julia and Adrah, Ali and Ihne-Schubert, Sandra M. and Papagianni, Aikaterini and Kort{\"u}m, K. Martin and Morbach, Caroline and St{\"o}rk, Stefan},
  title     = {Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study},
  series = {Journal of Clinical Medicine},
  volume    = {13},
  journal   = {Journal of Clinical Medicine},
  number    = {1},
  issn      = {2077-0383},
  doi       = {10.3390/jcm13010283},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-356024},
  year      = {2024},
  abstract  = {Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1\% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5\% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.},
  language  = {en}
}
@article{VogtKollikowskiWeidneretal.2022,
  author    = {Vogt, Marius L. and Kollikowski, Alexander M. and Weidner, Franziska and Strinitz, Marc and Feick, J{\"o}rn and Essig, Fabian and Neugebauer, Herrmann and Haeusler, Karl Georg and Pham, Mirko and Maerz, Alexander},
  title     = {Safety and Effectiveness of the New Generation APERIO® Hybrid Stent-retriever Device in Large Vessel Occlusion Stroke},
  series = {Clinical Neuroradiology},
  volume    = {32},
  journal   = {Clinical Neuroradiology},
  number    = {1},
  doi       = {10.1007/s00062-021-01122-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-264817},
  pages     = {141-151},
  year      = {2022},
  abstract  = {Background It is unknown whether technological advancement of stent-retriever devices influences typical observational indicators of safety or effectiveness. Methods Observational retrospective study of APERIO® (AP) vs. new generation APERIO® Hybrid (APH) (Acandis®, Pforzheim, Germany) stent-retriever device (01/2019-09/2020) for mechanical thrombectomy (MT) in large vessel occlusion (LVO) stroke. Primary effectiveness endpoint was successful recanalization eTICI (expanded Thrombolysis In Cerebral Ischemia) ≥ 2b67, primary safety endpoint was occurrence of hemorrhagic complications after MT. Secondary outcome measures were time from groin puncture to first pass and successful reperfusion, and the total number of passes needed to achieve the final recanalization result. Results A total of 298 patients with LVO stroke who were treated by MT matched the inclusion criteria: 148 patients (49.7\%) treated with AP vs. 150 patients (50.3\%) treated with new generation APH. Successful recanalization was not statistically different between both groups: 75.7\% for AP vs. 79.3\% for APH; p = 0.450. Postinterventional hemorrhagic complications and particularly subarachnoid hemorrhage as the entity possibly associated with stent-retriever device type was significantly less frequent in the group treated with the APH: 29.7\% for AP and 16.0\% for APH; p = 0.005; however, rates of symptomatic hemorrhage with clinical deterioration and in domo mortality were not statistically different. Neither the median number of stent-retriever passages needed to achieve final recanalization, time from groin puncture to first pass, time from groin puncture to final recanalization nor the number of cases in which successful recanalization could only be achieved by using a different stent-retriever as bail-out device differed between both groups. Conclusion In the specific example of the APERIO® stent-retriever device, we observed that further technological developments of the new generation device were not associated with disadvantages with respect to typical observational indicators of safety or effectiveness.},
  language  = {en}
}
@article{TonyBurmesterSchulzeKoopsetal.2011,
  author    = {Tony, Hans-Peter and Burmester, Gerd and Schulze-Koops, Hendrik and Grunke, Mathias and Henes, Joerg and K{\"o}tter, Ina and Haas, Judith and Unger, Leonore and Lovric, Svjetlana and Haubitz, Marion and Fischer-Betz, Rebecca and Chehab, Gamal and Rubbert-Roth, Andrea and Specker, Christof and Weinerth, Jutta and Holle, Julia and M{\"u}ller-Ladner, Ulf and K{\"o}nig, Ramona and Fiehn, Christoph and Burgwinkel, Philip and Budde, Klemens and S{\"o}rensen, Helmut and Meurer, Michael and Aringer, Martin and Kieseier, Bernd and Erfurt-Berge, Cornelia and Sticherling, Michael and Veelken, Roland and Ziemann, Ulf and Strutz, Frank and von Wussow, Praxis and Meier, Florian MP and Hunzelmann, Nico and Schmidt, Enno and Bergner, Raoul and Schwarting, Andreas and Eming, R{\"u}diger and Schwarz-Eywill, Michael and Wassenberg, Siegfried and Fleck, Martin and Metzler, Claudia and Zettl, Uwe and Westphal, Jens and Heitmann, Stefan and Herzog, Anna L. and Wiendl, Heinz and Jakob, Waltraud and Schmidt, Elvira and Freivogel, Klaus and D{\"o}rner, Thomas and Hertl, Michael and Stadler, Rudolf},
  title     = {Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)},
  series = {Arthritis Research \& Therapy},
  volume    = {13},
  journal   = {Arthritis Research \& Therapy},
  number    = {R75},
  doi       = {10.1186/ar3337},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-142856},
  pages     = {1-14},
  year      = {2011},
  abstract  = {Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0\% with systemic lupus erythematosus, 15.7\% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1\% multiple sclerosis and 10.0\% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0\% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3\% of patients showed no response, 45.1\% showed a partial response and 41.6\% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm)},
  language  = {en}
}
@article{WurmbSchlerethKredeletal.2014,
  author    = {Wurmb, Thomas Erik and Schlereth, Stefan and Kredel, Markus and Muellenbach, Ralf M. and Wunder, Christian and Brederlau, J{\"o}rg and Roewer, Norbert and Kenn, Werner and Kunze, Ekkehard},
  title     = {Routine Follow-Up Cranial Computed Tomography for Deeply Sedated, Intubated, and Ventilated Multiple Trauma Patients with Suspected Severe Head Injury},
  series = {BioMed Research International},
  journal   = {BioMed Research International},
  number    = {361949},
  doi       = {10.1155/2014/361949},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120084},
  year      = {2014},
  abstract  = {Background. Missed or delayed detection of progressive neuronal damage after traumatic brain injury (TBI) may have negative impact on the outcome. We investigated whether routine follow-up CT is beneficial in sedated and mechanically ventilated trauma patients. Methods. The study design is a retrospective chart review. A routine follow-up cCT was performed 6 hours after the admission scan. We defined 2 groups of patients, group I: patients with equal or recurrent pathologies and group II: patients with new findings or progression of known pathologies. Results. A progression of intracranial injury was found in 63 patients (42\%) and 18 patients (12\%) had new findings in cCT 2 (group II). In group II a change in therapy was found in 44 out of 81 patients (54\%). 55 patients with progression or new findings on the second cCT had no clinical signs of neurological deterioration. Of those 24 patients (44\%) had therapeutic consequences due to the results of the follow-up cCT. Conclusion. We found new diagnosis or progression of intracranial pathology in 54\% of the patients. In 54\% of patients with new findings and progression of pathology, therapy was changed due to the results of follow-up cCT. In trauma patients who are sedated and ventilated for different reasons a routine follow-up CT is beneficial.},
  language  = {en}
}
@article{AlbertWeissenbergerMenclHoppetal.2014,
  author    = {Albert-Weissenberger, Christiane and Mencl, Stine and Hopp, Sarah and Kleinschnitz, Christoph and Siren, Anna-Leena},
  title     = {Role of the kallikrein-kinin system in traumatic brain injury},
  series = {Frontiers in Cellular Neuroscience},
  volume    = {8},
  journal   = {Frontiers in Cellular Neuroscience},
  issn      = {1662-5102},
  doi       = {10.3389/fncel.2014.00345},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-118226},
  pages     = {345},
  year      = {2014},
  abstract  = {Traumatic brain injury (TBI) is a major cause of mortality and morbidity worldwide. Despite improvements in acute intensive care, there are currently no specific therapies to ameliorate the effects of TBI. Successful therapeutic strategies for TBI should target multiple pathophysiologic mechanisms that occur at different stages of brain injury. The kallikrein-kinin system is a promising therapeutic target for TBI as it mediates key pathologic events of traumatic brain damage, such as edema formation, inflammation, and thrombosis. Selective and specific kinin receptor antagonists and inhibitors of plasma kallikrein and coagulation factor XII have been developed, and have already shown therapeutic efficacy in animal models of stroke and TBI. However, conflicting preclinical evaluation, as well as limited and inconclusive data from clinical trials in TBI, suggests that caution should be taken before transferring observations made in animals to humans. This review summarizes current evidence on the pathologic significance of the kallikrein-kinin system during TBI in animal models and, where available, the experimental findings are compared with human data.},
  language  = {en}
}
@phdthesis{Subramanian2011,
  author    = {Subramanian, Narayan},
  title     = {Role of NaV1.9 in activity dependent axon growth in embryonic cultured motoneurons},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-57536},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Spontaneous neural activity has been shown to regulate crucial events in neurite growth including axonal branching and path finding. In animal models of spinal muscular atrophy (SMA) cultured embryonic mouse motoneurons show distinct defect in axon elongation and neural activity. This defect is governed by abnormal clustering of Ca2+ channels in the axonal regions and the protruding growth cone area. The mechanisms that regulate the opening of calcium channels in developing motoneurons are not yet clear. The question was addressed by blocking neural activity in embryonic cultured motoneurons by pharmacological inhibition of voltage-gated sodium channels (VGSC) by saxitoxin (STX) and tetrodotoxin (TTX). Low dosages of STX resulted in significant reduction of axon growth and neural activity in cultured motoneurons. This pharmacological treatment did not affect survival of motoneurons in comparison to control motoneurons that was grown in the presence of survival neurotrophic factors BDNF and CNTF. It was also found that STX was 10 times more potent than TTX a common inhibitor of VGSC with a reduced activity on the TTX-insensitive sodium channels NaV1.5, NaV1.8 and NaV1.9. Reverse Transcriptase-PCR experiments revealed the presence of NaV1.9 as the likely candidate that begins to express from embryonic stage sixteen in the mouse spinal cord. Immunolabelling experiments showed that the channel is expressed in the axonal compartments and axonal growth cones in cultured motoneurons. Suppression of NaV1.9 in cultured motoneurons by lentivirus mediated short hairpin-RNA (shRNA) resulted in shorter axon length in comparison with uninfected and scrambled constructs. Further, embryonic motoneurons cultured from NaV1.9 knockout mice also showed a significant reduction in neural activity and axon growth. The findings of this work highlight the role of NaV1.9 as an important contender in regulating activity dependent axon growth in embryonic cultured motoneurons. NaV1.9 could therefore be considered as a prospective molecule that could play an important role in regulating axon growth in motoneuron disease models like spinal muscular atrophy (SMA).},
  subject      = {Axon},
  language  = {en}
}
@phdthesis{KronerMilsch2008,
  author    = {Kroner-Milsch, Antje},
  title     = {Role of immune cells in hereditary myelinopathies},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-28976},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2008},
  abstract  = {Myelin mutations in the central and peripheral nervous system lead to severely disabling, currently untreatable diseases. In this study, we used transgenic PLP overexpressing mice (PLPtg) as a model for central inherited myelinopathies, such as leukodystrophies, and heterozygously P0 deficient (P0+/-) mice as models for peripheral hereditary polyneuropathies. Both models are characterized by low grade nervous tissue inflammation. Macrophages and CD8+ T- lymphocytes contribute to the myelin pathology as shown by crossbreeding experiments with immunodeficient mice. Having shown the relevance of CD8+ T- lymphocytes in PLPtg mice, we investigated the influence of one major cytotoxic molecule (granzyme B) on neural damage. By generation of granzyme B deficient PLPtg bone marrow chimeras, we could demonstrate a reduction of myelin pathology and oligodendrocyte death. Taken together, granzyme B is at least partly responsible for the cytotoxicity induced neural damage in PLPtg mice. To further explore the role of immune modulation, we focussed on the influence of the coinhibitory molecule PD-1, a CD28-related receptor expressed on activated T- and B-lymphocytes. By investigating myelin mutants of the CNS and PNS (PLPtg and P0+/-) with an additional PD-1 deficiency, induced by crossbreeding or bone marrow chimerization, we found a significant increase of CD8+ T- lymphocytes and massive increase of the myelin pathology in both the CNS and PNS model. In PLPtg mice, absence of PD-1 increased oligodendrocyte apoptosis, clonal expansions and a higher propensity of CNS but not peripheral CD8+ T- cells to secrete proinflammatory cytokines. In P0+/- mice, absence of PD-1 lead to moderate motor and sensory disturbances, confirming the important role of PD-1 in immune homeostasis. Taken together, we identified granzyme B as an important effector agent of cytotoxic T-lymphocytes in PLPtg mice and PD-1 as a crucial player in regulating the effector cells in our models of central and peripheral myelinopathy. Alterations of this regulatory pathway lead to overt neuroinflammation of high pathogenetic impact. These results might help to understand mechanisms responsible for high clinical variability of polygenic or even monogenic disorders of the nervous system.},
  subject      = {Myelinopathie},
  language  = {en}
}
@article{HaeuserWalittFitzcharlesetal.2014,
  author    = {H{\"a}user, Winfried and Walitt, Brian and Fitzcharles, Mary-Ann and Sommer, Claudia},
  title     = {Review of pharmacological therapies in fibromyalgia syndrome},
  series = {Arthritis Research \& Therapy},
  volume    = {16},
  journal   = {Arthritis Research \& Therapy},
  number    = {201},
  issn      = {1465-9913},
  doi       = {10.1186/ar4441},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121598},
  year      = {2014},
  abstract  = {This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration.},
  language  = {en}
}
@article{AsterRomanosWalitzaetal.2022,
  author    = {Aster, Hans-Christoph and Romanos, Marcel and Walitza, Susanne and Gerlach, Manfred and M{\"u}hlberger, Andreas and Rizzo, Albert and Andreatta, Marta and Hasenauer, Natalie and Hartrampf, Philipp E. and Nerlich, Kai and Reiners, Christoph and Lorenz, Reinhard and Buck, Andreas K. and Deserno, Lorenz},
  title     = {Responsivity of the striatal dopamine system to methylphenidate — A within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder},
  series = {Frontiers in Psychiatry},
  volume    = {13},
  journal   = {Frontiers in Psychiatry},
  issn      = {1664-0640},
  doi       = {10.3389/fpsyt.2022.804730},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-270862},
  year      = {2022},
  abstract  = {Background: Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning. Methods Thirteen adolescent male patients (9-16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH. Results On-MPH status was associated with a highly significant change (-29.9\%) of striatal DAT BP as compared to off-MPH (t = -4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04). Conclusion Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.},
  language  = {en}
}
@article{KornKleinschnitzMagnusetal.2016,
  author    = {Korn, Thomas and Kleinschnitz, Christoph and Magnus, Tim and Meuth, Sven G. and Linker, Ralf A.},
  title     = {Report on the 7th scientific meeting of the Association for the Advancement of Young Academics in Neurology (NEUROWIND e.V.) held in Motzen, Germany, October 30-November 1, 2015},
  series = {Experimental and Translational Stroke Medicine},
  volume    = {8},
  journal   = {Experimental and Translational Stroke Medicine},
  number    = {3},
  organization    = {7th NEUROWIND e.V. scientific meeting},
  doi       = {10.1186/s13231-016-0017-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146595},
  year      = {2016},
  abstract  = {From October 30-November 1, 2015, the 7th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Seventy doctoral students and postdocs from over 25 different groups working in German and Swiss University Hospitals or Research Institutes attended the meeting to discuss their latest experiments and findings in the fields of neuroimmunology, neurodegeneration and neurovascular research. This meeting report summarizes the many diverse presentations and the new preclinical to clinical neurology research data that were shared by the participants at the meeting.},
  language  = {en}
}
@article{KleinschnitzLinkerMagnusetal.2015,
  author    = {Kleinschnitz, Christoph and Linker, Ralf A. and Magnus, Tim and Korn, Thomas and Meuth, Sven G.},
  title     = {Report on the 6th scientific meeting of the "Verein zur F{\"o}rderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 31th - Nov. 2nd, 2014},
  series = {Experimental \& Translational Stroke Medicine},
  volume    = {7},
  journal   = {Experimental \& Translational Stroke Medicine},
  number    = {1},
  organization    = {on behalf of the speakers at the 6'th NEUROWIND e.V. scientific meeting},
  doi       = {10.1186/s13231-014-0013-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125049},
  year      = {2015},
  abstract  = {From October 31th - November 2nd, 2014, the 6th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. 70 doctoral students and postdocs from over 25 different groups working in German and Swiss university hospitals or research institutes attended the meeting to discuss their latest experiments and findings in the fields of neuroimmunology, neurodegeneration and neurovascular research. The meeting was regarded as a very well organized platform to support research of young investigators in Germany and all participants enjoyed the stimulating environment for lively in depth discussions. According to the major aim of NEUROWIND e.V. to support younger researchers in Germany the 4th NEUROWIND YOUNG SCIENTIST AWARD for experimental neurology was awarded to Michael Breckwoldt on his work in the group of Thomas Misgeld (Institute of Neuronal Cell Biology, Technische Universit{\"a}t M{\"u}nchen, Germany). The successful project was published in Nature Medicine entitled "Multiparametric optical analysis of mitochondrial redox signals during neuronal physiology and pathology in vivo". This outstanding paper deals with a molecular imaging approach in living mice to optically analyze the role of mitochondrial redox signals in axons in health and disease. The award is endowed with 20.000 Euro sponsored by Merck Serono GmbH, Darmstadt, Germany (unrestricted educational grant). This year's keynote lecture was given by Bernhard Hemmer, Head of the Department of Neurology at the Klinikum rechts der Isar, Technische Universit{\"a}t M{\"u}nchen. Dr. Hemmer highlighted the particular role of B cells and (auto)antibodies in multiple sclerosis (MS). As a new highlight Dr. Urbahns, head of global discovery technologies at Merck research laboratories, gave insights from research practice in the pharmaceutical industry and introduced a shift in the view on present-day drug discovery paradigms.},
  language  = {en}
}
@article{LinkerMagnusKornetal.2013,
  author    = {Linker, Ralf A. and Magnus, Tim and Korn, Thomas and Kleinschnitz, Christoph and Meuth, Sven G.},
  title     = {Report on the 5'th scientific meeting of the "Verein zur F{\"o}rderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 25th - Oct. 27th, 2013},
  series = {Experimental \& Translational Stroke Medicine},
  volume    = {5},
  journal   = {Experimental \& Translational Stroke Medicine},
  number    = {15},
  doi       = {10.1186/2040-7378-5-15},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-129230},
  year      = {2013},
  abstract  = {From october 25th - 27th 2013, the 5th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. This year more than 60 doctoral students and postdocs from over 25 different groups working in German university hospitals or research institutes attended the meeting to discuss their latest findings in the fields of neuroimmunology, neurodegeneration and neurovascular research. All participants appreciated the stimulating environment in Motzen, Brandenburg, and people took the opportunity for scientific exchange, discussion about ongoing projects and already started further collaborations. Like in the previous years, the symposium was regarded as a very well organized platform to support research of young investigators in Germany. According to the major aim of NEUROWIND e.V. to support younger researchers in Germany the 3rd NEUROWIND YOUNG SCIENTIST AWARD for experimental neurology was awarded to Ruth Stassart working in the group of Klaus Armin Nave and Wolfgang Br{\"u}ck (MPI G{\"o}ttingen and Department of Neuropathology, G{\"o}ttingen Germany). The successful work was published in Nature Neuroscience entitled "A role for Swann cell-derived neuregulin-1 in remyelination". This outstanding paper deals with the function of Schwann cell neuregulin as an endogenous factor for myelin repair. The award is endowed with 20.000 Euro sponsored by Merck Serono GmbH, Darmstadt, Germany (unrestricted educational grant). This year's keynote lecture was given by Albert Ludolph, Head of the Department of Neurology at the University Clinic of Ulm. Dr. Ludolph highlighted the particular role of individual scientists for the development of research concepts in Alzheimer´s disease (AD) and frontotemporal dementia (FTD).},
  language  = {en}
}
@techreport{LinkerMeuthMagnusetal.2012,
  author    = {Linker, Ralf, A. and Meuth, Sven G. and Magnus, Tim and Korn, Thomas and Kleinschnitz, Christoph},
  title     = {Report on the 4'th scientific meeting of the "Verein zur F{\"o}rderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Nov. 2'nd - Nov. 4'th, 2012 [meeting report]},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-76407},
  year      = {2012},
  abstract  = {From November 2nd - 4th 2012, the 4th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Again more than 60 participants, predominantly at the doctoral student or postdoc level, gathered to share their latest findings in the fields of neurovascular research, neurodegeneration and neuroinflammation. Like in the previous years, the symposium provided an excellent platform for scientific exchange and the presentation of innovative projects in the stimulating surroundings of the Brandenburg outback. This year's keynote lecture on the pathophysiological relevance of neuronal networks was given by Christian Gerloff, Head of the Department of Neurology at the University Clinic of Hamburg-Eppendorf. Another highlight of the meeting was the awarding of the NEUROWIND e.V. prize for young scientists working in the field of experimental neurology. The award is donated by the Merck Serono GmbH, Darmstadt, Germany and is endowed with 20.000 Euro. This year the jury decided unanimously to adjudge the award to Michael Gliem from the Department of Neurology at the University Clinic of D{\"u}sseldorf (group of Sebastian Jander), Germany, for his outstanding work on different macrophage subsets in the pathogenesis of ischemic stroke published in the Annals of Neurology in 2012.},
  subject      = {Medizin},
  language  = {en}
}
@article{KleinschnitzMeuthMagnusetal.2012,
  author    = {Kleinschnitz, Christph and Meuth, Sven G. and Magnus, Tim and Korn, Thomas and Linker, Ralf A.},
  title     = {Report on the 3'rd scientific meeting of the "Verein zur F{\"o}rderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Nov. 4'th - Nov. 6'th, 2011},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-75388},
  year      = {2012},
  abstract  = {From November 4th- 6th 2011, the 3rd NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Like in the previous years, the meeting provided an excellent platform for scientific exchange and the presentation of innovative projects for young colleagues in the fields of neurovascular research, neuroinflammation and neurodegeneration. As kick-off to the scientific sessions, Reinhard Hohlfeld, Head of the Institute for Clinical Neuroimmunology in Munich, gave an illustrious overview on the many fascinations of neuroimmunologic research. A particular highlight on the second day of the meeting was the award of the 1'st NEUROWIND e.V. prize for young academics in the field of experimental neurology. This award is posted for young colleagues under the age of 35 with a significant achievement in the field of neurovascular research, neuroinflammation or neurodegeneration and comprises an amount of 20.000 Euro, founded by Merck Serono GmbH, Darmstadt. Germany. The first prize was awarded to Ivana Nikic from Martin Kerschensteiner's group in Munich for her brilliant work on a reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis, published in Nature Medicine in 2011. This first prize award ceremony was a great incentive for the next call for proposals now upcoming in 2012.},
  subject      = {Medizin},
  language  = {en}
}
@techreport{MagnusLinkerMeuthetal.2011,
  author    = {Magnus, Tim and Linker, Ralf A. and Meuth, Sven G. and Kleinschnitz, Christoph and Korn, Thomas},
  title     = {Report on the 2nd scientific meeting of the "Verein zur Foerderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 29'th - Oct. 31'st, 2010},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68789},
  year      = {2011},
  abstract  = {Summary of the scientific contributions to the NEUROWIND meeting 2010: Contributions in the fields of neuroimmunology and neurodegeneration},
  subject      = {Wissenschaftlicher Nachwuchs},
  language  = {en}
}
@article{BraunEvdokimovFranketal.2022,
  author    = {Braun, Alexandra and Evdokimov, Dimitar and Frank, Johanna and Pauli, Paul and Wabel, Thomas and {\"U}{\c{c}}eyler, Nurcan and Sommer, Claudia},
  title     = {Relevance of Religiosity for Coping Strategies and Disability in Patients with Fibromyalgia Syndrome},
  series = {Journal of Religion and Health},
  volume    = {61},
  journal   = {Journal of Religion and Health},
  number    = {1},
  issn      = {1573-6571},
  doi       = {10.1007/s10943-020-01177-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-269135},
  pages     = {524-539},
  year      = {2022},
  abstract  = {Coping strategies are essential for the outcome of chronic pain. This study evaluated religiosity in a cohort of patients with fibromyalgia syndrome (FMS), its effect on pain and other symptoms, on coping and FMS-related disability. A total of 102 FMS patients were recruited who filled in questionnaires, a subgroup of 42 patients participated in a face-to-face interview, and data were evaluated by correlation and regression analyses. Few patients were traditionally religious, but the majority believed in a higher existence and described their spirituality as "transcendence conviction". The coping strategy "praying-hoping" and the ASP dimension "religious orientation" (r = 0.5, P < 0.05) showed a significant relationship independent of the grade of religiosity (P < 0.05). A high grade of belief in a higher existence was negatively associated with the choice of ignoring as coping strategy (r = - 0.4, P < 0.05). Mood and affect-related variables had the highest impact on disability (b = 0.5, P < 0.05). In this cohort, the grade of religiosity played a role in the choice of coping strategies, but had no effects on health and mood outcome.},
  language  = {en}
}
@article{ElhfnawyAbdEl‐RaoufVolkmannetal.2020,
  author    = {Elhfnawy, Ahmed Mohamed and Abd El-Raouf, Mervat and Volkmann, Jens and Fluri, Felix and Elsalamawy, Doaa},
  title     = {Relation of infarction location and volume to vertigo in vertebrobasilar stroke},
  series = {Brain and Behavior},
  volume    = {10},
  journal   = {Brain and Behavior},
  number    = {3},
  doi       = {10.1002/brb3.1564},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-218047},
  year      = {2020},
  abstract  = {Objective Vertigo is a common presentation of vertebrobasilar stroke. Anecdotal reports have shown that vertigo occurs more often in multiple than in single brainstem or cerebellar infarctions. We examined the relation between the location and volume of infarction and vertigo in patients with vertebrobasilar stroke. Methods Consecutive patients with vertebrobasilar stroke were prospectively recruited. The infarction location and volume were assessed in the diffusion-weighted magnetic resonance imaging. Results Fifty-nine patients were included, 32 (54.2\%) with vertigo and 27 (45.8\%) without vertigo. The infarction volume did not correlate with National Institute of Health Stroke Scale (NIHSS) score on admission (Spearman ρ = .077, p = .56) but correlated with modified Rankin Scale (ρ = .37, p = .004) on discharge. In the vertigo group, the proportion of men was lower (53.1\% vs. 77.8\%, p = .049), fewer patients had focal neurological deficits (65.6\% vs. 96.3\%, p = .004), patients tended to present later (median [IQR] was 7.5 [4-46] vs. 4 [2-12] hours, p = .052), numerically fewer patients received intravenous thrombolysis (15.6\% vs. 37\%, p = .06), and the total infarction volume was larger (5.6 vs. 0.42 cm3, p = .008) than in nonvertigo group. In multivariate logistic regression, infarction location either in the cerebellum or in the dorsal brainstem (odds ratio [OR] 16.97, 95\% CI 3.1-92.95, p = .001) and a total infarction volume of >0.48 cm3 (OR 4.4, 95\% CI 1.05-18.58, p = .043) were related to vertigo. In another multivariate logistic regression, after adjusting for age, sex, intravenous thrombolysis, serum level of white blood cells, and atrial fibrillation, vertigo independently predicted a total infarction volume of >0.48 cm3 (OR 5.75, 95\% CI 1.43-23.08, p = .01). Conclusion Infarction location in the cerebellum and/or dorsal brainstem is an independent predictor of vertigo. Furthermore, larger infarction volume in these structures is associated with vertigo. A considerable proportion of patients with vascular vertigo present without focal neurological deficits posing a diagnostic challenge. National Institute of Health Stroke Scale is not sensitive for vertebrobasilar stroke.},
  language  = {en}
}
@phdthesis{Elhfnawy2019,
  author    = {Elhfnawy, Ahmed},
  title     = {Relation between the length of the internal carotid stenotic segment and ischemic cerebrovascular events as well as white matter lesion load},
  doi       = {10.25972/OPUS-19161},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-191616},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Background and Purpose: Internal carotid artery stenosis ≥70\% is a leading cause of ischemic cerebrovascular events. However, a considerable percentage of stroke survivors with symptomatic internal carotid artery stenosis have <70\% stenosis with a vulnerable plaque. Whether the length of internal carotid artery stenosis is associated with high risk of ischemic cerebrovascular events or with white matter lesions is poorly investigated. Our main aim was to investigate the relation between the length of internal carotid artery stenosis and the development of ischemic cerebrovascular events as well as ipsi-, contralateral as well as mean white matter lesion load. Methods: In a retrospective cross-sectional study, 168 patients with 208 internal carotid artery stenosis were identified. The degree and length of internal carotid artery stenosis as well as plaque morphology (hypoechoic, mixed or echogenic) were assessed on ultrasound scans. The white matter lesions were assessed in 4 areas separately, (periventricular and deep white matter lesions on each hemisphere), using the Fazekas scale. The mean white matter lesions load was calculated as the mean of these four values. Results: A statistically significant inverse correlation between the ultrasound-measured length and degree of internal carotid artery stenosis was detected for symptomatic internal carotid artery stenosis ≥70\% (Spearman correlation coefficient ρ = -0.57, p < 0.001, n = 51) but neither for symptomatic internal carotid artery stenosis <70\% (ρ = 0.15, p = 0.45, n = 27) nor for asymptomatic internal carotid artery stenosis (ρ = 0.07, p = 0.64, n = 54). The median (IQR) length for symptomatic internal carotid artery stenosis <70\% and ≥70\% was 17 (15-20) and 15 (12-19) mm (p = 0.06), respectively, while that for symptomatic internal carotid artery stenosis <90\% and symptomatic internal carotid artery stenosis 90\% was 18 (15-21) and 13 (10-16) mm, respectively (p < 0.001). Among patients with internal carotid artery stenosis <70\%, a cut-off length of ≥16 mm was found for symptomatic internal carotid artery stenosis rather than asymptomatic internal carotid artery stenosis with a sensitivity and specificity of 74.1\% and 51.1\%, respectively. Irrespective of the stenotic degree, plaques of the symptomatic internal carotid artery stenosis compared to asymptomatic internal carotid artery stenosis were significantly more often echolucent (43.2 vs. 24.6\%, p = 0.02). The length but not the degree of internal carotid artery stenosis showed a very slight trend toward association with ipsilateral white matter lesions and with mean white matter lesions load. Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of symptomatic internal carotid artery stenosis <70\% to be longer than that of symptomatic internal carotid artery stenosis ≥70\%. Moreover, the ultrasound-measured length of symptomatic internal carotid artery stenosis <90\% was significantly longer than that of symptomatic internal carotid artery stenosis 90\%. Among patients with symptomatic internal carotid artery stenosis ≥70\%, the degree and length of stenosis were inversely correlated. Furthermore, we have shown that a slight correlation exists between the length of stenosis and the presence of ipsilateral white matter lesions which might be due to microembolisation originating from the carotid plaque. Larger studies are needed before a clinical implication can be drawn from these results.},
  subject      = {Carotisstenose},
  language  = {en}
}
@phdthesis{Schmid2012,
  author    = {Schmid, Benedikt},
  title     = {Relation between cerebral arterio-venous transit time and neuropsychological performance in patients with vascular dementia},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-71234},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2012},
  abstract  = {Dementia, or any form of degenerative cognitive decline, is one of the major problems in present, and even more will be in future medicine. With Alzheimer's disease (AD) being the most prevalent, Vascular Dementia is the second most entity of dementing processes in the elderly. As diagnostic criteria are still imprecise and in many cases do not embrace early stages of the disease, recent studies have proposed more detailed classifications of the newly created condition Vascular Cognitive Impairment (VCI). Of all conditions subsumed under this term, subcortical small-vessel alterations are the most common cause for cognitive decline. The diagnosis of dementia / cognitive impairment is presently often made in late stages of the disease, when therapeutical options are poor. Thus, early detection of changes of the subcortical small vessels is desirable, when there is still time to identify and aggressively treat risk factors and underlying conditions like diabetes, hyper- or hypotension, and hyperlipidemia. This study aimed to evaluate whether cTT correlates to cognitive dysfunction, i.e. if cTT is fit as an early diagnostic tool for VCI. The study cohort included 38 patients from the Neurological Clinic of the W{\"u}rzburg University hospital admitted due to diagnoses other than dementia or stroke. As a result of this study it turned out that cTT is certainly capable of fulfilling the task to easily and effectively detect and evaluate possible microvascular lesions of the brain with respect to the actual clinical relevance for the patient. When compared to the other proposed diagnostic tools, neuropsychological testing and MRI, the advantages of cTT are obvious: its measurement is a low-cost and quick procedure which would spare both patients and examiners a long neuropsychological exam or complement it. cTT is safe to assess as the only possible risks derive from the use of the contrast agent, which are rare and easily manageable. It has also proven to be more accurate in showing the extent of cognitive impairment than MRI. Finally, it is widely available. The only prerequisite is an ultrasound machine capable of transcranial color-coded duplex sonography. No cost-intensive procedures like MRI are needed. So, with neuropsychological testing remaining the gold standard, cTT here proved to be a reliable alternative which is more time- and cost-effective than MRI.},
  subject      = {Demenz},
  language  = {en}
}
@phdthesis{Schanz2022,
  author    = {Schanz, Stefan},
  title     = {Rehabilitation des Schlaganfalls - Evaluation eines interdisziplin{\"a}ren Behandlungskonzepts auf einer spezialisierten Station},
  doi       = {10.25972/OPUS-26001},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260011},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Die Rehabilitation von Schlaganfallpatienten erfordert ein interdisziplin{\"a}res Vorgehen. Dies ist im klinischen Alltag oft nur schwer umsetzbar. Im Jahr 2011 wurde daher im Neurologischen Rehabilitationszentrum Quellenhof in Bad Wildbad ein spezielles Behandlungskonzept f{\"u}r Schlaganfallpatienten entwickelt. Mit dieser Studie sollte die Wirksamkeit dieses neuen Konzepts untersucht werden. Dabei wurde die Behandlung im Schlaganfallkonzept mit der bisher {\"u}blichen Behandlung verglichen. Zielparameter waren der Barthel-Index und die modifizierte Rankin-Skala bei Aufnahme und bei Entlassung. Die Ergebnisse zeigen, dass sowohl die bisherige Behandlung als auch die Behandlung im Schlaganfallkonzept effektiv sind. Im Schlaganfallkonzept konnte jedoch ein gr{\"o}ßerer Zugewinn an alltagsrelevanten F{\"a}higkeiten erzielt werden; zudem berichteten Pflegekr{\"a}fte und Therapeuten eine verbesserte Zusammenarbeit. Somit steigert das Schlaganfallkonzept nicht nur die Alltagskompetenz der Patienten, sondern auch den Wissenstransfer zwischen den Berufsgruppen und die Interdisziplinarit{\"a}t.},
  subject      = {Schlaganfall},
  language  = {de}
}
@article{KraftDrechslerGunrebenetal.2014,
  author    = {Kraft, Peter and Drechsler, Christiane and Gunreben, Ignaz and Heuschmann, Peter Ulrich and Kleinschnitz, Christoph},
  title     = {Regulation of Blood Coagulation Factors XI and XII in Patients with Acute and Chronic Cerebrovascular Disease: A Case-Control Study},
  series = {Cerebrovascular Diseases},
  volume    = {38},
  journal   = {Cerebrovascular Diseases},
  number    = {5},
  issn      = {1015-9770},
  doi       = {10.1159/000368434},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-199076},
  pages     = {337-343},
  year      = {2014},
  abstract  = {Background: Animal models have implicated an integral role for coagulation factors XI (FXI) and XII (FXII) in thrombus formation and propagation of ischemic stroke (IS). However, it is unknown if these molecules contribute to IS pathophysiology in humans, and might be of use as biomarkers for IS risk and severity. This study aimed to identify predictors of altered FXI and FXII levels and to determine whether there are differences in the levels of these coagulation factors between acute cerebrovascular events and chronic cerebrovascular disease (CCD). Methods: In this case-control study, 116 patients with acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HVs) were enrolled between 2010 and 2013 at our University hospital. Blood sampling was undertaken once in the CCD and HV groups and on days 0, 1, and 3 after stroke onset in patients with AIS or TIA. Correlations between serum FXI and FXII levels and demographic and clinical parameters were tested by linear regression and analysis of variance. Results: The mean age of AIS/TIA patients was 70 ± 12. Baseline clinical severity measured with NIHSS and Barthel Index was 4.8 ± 6.0 and 74 ± 30, respectively. More than half of the patients had an AIS (58\%). FXI levels were significantly correlated with different leukocyte subsets (p < 0.05). In contrast, FXII serum levels showed no significant correlation (p > 0.1). Neither FXI nor FXII levels correlated with CRP (p > 0.2). FXII levels were significantly higher in patients with CCD compared with those with AIS/TIA (mean ± SD 106 ± 26\% vs. 97 ± 24\%; univariate analysis: p < 0.05); these differences did not reach significance in multivariate analysis adjusted for sex and age. FXI levels did not differ significantly between study groups. Sex and age were significantly associated with FXI and/or FXII levels in patients with AIS/TIA (p < 0.05). In contrast, no statistical significant influence was found for treatment modality (thrombolysis or not), pre-treatment with platelet inhibitors, and severity of stroke. Conclusions: In this study, there was no differential regulation of FXI and FXII levels between disease subtypes but biomarker levels were associated with patient and clinical characteristics. FXI and FXII levels might be no valid biomarker for predicting stroke risk.},
  language  = {en}
}
@phdthesis{Klein2004,
  author    = {Klein, Oliver},
  title     = {Regulation der Chemokinexpression in humanen zerebralen Endothelzellen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-11567},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2004},
  abstract  = {Humane zerebrale Endothelzellen sind in vitro in der Lage nach Stimulation mit proinflammatorischen Zytokinen Chemokine zu produzieren. Diese sind von Bedeutung in der Entwicklung von entz{\"u}ndlichen ZNS-Erkrankungen. So scheinen zerebrale Endothelzellen neben Astrozyten und Mikroglia als Produzenten dieser Schl{\"u}sselmolek{\"u}le zu fungieren.},
  language  = {de}
}
@phdthesis{Goessler2003,
  author    = {G{\"o}ßler, Ulrich},
  title     = {Regulation der Capsaicin-Sensitivit{\"a}t von murinen Spinalganglienzellen durch neurotrophe Faktoren},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-8500},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {In der vorliegenden Arbeit konnte anhand von Zellkulturen von Spinalganglienzellen herausgearbeitet werden, dass die Regulation der Capsaicin-Sensitivit{\"a}t in der Maus von vielen Faktoren abh{\"a}ngig ist: Es ließ sich ein komplexes System der Regulation von Capsaicin-induziertem Cobalt-Uptake als Surrogat-Marker f{\"u}r nozizeptive Neurone herausarbeiten: Zum einen konnte gezeigt werden, dass NGF dosisabh{\"a}ngig Einfluss auf die peptiderge Neuronenpopulation nimmt und {\"u}ber den niederaffinen NGF-Rezeptor p75NTR Capsaicin-Empfindlichkeit, CGRP-Expression und VR1-Expression reguliert. Dieser Rezeptor hat dabei keine Bedeutung f{\"u}r den konstitutiven Cobalt-Uptake, jedoch f{\"u}r die Aufrechterhaltung des Cobalt-Uptakes in der Zellkultur. Zum anderen konnte gezeigt werden, dass GDNF dosisabh{\"a}ngig den Anteil der Neurone mit Capsaicin-induziertem Cobalt-Uptake reguliert und dosisabh{\"a}ngig parallel in zwei Gruppen von Spinalganglienzellen den Cobalt-Uptake induziert: einerseits {\"u}ber den GDNF-Rezeptor GFRa2 und die Rezeptortyrosinkinase c-RET in der IB4-Population, andererseits {\"u}ber GFRa1 und SRC-Kinasen in der GFRa1-Population. In der vorliegenden Arbeit konnte gezeigt werden, dass Spinalganglienzellen die Sensibilit{\"a}t gegen{\"u}ber noxischen Reizen selbst{\"a}ndig komplex regulieren und damit auf {\"a}ußere Einfl{\"u}sse reagieren k{\"o}nnen. M{\"o}glicherweise ergeben sich in Zukunft neue Ansatzpunkte der Therapie dadurch, dass die Neurone direkt beeinflusst werden k{\"o}nnen.},
  language  = {de}
}
@article{HaarmannZimmermannBieberetal.2022,
  author    = {Haarmann, Axel and Zimmermann, Lena and Bieber, Michael and Silwedel, Christine and Stoll, Guido and Schuhmann, Michael K.},
  title     = {Regulation and release of vasoactive endoglin by brain endothelium in response to hypoxia/reoxygenation in stroke},
  series = {International Journal of Molecular Sciences},
  volume    = {23},
  journal   = {International Journal of Molecular Sciences},
  number    = {13},
  issn      = {1422-0067},
  doi       = {10.3390/ijms23137085},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284361},
  year      = {2022},
  abstract  = {In large vessel occlusion stroke, recanalization to restore cerebral perfusion is essential but not necessarily sufficient for a favorable outcome. Paradoxically, in some patients, reperfusion carries the risk of increased tissue damage and cerebral hemorrhage. Experimental and clinical data suggest that endothelial cells, representing the interface for detrimental platelet and leukocyte responses, likely play a crucial role in the phenomenon referred to as ischemia/reperfusion (I/R)-injury, but the mechanisms are unknown. We aimed to determine the role of endoglin in cerebral I/R-injury; endoglin is a membrane-bound protein abundantly expressed by endothelial cells that has previously been shown to be involved in the maintenance of vascular homeostasis. We investigated the expression of membranous endoglin (using Western blotting and RT-PCR) and the generation of soluble endoglin (using an enzyme-linked immunosorbent assay of cell culture supernatants) after hypoxia and subsequent reoxygenation in human non-immortalized brain endothelial cells. To validate these in vitro data, we additionally examined endoglin expression in an intraluminal monofilament model of permanent and transient middle cerebral artery occlusion in mice. Subsequently, the effects of recombinant human soluble endoglin were assessed by label-free impedance-based measurement of endothelial monolayer integrity (using the xCELLigence DP system) and immunocytochemistry. Endoglin expression is highly inducible by hypoxia in human brain endothelial monolayers in vitro, and subsequent reoxygenation induced its shedding. These findings were corroborated in mice during MCAO; an upregulation of endoglin was displayed in the infarcted hemispheres under occlusion, whereas endoglin expression was significantly diminished after transient MCAO, which is indicative of shedding. Of note is the finding that soluble endoglin induced an inflammatory phenotype in endothelial monolayers. The treatment of HBMEC with endoglin resulted in a decrease in transendothelial resistance and the downregulation of VE-cadherin. Our data establish a novel mechanism in which hypoxia triggers the initial endothelial upregulation of endoglin and subsequent reoxygenation triggers its release as a vasoactive mediator that, when rinsed into adjacent vascular beds after recanalization, can contribute to cerebral reperfusion injury.},
  language  = {en}
}
@phdthesis{Fischer2008,
  author    = {Fischer, Stefan Martin},
  title     = {Regulation and functional consequences of MCP-1 expression in a model of Charcot-Marie-Tooth 1B disease},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-29189},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2008},
  abstract  = {Charcot-Marie-Tooth 1B (CMT1B) is a progressive inherited demyelinating disease of human peripheral nervous system leading to sensory and/or motor function disability and is caused by mutations in the P0 gene. Mice heterozygously deficient for P0 (P0+/-) are an adequate model of this human disorder showing myelin degeneration, formation of onion bulbs, remyelination and a reduced motor conduction velocity of around 30m/s similar to patients. Previously, it had been shown that T-lymphocytes and macrophages play a crucial role during pathogenesis in peripheral nerves of P0+/- mice. Both, T-lymphocytes and macrophages increase in number in the endoneurium and deletion of T-lymphocytes or deletion of a macrophage-directed cytokine ameliorates the disease. In this study the monocyte chemoattractant protein-1 (MCP-1) was identified as an early regulated cytokine before onset of disease is visible at the age of six months. MCP-1 mRNA and protein expression could be detected in femoral quadriceps and sciatic nerves of P0+/- mice already at the age of one month but not in cutaneous saphenous nerves which are never affected by the disease. MCP-1 was shown to be expressed by Schwann cells and to mediate the immigration of immune cells into peripheral nerves. Deletion of MCP-1 in P0+/- mice accomplished by crossbreeding P0 and MCP-1 deficient mice revealed a substantial reduction of immune cells in peripheral nerves of P0+/-/MCP-1+/- and P0+/-/MCP-1-/- mice at the age of six months. In twelve months old mice reduction of immune cells in peripheral nerves is accompanied by amelioration of demyelinating disease in P0+/-/MCP-1+/- and aggravation of demyelinating disease in lumbar ventral roots of P0+/ /MCP-1-/- mice in comparison to P0+/ /MCP 1+/+ mice. Furthermore, activation of the MEK1/2-ERK1/2 signalling cascade could be demonstrated to take place in Schwann cells of affected peripheral nerves of P0+/- mice overlapping temporarily and spatially with MCP-1 expression. An animal experiment using a MEK1/2-inhibitor in vivo, CI-1040, revealed that upon reduction of ERK1/2 phosphorylation MCP-1 mRNA expression is diminished suggesting that the activation of the MEK1/2-ERK1/2 signalling cascade is necessary for MCP-1 expression. Additionally, peripheral nerves of P0+/- mice showing reduced ERK1/2 phosphorylation and MCP-1 mRNA expression also show reduced numbers of macrophages in the endoneurium. This study shows a molecular link between a Schwann cell based mutation and immune cell function. Inhibition of the identified signalling cascade might be a putative target for therapeutic approaches.},
  subject      = {Schwann-Zelle},
  language  = {en}
}
@article{EvdokimovFrankKlitschetal.2019,
  author    = {Evdokimov, Dimitar and Frank, Johanna and Klitsch, Alexander and Unterecker, Stefan and Warrings, Bodo and Serra, Jordi and Papagianni, Aikaterini and Saffer, Nadine and Meyer zu Altenschildesche, Caren and Kampik, Daniel and Malik, Rayaz A. and Sommer, Claudia and {\"U}ceyler, Nurcan},
  title     = {Reduction of skin innervation is associated with a severe fibromyalgia phenotype},
  series = {Annals of Neurology},
  volume    = {86},
  journal   = {Annals of Neurology},
  number    = {4},
  doi       = {10.1002/ana.25565},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-206168},
  pages     = {504-516},
  year      = {2019},
  abstract  = {Objective: To assess patterns and impact of small nerve fiber dysfunction and pathology in patients with fibromyalgia syndrome (FMS). Methods: One hundred seventeen women with FMS underwent neurological examination, questionnaire assessment, neurophysiology assessment, and small fiber tests: skin punch biopsy, corneal confocal microscopy, microneurography, quantitative sensory testing including C-tactile afferents, and pain-related evoked potentials. Data were compared with those of women with major depressive disorder and chronic widespread pain (MD-P) and healthy women. Results: Intraepidermal nerve fiber density (IENFD) was reduced at different biopsy sites in 63\% of FMS patients (MDP: 10\%, controls: 18\%; p < 0.001 for each). We found 4 patterns of skin innervation in FMS: normal, distally reduced, proximally reduced, and both distally and proximally reduced (p < 0.01 for each compared to controls). Microneurography revealed initial activity-dependent acceleration of conduction velocity upon low frequencies of stimulation in 1A fibers, besides 1B fiber spontaneous activity and mechanical sensitization in FMS patients. FMS patients had elevated warm detection thresholds (p < 0.01), impaired C-tactile afferents (p < 0.05), and reduced amplitudes (p < 0.001) of pain-related evoked potentials compared to controls. Compared to FMS patients with normal skin innervation, those with generalized IENFD reduction had higher pain intensity and impairment due to pain, higher disease burden, more stabbing pain and paresthesias, and more anxiety (p < 0.05 for each). FMS patients with generalized IENFD reduction also had lower corneal nerve fiber density (p < 0.01) and length (p < 0.05). Interpretation: The extent of small fiber pathology is related to symptom severity in FMS. This knowledge may have implications for the diagnostic classification and treatment of patients with FMS.},
  language  = {en}
}
@article{LangeSteigerwaldMalzacheretal.2021,
  author    = {Lange, Florian and Steigerwald, Frank and Malzacher, Tobias and Brandt, Gregor Alexander and Odorfer, Thorsten Michael and Roothans, Jonas and Reich, Martin M. and Fricke, Patrick and Volkmann, Jens and Matthies, Cordula and Capetian, Philipp D.},
  title     = {Reduced Programming Time and Strong Symptom Control Even in Chronic Course Through Imaging-Based DBS Programming},
  series = {Frontiers in Neurology},
  volume    = {12},
  journal   = {Frontiers in Neurology},
  issn      = {1664-2295},
  doi       = {10.3389/fneur.2021.785529},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-249634},
  year      = {2021},
  abstract  = {Objectives: Deep brain stimulation (DBS) programming is based on clinical response testing. Our clinical pilot trial assessed the feasibility of image-guided programing using software depicting the lead location in a patient-specific anatomical model. Methods: Parkinson's disease patients with subthalamic nucleus-DBS were randomly assigned to standard clinical-based programming (CBP) or anatomical-based (imaging-guided) programming (ABP) in an 8-week crossover trial. Programming characteristics and clinical outcomes were evaluated. Results: In 10 patients, both programs led to similar motor symptom control (MDS-UPDRS III) after 4 weeks (medicationOFF/stimulationON; CPB: 18.27 ± 9.23; ABP: 18.37 ± 6.66). Stimulation settings were not significantly different, apart from higher frequency in the baseline program than CBP (p = 0.01) or ABP (p = 0.003). Time spent in a program was not significantly different (CBP: 86.1 ± 29.82\%, ABP: 88.6 ± 29.0\%). Programing time was significantly shorter (p = 0.039) with ABP (19.78 ± 5.86 min) than CBP (45.22 ± 18.32). Conclusion: Image-guided DBS programming in PD patients drastically reduces programming time without compromising symptom control and patient satisfaction in this small feasibility trial.},
  language  = {en}
}
@article{UeceylerSchliesserEvdokimovetal.2022,
  author    = {{\"U}{\c{c}}eyler, Nurcan and Schließer, Mira and Evdokimov, Dimitar and Radziwon, Jakub and Feulner, Betty and Unterecker, Stefan and Rimmele, Florian and Walter, Uwe},
  title     = {Reduced midbrain raphe echogenicity in patients with fibromyalgia syndrome},
  series = {PloS One},
  volume    = {17},
  journal   = {PloS One},
  number    = {11},
  doi       = {10.1371/journal.pone.0277316},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300639},
  year      = {2022},
  abstract  = {Objectives The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS. Methods Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis. Results Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms. Conclusion We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.},
  language  = {en}
}
@article{KlitschEvdokimovFranketal.2020,
  author    = {Klitsch, Alexander and Evdokimov, Dimitar and Frank, Johanna and Thomas, Dominique and Saffer, Nadine and Meyer zu Altenschildesche, Caren and Sisignano, Marco and Kampik, Daniel and Malik, Rayaz A. and Sommer, Claudia and {\"U}{\c{c}}eyler, Nurcan},
  title     = {Reduced association between dendritic cells and corneal sub-basal nerve fibers in patients with fibromyalgia syndrome},
  series = {Journal of the Peripheral Nervous System},
  volume    = {25},
  journal   = {Journal of the Peripheral Nervous System},
  number    = {1},
  doi       = {10.1111/jns.12360},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-214150},
  pages     = {9-18},
  year      = {2020},
  abstract  = {In our study, we aimed at investigating corneal langerhans cells (LC) in patients with fibromyalgia syndrome (FMS) and small fiber neuropathy (SFN) as potential contributors to corneal small fiber pathology. We enrolled women with FMS (n = 134) and SFN (n = 41) who underwent neurological examination, neurophysiology, prostaglandin analysis in tear fluid, and corneal confocal microscopy (CCM). Data were compared with those of 60 age-matched female controls. After screening for dry eye disease, corneal LC were counted and sub-classified as dendritic (dLC) and non-dendritic (ndLC) cells with or without nerve fiber association. We further analyzed corneal nerve fiber density (CNFD), length (CNFL), and branch density (CNBD). Neurological examination indicated deficits of small fiber function in patients with SFN. Nerve conduction studies were normal in all participants. Dry eye disease was more prevalent in FMS (17\%) and SFN (28\%) patients than in controls (5\%). Tear fluid prostaglandin levels did not differ between FMS patients and controls. While corneal LC density in FMS and SFN patients was not different from controls, there were fewer dLC in association with nerve fibers in FMS and SFN patients than in controls (P < .01 each). Compared to controls, CNFL was lower in FMS and SFN patients (P < .05 each), CNFD was lower only in FMS patients (P < .05), and CNBD was lower only in SFN patients (P < .001). There was no difference in any CCM parameter between patients with and without dry eyes. Our data indicate changes in corneal innervation and LC distribution in FMS and SFN, potentially based on altered LC signaling.},
  language  = {en}
}
@article{ElhfnawyElsalamawyAbdelraoufetal.2020,
  author    = {Elhfnawy, Ahmed Mohamed and Elsalamawy, Doaa and Abdelraouf, Mervat and Schliesser, Mira and Volkmann, Jens and Fluri, Felix},
  title     = {Red flags for a concomitant giant cell arteritis in patients with vertebrobasilar stroke: a cross-sectional study and systematic review},
  series = {Acta Neurologica Belgica},
  volume    = {120},
  journal   = {Acta Neurologica Belgica},
  number    = {6},
  issn      = {0300-9009},
  doi       = {10.1007/s13760-020-01344-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-315610},
  pages     = {1389-1398},
  year      = {2020},
  abstract  = {Giant cell arteritis (GCA) may affect the brain-supplying arteries, resulting in ischemic stroke, whereby the vertebrobasilar territory is most often involved. Since etiology is unknown in 25\% of stroke patients and GCA is hardly considered as a cause, we examined in a pilot study, whether screening for GCA after vertebrobasilar stroke might unmask an otherwise missed disease. Consecutive patients with vertebrobasilar stroke were prospectively screened for GCA using erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, and halo sign of the temporal and vertebral artery on ultrasound. Furthermore, we conducted a systematic literature review for relevant studies. Sixty-five patients were included, and two patients (3.1\%) were diagnosed with GCA. Patients with GCA were older in age (median 85 versus 69 years, p = 0.02). ESR and CRP were significantly increased and hemoglobin was significantly lower in GCA patients compared to non-GCA patients (median, 75 versus 11 mm in 1 h, p = 0.001; 3.84 versus 0.25 mg/dl, p = 0.01, 10.4 versus 14.6 mg/dl, p = 0.003, respectively). Multiple stenoses/occlusions in the vertebrobasilar territory affected our two GCA patients (100\%), but only five (7.9\%) non-GCA patients (p = 0.01). Our literature review identified 13 articles with 136 stroke patients with concomitant GCA. Those were old in age. Headache, increased inflammatory markers, and anemia were frequently reported. Multiple stenoses/occlusions in the vertebrobasilar territory affected around 70\% of stroke patients with GCA. Increased inflammatory markers, older age, anemia, and multiple stenoses/occlusions in the vertebrobasilar territory may be regarded as red flags for GCA among patients with vertebrobasilar stroke.},
  language  = {en}
}
@article{BiegstraatenArngrimssonBarbeyetal.2015,
  author    = {Biegstraaten, Marieke and Arngr{\´i}msson, Reynir and Barbey, Frederic and Boks, Lut and Cecchi, Franco and Deegan, Patrick B and Feldt-Rasmussen, Ulla and Geberhiwot, Tarekegn and Germain, Dominique P and Hendriksz, Chris and Hughes, Derralynn A and Kantola, Ilkka and Karabul, Nesrin and Lavery, Christine and Linthorst, Gabor E and Mehta, Atul and van de Mheen, Erica and Oliveira, Jo{\~a}o P and Parini, Rossella and Ramaswami, Uma and Rudnicki, Michael and Serra, Andreas and Sommer, Claudia and Sunder-Plassmann, Gere and Svarstad, Einar and Sweeb, Annelies and Terryn, Wim and Tylki-Szymanska, Anna and T{\o}ndel, Camilla and Vujkovac, Bojan and Weidemann, Frank and Wijburg, Frits A and Woolfson, Peter and Hollak, Carla EM},
  title     = {Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {10},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {36},
  doi       = {10.1186/s13023-015-0253-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-175374},
  year      = {2015},
  abstract  = {Introduction: Fabry disease (FD) is a lysosomal storage disorder resulting in progressive nervous system, kidney and heart disease. Enzyme replacement therapy (ERT) may halt or attenuate disease progression. Since administration is burdensome and expensive, appropriate use is mandatory. We aimed to define European consensus recommendations for the initiation and cessation of ERT in patients with FD. Methods: A Delphi procedure was conducted with an online survey (n = 28) and a meeting (n = 15). Patient organization representatives were present at the meeting to give their views. Recommendations were accepted with ≥75\% agreement and no disagreement. Results: For classically affected males, consensus was achieved that ERT is recommended as soon as there are early clinical signs of kidney, heart or brain involvement, but may be considered in patients of ≥16 years in the absence of clinical signs or symptoms of organ involvement. Classically affected females and males with non-classical FD should be treated as soon as there are early clinical signs of kidney, heart or brain involvement, while treatment may be considered in females with non-classical FD with early clinical signs that are considered to be due to FD. Consensus was achieved that treatment should not be withheld from patients with severe renal insufficiency (GFR < 45 ml/min/1.73 m\(^{2}\)) and from those on dialysis or with cognitive decline, but carefully considered on an individual basis. Stopping ERT may be considered in patients with end stage FD or other co-morbidities, leading to a life expectancy of <1 year. In those with cognitive decline of any cause, or lack of response for 1 year when the sole indication for ERT is neuropathic pain, stopping ERT may be considered. Also, in patients with end stage renal disease, without an option for renal transplantation, in combination with advanced heart failure (NYHA class IV), cessation of ERT should be considered. ERT in patients who are non-compliant or fail to attend regularly at visits should be stopped. Conclusion: The recommendations can be used as a benchmark for initiation and cessation of ERT, although final decisions should be made on an individual basis. Future collaborative efforts are needed for optimization of these recommendations.},
  language  = {en}
}
@article{FriedrichHartigPruessetal.2022,
  author    = {Friedrich, Maximilian and Hartig, Johannes and Pr{\"u}ss, Harald and Ip, Wang Chi and Volkmann, Jens},
  title     = {Rapidly progressive dementia: Extending the spectrum of GFAP-astrocytopathies?},
  series = {Annals of Clinical and Translational Neurology},
  volume    = {9},
  journal   = {Annals of Clinical and Translational Neurology},
  number    = {3},
  doi       = {10.1002/acn3.51513},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-312957},
  pages     = {410-415},
  year      = {2022},
  abstract  = {Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is a steroid-responsive meningoencephalomyelitis, sometimes presenting with atypical clinical signs such as movement disorders or psychiatric and autonomic features. Beyond clinical presentation and imaging, diagnosis relies on detection of GFAP-antibodies (AB) in CSF. Using quantitative behavioral, serologic, and immunohistochemical analyses, we characterize two patients longitudinally over 18-24 months who presented with rapidly progressive neurocognitive deterioration in the context of GFAP-AB in CSF and unremarkable cranial MRI studies. Intensified immunotherapy was associated with clinical stabilization. The value of GFAP-AB screening in selected cases of rapidly progressive dementias is discussed.},
  language  = {en}
}
@phdthesis{Scheytt2013,
  author    = {Scheytt, Sarah},
  title     = {Quantifizierung von GAP 43 positiven intraepidermalen Nervenfasern bei Patienten mit Polyneuropathie und gesunden Kontrollen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-94782},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Polyneuropathien (PNP) sind mit einer Pr{\"a}valenz von bis zu 7\% in der Gesamtbev{\"o}lkerung eine h{\"a}ufige Diagnose. Bei der Ursachenabkl{\"a}rung der PNP hat sich in den letzten Jahren die immunhistochemische Bestimmung der intraepidermalen Nervenfaserdichte aus Hautstanzbiopsien mittels einer axonalen PGP 9.5 F{\"a}rbung etabliert. Ein zus{\"a}tzlicher Marker ist GAP 43 - ein axonales Protein, das von regenerierenden Nervenfasern exprimiert wird. In der vorliegenden Studie wurde die Dichte von PGP 9.5 und GAP 43 positiven Nervenfasern anhand immunhistochemischer F{\"a}rbungen an Hautstanzbiopsien vom lateralen Unter- und Oberschenkel von Patienten mit PNP unterschiedlicher Genese und von gesunden Kontrollen quantifiziert. Wir konnten zeigen, dass PNP Patienten im Vergleich zu Kontrollpersonen deutlich weniger GAP 43 positive Nervenfasern in ihren Hautbiopsien aufweisen. Obwohl sich bei PNP Patienten absolut gesehen weniger GAP 43 positive Nervenfasern fanden, war der Anteil an GAP 43 positiven Nervenfasern im Vergleich zur Kontrollgruppe h{\"o}her, was mit einer gesteigerten regenerativen Aktivit{\"a}t in gesch{\"a}digten Nervenfasern zusammenh{\"a}ngen kann. In der Patienten- und Kontrollgruppe fanden sich mehr PGP 9.5 und GAP 43 positive Nervenfasern am Ober- als am Unterschenkel, was durch die grunds{\"a}tzlich dichtere Innervation proximaler Hautareale bedingt ist und bei PNP Patienten durch den im Krankheitsverslauf typischerweise l{\"a}ngenabh{\"a}ngigen Verlust der peripheren kutanen Innervation noch verst{\"a}rkt wird. Die Analyse potentieller Einflussfaktoren ergab beim Unterschenkel f{\"u}r beide F{\"a}rbungen eine negative Korrelation zwischen Alter und Nervenfaserdichte. Das Geschlecht und das Vorhandensein von Schmerzen hatten keinen Einfluss auf die Hautinnervation. Die Arbeit zeigt anhand des bisher gr{\"o}ßten Patienten- und Kontrollkollektivs, dass regenerierende intraepidermale Nervenfasern mittels einer Immunhistochemie f{\"u}r GAP 43 zuverl{\"a}ssig quantifizierbar sind. Bei k{\"u}nftigen longitudinalen Studien kann nun ein m{\"o}glicher Zusammenhang zwischen der Dichte GAP 43 positiver Nervenfasern und der Prognose bzw. dem Ansprechen auf Therapien untersucht werden.},
  subject      = {Polyneuropathie},
  language  = {de}
}
@phdthesis{Braun2021,
  author    = {Braun, Alexandra},
  title     = {Psychosocial and somatic resilience factors of patients with fibromyalgia syndrome (FMS)},
  doi       = {10.25972/OPUS-24280},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-242809},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Background: In recent years, health care has increasingly become the focus of public interest, politics, health insurance companies, and research. This includes the development of therapeutic concepts that can respond individually to patients' resources in order to improve coping with chronic diseases. Research into psychosocial and biological resilience factors is very important and the basic objective of the present work. I studied patients with fibromyalgia syndrome (FMS), who suffer among others from chronic pain, fatigue, sleep and gastrointestinal problems. This patient cohort is characterized by a pronounced heterogeneity in terms of clinical outcome, degree in disability and coping. FMS has a prevalence of 3 - 8 \% in the Western population and has a significant socio-economic impact. Validated psychosocial resilience factors include optimism, humor, coherence, self-efficacy, awareness with one's own resources and the ability to apply them profitably (coping), and a healthy social environment with positive relationships. Studies in patients with cancer revealed religiosity as positive and negative factor on the health outcome, but there is little data on religious aspects of pain resilience. Various genetic polymorphisms and anti-inflammatory cytokines are known as biological resilience factors. Various microRNA (miRNA) were detected to contribute to resilience in the context of stress and psychiatric disorders. Objective: The underlying research question of this work is to understand the factors that make some FMS patients resilient and others not, even though they suffer from the same disease. The long-term aim was to understand mechanisms and influencing factors of resilience to design preventive and resource-oriented therapies for FMS patients. Material and Methods: Three studies examined religious, physiological, biological, and psychosocial factors which may contribute to resilience in FMS patients. Study one combined data of questionnaires, a psychosocial interview, and regression analyses to investigate the relevance of religiosity for coping and resilience. Study two examined variance explaining factors and defined clusters among FMS patients by their differences in coping, pain phenotype and disability. The factor analysis used variables derived from questionnaires and qPCR of cytokines in white blood samples (WBC) of patients and healthy controls. Study three assessed cluster-wise miRNA signatures which may underly differences in behaviour, emotional and physiological disability, and resilience among patient clusters. A cluster-specific speculative model of a miRNA-mediated regulatory cycle was proposed and its potential targets verified by an online tool. Results: The data from the first study revealed a not very religious patient cohort, which was rather ambivalent towards the institution church, but described itself as a believer. The degree of religiosity played a role in the choice of coping strategy but had no effect on psychological parameters or health outcomes. The coping strategy "reinterpretation", which is closely related iv to the religious coping "reappraisal", had the highest influence on FMS related disability. Cognitive active coping strategies such as reappraisal which belongs to religious coping had the highest effect on FMS related disability (resilience) and could be trained by a therapist. Results from the second study showed high variances of all measured cytokines within the patient group and no difference between patient and control group. The high dispersion indicated cluster among patients. Factor analysis extracted four variance-explaining factors named as affective load, coping, pain, and pro-inflammatory cytokines. Psychological factors such as depression were the most decisive factors of everyday stress in life and represented the greatest influence on the variance of the data. Study two identified four clusters with respective differences in the factors and characterized them as poorly adapted (maladaptive), well adapted (adaptive), vulnerable and resilient. Their naming was based on characteristics of both resilience concepts, indicated by patients who were less stress-sensitive and impaired as a personal characteristic and by patients who emerged as more resilient from a learning and adaptive process. The data from the variance analysis suggests that problem- and emotion-focused coping strategies and a more anti-inflammatory cytokine pattern are associated with low impairment and contribute to resilience. Additional favorable factors include low anxiety, acceptance, and persistence. Some cluster-specific intervention proposals were created that combine existing concepts of behavioral and mindfulness therapies with alternative therapies such as vitamin D supplementation and a healthy intestinal flora. The results of the third study revealed lower relative gene expression of miR103a-3p, miR107, and miR130a-3p in the FMS cohort compared to the healthy controls with a large effect size. The adaptive cluster had the highest gene expression of miR103a-3p and tendentially of miR107, which was correlated with the subscale score "physical abuse" of the trauma questionnaire. Further correlations were found in particular with pain catastrophizing and FMS-related disability. MiR103a-3p and miR107 form a miRNA-family. Based on this, we proposed a miR103a/107 regulated model of an adaptive process to stress, inflammation and pain by targeting genetic factors which are included in different anti-inflammatory and stress-regulating pathways. Conclusion: All three studies provide new insights into resilience in FMS patients. Cognitive coping (reappraisal/reinterpretation) plays a central role and thus offers therapeutic targets (reframing in the context of behavioral therapy). Religosity as a resilience factor was only partially valid for our patient cohort. Basically, the use of resource-oriented therapy in large institutions still requires research and interdisciplinary cooperation to create a consensus between the humanities, natural sciences and humanism.},
  subject      = {Resilienz},
  language  = {en}
}
@phdthesis{Ostertag2023,
  author    = {Ostertag, Viktoria Charlotte Caroline},
  title     = {Pr{\"a}ventive und therapeutische Behandlung mit einem CSF-1-Rezeptorinhibitor bei verschiedenen Charcot-Marie-Tooth Mausmodellen},
  doi       = {10.25972/OPUS-30852},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-308528},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Die Charcot-Marie-Tooth-Neuropathie umfasst eine heterogene Gruppe von erblichen unter anderem demyelinisierenden Erkrankungen des peripheren Nervensystems. Trotz ihrer hohen Pr{\"a}valenz von 1:2.500 gibt es bis dato keine kausalen Therapiem{\"o}glichkeiten. Durch den progressiven Krankheitsverlauf wird die Lebensqualit{\"a}t der Patienten stetig gemindert; der fortschreitende Verlust der Muskelkraft und St{\"o}rungen des Gangbildes sind besonders belastend. Urs{\"a}chlich f{\"u}r die CMT1-Neuropathie sind unter anderem Mutationen in Genen, die f{\"u}r Molek{\"u}le des Myelins von Schwannzellen codieren. Diese Mutationen f{\"u}hren zu einer verminderten Stabilit{\"a}t und Funktion des Myelins und so letzten Endes zu einer Demyelinisierung und axonalen Sch{\"a}digung der peripheren Nerven. Weitere Studien in CMT1-Mausmodellen zeigten jedoch, dass nicht nur die verringerte Myelinstabilit{\"a}t sondern auch eine durch das Immunsystem vermittelte geringgradige Entz{\"u}ndungsreaktion f{\"u}r die Symptome urs{\"a}chlich sein k{\"o}nnte. Hier spielen vor allem Makrophagen eine zentrale Rolle. Das Zytokin CSF-1 aktiviert die Makrophagen und verursacht so eine Demyelinisierung der peripheren Nerven. In P0het und Cx32def Mausmodellen konnte nachgewiesen werden, dass eine medikament{\"o}se Inhibition des CSF-1-Rezeptors an Makrophagen zu einem verbesserten Nervph{\"a}notypen und einer deutlichen Abmilderung des Krankheitsbildes f{\"u}hrte. In dieser Arbeit wurden in P0het und Cx32def Mausmodellen weiterf{\"u}hrende Behandlungsstudien mit einem CSF-1-RI durchgef{\"u}hrt, die untersuchen, zu welchem Zeitpunkt innerhalb des Krankheitsverlaufs (therapeutisch oder pr{\"a}ventiv) eine erfolgreiche Therapie noch m{\"o}glich ist und ob bei einem fr{\"u}heren Beginn eine noch bessere Wirkung erzielt werden kann. Abh{\"a}ngig von den verschiedenen Start- und Endpunkten waren unterschiedliche Ergebnisse zu beobachten: Hinsichtlich der klinischen Parameter wie der Greifkraft und der Anzahl an abnormal innervierten Synapsen zeigten die Tiere im pr{\"a}ventiven Behandlungszweig in beiden Mausmodellen das beste Ergebnis im Vergleich zu den Kontrolltieren. Diese substantielle Verbesserung ließ sich unabh{\"a}ngig von einem Makrophagen-Reflux sogar noch 6 Monate nach Behandlungsabbruch nachweisen. Bez{\"u}glich der endoneuralen Makrophagendepletion war sowohl in den P0het als auch den Cx32def Tieren im pr{\"a}ventiven sowie im therapeutischen Behandlungszweig eine signifikante Verbesserung zu beobachten. Diese Ergebnisse heben ein weiteres Mal die Bedeutung der Makrophagen als Teil einer Entz{\"u}ndungsreaktion in der Pathogenese der CMT1-Neuropathie hervor. Des Weiteren konnte die These gefestigt werden, dass eine Inhibition des CSF-1-Rezeptors zu verbesserten histopathologischen sowie funktionellen Parametern f{\"u}hrt. Um ein gutes Ansprechen auf die Therapie zu erzielen, m{\"u}ssen ein m{\"o}glichst fr{\"u}her Therapiebeginn sowie eine nachhaltige Behandlungsdauer gew{\"a}hrleistet sein.},
  subject      = {Charcot-Marie-Syndrom},
  language  = {de}
}
@phdthesis{Pausch2017,
  author    = {Pausch, Jonas Franz},
  title     = {Pr{\"a}ferentielle Lokalisation von Makrophagen im r{\"a}umlichen Umfeld von Ranvier'schen Schn{\"u}rringen - Morphologische Analysen zur r{\"a}umlichen Verteilung von Makrophagen in Mausmodellen f{\"u}r erbliche Neuropathien},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143801},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {Die Charcot-Marie-Tooth Typ 1 Erkrankungen sind eine genetisch heterogene Gruppe, aktuell nicht kurativ therapierbarer, erblicher Neuropathien des Peripheren Nervensystems. Klinische Manifestationen reichen von Sensibilit{\"a}ts-st{\"o}rungen, verminderten Muskeleigenreflexen, sowie fortschreitenden L{\"a}hmungen, bis hin zu Muskelatrophie und bedeuten f{\"u}r die betroffenen Patienten eine starke Einschr{\"a}nkung der Lebensqualit{\"a}t. Anhand fr{\"u}herer Studien wurde Makrophagen, als Teil des angeborenen Immunsystems, eine entscheidende Rolle in der Pathogenese dreier CMT1-Unterformen zugeschrieben. Abgesehen von den morphologischen Manifestationen der demyelinisierenden CMT1-Erkrankungen, wie simultanes Auftreten von Dedifferenzierung, sowie Hypo-, und Demyelinisierung erkrankter Schwann-Zellen, sind pathologische Ver{\"a}nderungen der Dom{\"a}nengliederung der Ranvier'schen Schn{\"u}rringe betroffener Nervenfasern ebenfalls von der Aktivierung pathogener Makrophagen abh{\"a}ngig. Auf der Basis verschiedener ver{\"o}ffentlichter Studien, welche sowohl demyelinisierende Erkrankungen des ZNS, aber auch prim{\"a}r durch axonale Sch{\"a}den gekennzeichnete Erkrankungen des PNS beinhalten, besteht ein m{\"o}glicher r{\"a}umlicher Zusammenhang zwischen Architekturst{\"o}rungen der RS und aktivierten pathogenen Mikrogliazellen bzw. Makrophagen. In dieser Studie konnte, anhand morphologischer Analysen von peripherem Nervengewebe, in Wt-M{\"a}usen erstmals eine unerwartete pr{\"a}ferentielle Lokalisation von Makrophagen im r{\"a}umlichen Umfeld von RS beobachtet werden. Hierbei scheint, trotz des Fehlens einer direkten Zell-Zell-Interaktion zwischen Makrophagen und RS, vor allem im Hinblick auf die ebenfalls im r{\"a}umlichen Umfeld von RS nachweisbare EZM und Fibroblasten, eine funktionelle Relevanz der assoziierten Makrophagen f{\"u}r die Aufrechterhaltung der Dom{\"a}nengliederung bzw. elektrophysiologischen Eigenschaften myelinisierter peripherer Nervenfasern denkbar. Im Gegensatz dazu wurde trotz der signifikanten Zunahme der Makrophagenanzahlen in den drei untersuchten CMT1-Mausmodellen keine erh{\"o}hte r{\"a}umliche Assoziation mit den RS der mutierten Schwann-Zellen beobachtet. Vielmehr konnten anhand des Vergleiches mit wildtypischen Kontrollm{\"a}usen signifikant erniedrigte Assoziationsraten beider Strukturen in den CMT1-Modelltieren festgestellt werden. Folglich scheint die von der Einwanderung und Aktivierung pathogener Makrophagen abh{\"a}ngige St{\"o}rung der Dom{\"a}nengliederung der RS der mutierten Schwann-Zellen, nicht durch eine direkte Interaktion bzw. r{\"a}umliche Assoziation von Makrophagen mit RS ausgel{\"o}st zu werden.},
  subject      = {Makrophagen},
  language  = {de}
}
@phdthesis{Beaucamp2021,
  author    = {Beaucamp, Marcel},
  title     = {Pr{\"a}diktion des Verschlusses großer intrakranieller Arterien anhand pr{\"a}klinischer Schlaganfallscores},
  doi       = {10.25972/OPUS-21511},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-215117},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {2015 konnte in mehreren Studien ESCAPE, EXTENDED IA, MR CLEAN, REVASCAT, SWIFT-PRIME eine signifikante {\"U}berlegenheit der mechanischen Thrombektomie verglichen mit der alleinigen i. v. Lysetherapie mit rtPA bezogen auf Revaskularisierung bei Patienten mit einer LVO (large vessel occlusion) nachgewiesen werden. Diese neue Therapiem{\"o}glichkeit erforderte eine Aufteilung der Patienten die von einer Thrombektomie profitieren (LVO) und der Patienten, die keiner Thrombektomie zugef{\"u}hrt werden k{\"o}nnen (nLVO). Die zentrale Fragestellung der Studie ist: Kann ein symptomorientierter Schlaganfallscore die Wahrscheinlichkeit eines großen intrakraniellen Gef{\"a}ßverschlusses mit hinreichender Pr{\"a}zision vorhersagen und kann auf Basis dieser Vorhersage ein Patient direkt in ein {\"u}bergeordnetes Schlagfanfallzentrum gebracht werden, obwohl sich dadurch eine Bridging Lysetherapie verz{\"o}gern w{\"u}rde? Um diesen Fragen auf den Grund zu gehen f{\"u}hrten wir eine monozentrische Querschnittstudie durch, in deren Rahmen 215 Patienten rekrutiert wurden. Die Rekrutierung erfolgte mittels eines aus Subitems bereits etablierter Schlafanfallscores (FAST, CPSS, LAPSS, 3ISS, RACE), zusammengesetzten Fragebogens. Die ausgef{\"u}llten Frageb{\"o}gen wurde in Excel digitalisiert und mittels SPSS, Signifikanz und Odds Ratio berechnet. Anschließend wurde aus den signifikanten Subitems mit der h{\"o}chsten Odds Ratio ein neuer einfach anzuwendender Schlaganfallscore, bestehend aus den pr{\"a}klinisch erhobenen Daten gebildet (W{\"u}rzburg Score of Large Vessel Occlusions, WOLVE- Score). Weiter wurden Signifikanz, Odds Ratio, Sensitivit{\"a}t und Spezifit{\"a}t des WOLVE-Score mit denen der oben genannten etablieren Scores verglichen.},
  subject      = {Schlaganfall},
  language  = {de}
}
@phdthesis{Moenter2004,
  author    = {M{\"o}nter, Boris},
  title     = {Protonenempfindlichkeit von Spinalganglienneuronen bei Wildtypm{\"a}usen und Mausmutanten mit einem Mangel an TRPV 1 oder ASIC 3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-10271},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2004},
  abstract  = {In den letzten Jahren wurden große Fortschritte in der Aufkl{\"a}rung von Mechanismen der Protonensensibilit{\"a}t auf molekularer Ebene gemacht, die ein wesentliches Element der Nozizeption darstellt. In dieser Arbeit wurde der Einfluss von den in diesem Zusammenhang entdeckten Kan{\"a}len TRPV1 und ASIC3 auf die Protonensensitivit{\"a}t von nativen Spinalganglienneuronen, sowie Unterschiede zwischen der IB4-positiven und der IB4-negativen Population untersucht. Hierzu wurden Patch-Clamp-Studien an isolierten Neuronen von TRPV1-defizienten und ASIC3-defizienten M{\"a}usen durchgef{\"u}hrt. Die Ergebnisse dieser Experimente best{\"a}tigen dabei die wesentliche Rolle von TRPV1 f{\"u}r die Protonensensibilit{\"a}t. Insbesondere f{\"u}r nicht desensibilisierende Komponenten von protoneninduzierten Str{\"o}men, die f{\"u}r die Transduktion extrazellu{\"a}rer azidotischer Schmerzzust{\"a}nde in eine anhaltende Erregung des nozizeptiven Systems verantwortlich sind, ist TRPV1 von großer Bedeutung. Diese sind in den TRPV1-defizienten Neuronen stark reduziert. Der Einfluss von ASIC3 auf diese Komponenten ist hingegen gering, auch wenn es Hinweise auf eine Beteiligung dieses Rezeptors an diesen Komponenten gibt. Gr{\"o}ßere Bedeutung hat ASIC3 f{\"u}r schnell desensibilisierende Komponenten der Reaktion dieser Neurone auf Protonen, die von ASIC3-defizienten seltener als von Wildtyp-Neuronen gezeigt werden. Die Bedeutung dieser transienten Komponenten ist nicht gekl{\"a}rt, wahrscheinlich erf{\"u}llen sie eine modulatorische Funktion, nicht nur im nozizeptiven System. Noch wenig ist {\"u}ber die funktionellen Unterschiede der zwei verschiedenen Subpopulationen nozizeptiver Neurone bekannt, die durch die Bindung des Isolektins B4 differenziert werden k{\"o}nnen. Diese Arbeit gibt Hinweise darauf, dass sich diese auch in ihrer Protonensensitivit{\"a}t unterscheiden. Das k{\"o}nnte Ausdruck daf{\"u}r sei, dass diese an der Wahrnehmung unterschiedlicher Schmerzzust{\"a}nde beteiligt sind. Die Charakterisierung der Mechanismen des komplexen nozizeptiven Systems auf zellul{\"a}rer und molekularer Ebene ist Vorraussetzung zur Entwicklung von gezielt wirkenden, analgetischen Pharmaka. Die schon lange bekannte Wirksamkeit von Capsaicin - dem wohl bekanntesten Agonisten von TRPV1 - bei verschiedenen schmerzhaften Zust{\"a}nden und fortschreitende Erkenntnisse {\"u}ber die Bedeutung dieses und der ASIC-Rezeptoren bei der Wahrnehmung von schmerzassoziierter Gewebsazidose, zeigt Wege auf, {\"u}ber die solche Medikamente ihre Wirkung entfalten k{\"o}nnten.},
  language  = {de}
}
@phdthesis{Peterka2021,
  author    = {Peterka, Manuel},
  title     = {Propriozeptive St{\"o}rungen bei Morbus Parkinson - Explorative Untersuchungen zu Art, Ausmaß und potenzieller Rekalibrierung mithilfe der LSVT-BIG-Therapie},
  doi       = {10.25972/OPUS-22612},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226129},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Beim idiopathischen Parkinson Syndrom (IPS) gewinnen nicht-motorische Symptome in Forschung und Klinik zunehmend an Bedeutung. So findet sich in der Literatur vermehrt Evidenz, dass die Propriozeption bei Patienten mit IPS (PmIPS) gest{\"o}rt ist. Verschiedene klinische und neuroanatomische Studien weisen darauf hin, dass es beim IPS zu einer fehlerhaften sensomotorischen Integration von propriozeptiven Informationen in den Basalganglien kommt. Zudem gibt es Hinweise, dass die passiv-sensible Wahrnehmung von Propriozeption pathologisch ver{\"a}ndert ist. Außerdem wird vermutet, dass durch propriozeptives Training eine Verbesserung der Parkinsonsymptomatik erreicht werden kann. Ein spezielles Trainingsprogramm, die LSVT-BIG-Therapie, bei der gezielt trainiert wird, Bewegungen mit einer großen Amplitude durchzuf{\"u}hren, konnte motorische Symptome und Mobilit{\"a}t beim IPS effektiv verbessern. In der vorliegenden Arbeit stellten wir folgende Hypothesen auf: Das IPS geht mit einer fehlerhaften sensomotorischen Integration von Propriozeption einher. Die afferente propriozeptive Wahrnehmung ist ebenfalls pathologisch ver{\"a}ndert. Eine propriozeptive Rekalibrierung ist mithilfe der LSVT-BIG-Therapie m{\"o}glich. F{\"u}r die {\"U}berpr{\"u}fung dieser Hypothesen schlossen wir 30 PmIPS und 15 gesunde Probanden in unsere Fall-Kontroll-Studie ein und f{\"u}hrten eine Eingangsuntersuchung durch. 11 PmIPS absolvierten anschließend eine vierw{\"o}chige LSVT-BIG-Therapie. Die Folgeuntersuchungen fanden 4 und 8 Wochen nach der Eingangsuntersuchung statt. 78 Diese beinhalteten neuropsychologische Testungen, außerdem die Bestimmung der Lebensqualit{\"a}t, die Erhebung des motorischen Teils der Movement Disorder Society Unified Parkinson´s Disease Rating Scale (MDS-UPDRS III), Untersuchungen zur Feinmotorik, die Durchf{\"u}hrung einer diagnostischen Transkraniellen Magnetstimulation (TMS) sowie Testverfahren zur Propriozeption, darunter sowohl Zeigeversuche, als auch die Bestimmung der Position einer Extremit{\"a}t, ohne visuelle Kontrolle. Die Ergebnisse zeigten, dass die IPS-Gruppe gegen{\"u}ber der gesunden Kontrollgruppe signifikant gr{\"o}ßere Zeigefehler machte, wohingegen die Bestimmung der Position einer Extremit{\"a}t in beiden Gruppen vergleichbar pr{\"a}zise m{\"o}glich war. Zus{\"a}tzlich zeigte eine von sieben Messungen der Feinmotorik einen signifikanten Unterschied zwischen PmIPS und Kontrollen. Die Messungen der TMS erbrachten hingegen keine signifikant messbaren Unterschiede zwischen den Gruppen. In den Folgeuntersuchungen nach therapeutischer Intervention ergaben die Zeige{\"u}bungen eine signifikante Verbesserung der BIG-Gruppe im Zeitverlauf. Die Untersuchungen zu Feinmotorik und MDS-UPDRS III ergaben zwar eine tendenzielle Verbesserung durch die LSVT-BIG-Therapie, waren jedoch statistisch nicht signifikant. Die Lebensqualit{\"a}t der PmIPS in der BIG-Gruppe verbesserte sich signifikant nach Intervention. Die Ergebnisse sprechen f{\"u}r die Hypothese der fehlerhaften propriozeptiven Integration beim Morbus Parkinson. Dies zeigte sich f{\"u}r aktive sensomotorische Tasks, nicht hingegen in der passiv-sensiblen propriozeptiven Testung. Auch wenn weitere Studien mit gr{\"o}ßeren Kohorten ben{\"o}tigt werden, legt unsere Studie nahe, dass die LSVT-BIG-Therapie mit einer propriozeptiven Rekalibrierung einhergeht. Damit erkl{\"a}rt sich m{\"o}glicherweise der nachhaltige Erfolg der Therapie.},
  subject      = {Propriozeption},
  language  = {de}
}
@article{SteinhardtWiercinskaPhametal.2020,
  author    = {Steinhardt, M. J. and Wiercinska, E. and Pham, M. and Grigoleit, G. U. and Mazzoni, A. and Da-Via, M. and Zhou, X. and Meckel, K. and Nickel, K. and Duell, J. and Krummenast, F. C. and Kraus, S. and Hopkinson, C. and Weissbrich, B. and M{\"u}llges, W. and Stoll, G. and Kort{\"u}m, K. M. and Einsele, H. and Bonig, H. and Rasche, L.},
  title     = {Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes},
  series = {Journal of Translational Medicine},
  volume    = {18},
  journal   = {Journal of Translational Medicine},
  doi       = {10.1186/s12967-020-02337-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229307},
  year      = {2020},
  abstract  = {Background Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due to demyelination. Patients usually present with confusion and seizures. Late diagnosis and lack of adequate therapy options persistently result in permanent impairment of brain functions. Due to profound T cell depletion, impairment of T-cell function and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation recipients are at high risk for JCV reactivation. To date, PML is almost universally fatal when occurring after allo-HCT. Methods To optimize therapy specificity, we enriched JCV specific T-cells out of the donor T-cell repertoire from the HLA-identical, anti-JCV-antibody positive family stem cell donor by unstimulated peripheral apheresis [1]. For this, we selected T cells responsive to five JCV peptide libraries via the Cytokine Capture System technology. It enables the enrichment of JCV specific T cells via identification of stimulus-induced interferon gamma secretion. Results Despite low frequencies of responsive T cells, we succeeded in generating a product containing 20 000 JCV reactive T cells ready for patient infusion. The adoptive cell transfer was performed without complication. Consequently, the clinical course stabilized and the patient slowly went into remission of PML with JCV negative CSF and containment of PML lesion expansion. Conclusion We report for the first time feasibility of generating T cells with possible anti-JCV activity from a seropositive family donor, a variation of virus specific T-cell therapies suitable for the post allo transplant setting. We also present the unusual case for successful treatment of PML after allo-HCT via virus specific T-cell therapy.},
  language  = {en}
}
@phdthesis{Yin2023,
  author    = {Yin, Jing},
  title     = {Progressive alterations of pro- and antidegeneration markers in the nigrostriatal tract of the AAV1/2-A53T-α synuclein rat model of Parkinson's disease},
  doi       = {10.25972/OPUS-26064},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260645},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Neurodegeneration plays an essential role in Parkinson's disease (PD). Several crucial neuronal pro-and antidegeneration markers were described to be altered in disease models accompanied by neurodegeneration. In the AAV1/2-A53T-aSyn PD rat model progressive time-dependent motor impairment and neurodegeneration in the nigrostriatal tract starting from 2 weeks after PD model induction could be found. Downregulation of Nrf2 in SN and nigrostriatal axon localization, a trend of Tau downregulation in SN and upregulation in axon localization in the AAV1/2-A53T-aSyn PD rat model were observed, indicating potential therapeutic value of these two molecular targets in PD. No alterations of SARM1 and NMNAT2 could be detected, indicating little relevance of these two molecules with our AAV1/2-A53T-aSyn rat model.},
  language  = {en}
}
@phdthesis{Pizon2010,
  author    = {Pizon, Dorothea},
  title     = {Prognose des raumfordernden Mediainfarktes bei konservativer vs. operativer Therapie am Universit{\"a}tsklinikum W{\"u}rzburg 1993-2005},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-70232},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {In dieser Studie wurden Schlaganfallpatienten untersucht, die einen ausgedehnten Infarkt im Versorgungsgebiet der A.cerebri media erlitten und wegen Bewusstseinstr{\"u}bung (sog. Maligner Mediainfarkt) auf der Neurologischen Intensivstation des Universit{\"a}tsklinikums W{\"u}rzburg im Zeitraum von 1991 bis 2005 behandelt wurde, um herauszufinden, welchen Einfluss eine operative Behandlung auf den kritisch erh{\"o}hten Hirnsdrucks zus{\"a}tzlich zur konservativen Intensivtherapie auf Mortalit{\"a}t sowie langfristige Lebensqualit{\"a}t hatte. Insgesamt konnten die Daten von 292 Patienten ausgewertet werden, wovon 259 konservativ und 33 operativ behandelt worden waren. Es zeigte sich insgesamt, dass eine stillschweigende g{\"u}nstige Selektion f{\"u}r eine Trepanation sprach (j{\"u}nger, eher keine Aphasie, weniger Komorbidit{\"a}ten). Die Hemikraniektomie senkte die Mortalit{\"a}t in der Akutphase hochsignifikant (K: 22, 4\%, T: 3,0\%; p=0,009). Sie hatte erwartungsgem{\"a}ß auch einen positiven Einfluss auf das Vigilanzniveau: die Quote von wachen Patienten war bei Entlassung der Trepanierten um 66\% h{\"o}her als bei Aufnahme, bei den konservativ Behandelten war sie nur um 33,3 \% gestiegen. Das vorherrschende Symptom bei Aufnahme und Entlassung war eine motorische bzw. sensomotorische Hemiparese. Der Anteil der Aphasiker bei den 201 konservativ therapierten Patienten, die den station{\"a}ren Aufenthalt {\"u}berlebt haben, ist von bei Aufnahme 56,2\% auf bei Entlassung 48,6\% gesunken. Bei den 32 trepanierten Patienten ist er dagegen mit 50\% gleich geblieben, obwohl 2/3 aller Patienten an der nicht-dominanten Hemisph{\"a}re operiert worden waren. Es war und ist auch nicht zu erwarten, dass eine Entlastung von Hirndruck qualitativ die hirninfarktbedingten Symptome beseitigt. Die Nachbefragung der Patienten fand im Schnitt 64,7 Monate nach erlittenem Mediainfarkt statt. Inzwischen waren von den 259 konservativ Behandelten 47,1\% verstorben, von den 33 Hemikraniektomierten nur 24,2\%. Die poststation{\"a}re Mortalit{\"a}t im weiteren Verlauf war anteilsm{\"a}ßig gering (K: 24\%, T: 21,2\%). Die {\"U}berlebensdauer der Trepanierten war dreimal so lang wie die der nicht operierten (K: 11,6 Monate, T: 34,4 Monate). Diese Unterschiede im Langzeit{\"u}berleben sind wahrscheinlicher auf die geringeren Komorbidit{\"a}ten der Trepanierten zur{\"u}ckzuf{\"u}hren, als auf die stattgehabte Operation an sich. Allerdings ist nicht auszuschließen, dass die durch Trepanation fr{\"u}hzeitiger verbesserte Wachheit sich auch g{\"u}nstig auf lebensverk{\"u}rzende Folgekomplikationen ausgewirkt haben k{\"o}nnte. In der Nachbefragung zeigte sich, dass bez{\"u}glich der erworbenen k{\"o}rperlichen Funktionsdefizite, gemessen am Barthel Index, zwischen den beiden Kollektiven kein signifikanter Unterschied bestand. Die ehemals konservativ behandelten Patienten kamen auf durchschnittlich 75, die trepanierten Patienten auf 60 von 100 Punkten. Im Lebensalltag schl{\"a}gt sich dieser Unterschied von 15 Punkten relevant nieder, aber insgesamt liegen beide Patientenkollektive im Bereich einer leichten bis nicht vorhandenen Abh{\"a}ngigkeit. Die vergleichbaren Langzeitdaten von Patienten mit Mediainfarkt liegen in einem {\"a}hnlichen Bereich. Erstmalig werden hier Langzeitdaten solcher Patienten {\"u}ber die Lebensqualit{\"a}t vorgelegt, gemessen mit dem SF-36. Nachvollziehbar zeigte sich ein deutlicher Unterschied zur Lebensqualit{\"a}t der Durchschnittsbev{\"o}lkerung, insbesondere im Bereich der k{\"o}rperlichen Belastbarkeit. F{\"u}r uns unerwartet g{\"u}nstig fielen die Antworten auf der eher psychologischen Ebene aus. Es zeigten sich bei allen Punkten des SF-36 keine signifikanten Unterschiede zwischen dem konservativ behandelten und den hemikraniektomierten Patienten, so dass die Operation als solche keinen eigenst{\"a}ndigen Einfluss auf die langfristige Lebensqualit{\"a}t nahm. Zusammengefasst verbesserte die osteoklastische Trepanation des raumfordernden malignen Mediainfarkts die {\"U}berlebenschance in der Akutphase signifikant, was mit inzwischen publizierten kontrollierten Studienergebnissen {\"u}bereinstimmt. Der Langzeitverlauf nach {\"u}berlebter Akutkrankheit gestaltet sich unabh{\"a}ngig von der Trepanation. Es gibt aufgrund der erworbenen Behinderung eine weiterhin relativ hohe l{\"a}ngerfristige Sterblichkeit. Bemerkenswert ist, dass die Selbsteinsch{\"a}tzung der Lebensqualit{\"a}t von Patienten mit einer erheblichen infarktbedingen k{\"o}rperlichen Behinderung psychologisch-emotional nur geringf{\"u}gig von der Selbstwahrnehmung in der nicht- behinderten Durchschnittsbev{\"o}lkerung. Dass bedeutet, dass Spekulationen {\"u}ber die zuk{\"u}nftige Lebensqualit{\"a}t keinen Einfluss auf die Operationsindikation nehmen sollten.},
  subject      = {Arteria cerebri media},
  language  = {de}
}
@article{GoepfertTraubSelletal.2023,
  author    = {G{\"o}pfert, Dennis and Traub, Jan and Sell, Roxane and Homola, Gy{\"o}rgy A. and Vogt, Marius and Pham, Mirko and Frantz, Stefan and St{\"o}rk, Stefan and Stoll, Guido and Frey, Anna},
  title     = {Profiles of cognitive impairment in chronic heart failure—A cluster analytic approach},
  series = {Frontiers in Human Neuroscience},
  volume    = {17},
  journal   = {Frontiers in Human Neuroscience},
  doi       = {10.3389/fnhum.2023.1126553},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-313429},
  year      = {2023},
  abstract  = {Background Cognitive impairment is a major comorbidity in patients with chronic heart failure (HF) with a wide range of phenotypes. In this study, we aimed to identify and compare different clusters of cognitive deficits. Methods The prospective cohort study "Cognition.Matters-HF" recruited 147 chronic HF patients (aged 64.5 ± 10.8 years; 16.2\% female) of any etiology. All patients underwent extensive neuropsychological testing. We performed a hierarchical cluster analysis of the cognitive domains, such as intensity of attention, visual/verbal memory, and executive function. Generated clusters were compared exploratively with respect to the results of cardiological, neurological, and neuroradiological examinations without correction for multiple testing. Results Dendrogram and the scree plot suggested three distinct cognitive profiles: In the first cluster, 42 patients (28.6\%) performed without any deficits in all domains. Exclusively, the intensity of attention deficits was seen in the second cluster, including 55 patients (37.4\%). A third cluster with 50 patients (34.0\%) was characterized by deficits in all cognitive domains. Age (p = 0.163) and typical clinical markers of chronic HF, such as ejection fraction (p = 0.222), 6-min walking test distance (p = 0.138), NT-proBNP (p = 0.364), and New York Heart Association class (p = 0.868) did not differ between clusters. However, we observed that women (p = 0.012) and patients with previous cardiac valve surgery (p = 0.005) prevailed in the "global deficits" cluster and the "no deficits" group had a lower prevalence of underlying arterial hypertension (p = 0.029). Total brain volume (p = 0.017) was smaller in the global deficit cluster, and serum levels of glial fibrillary acidic protein were increased (p = 0.048). Conclusion Apart from cognitively healthy and globally impaired HF patients, we identified a group with deficits only in the intensity of attention. Women and patients with previous cardiac valve surgery are at risk for global cognitive impairment when suffering HF and could benefit from special multimodal treatment addressing the psychosocial condition.},
  language  = {en}
}
@article{DeebGiordanoRossietal.2016,
  author    = {Deeb, Wissam and Giordano, James J. and Rossi, Peter J. and Mogilner, Alon Y. and Gunduz, Aysegul and Judy, Jack W. and Klassen, Bryan T. and Butson, Christopher R. and Van Horne, Craig and Deny, Damiaan and Dougherty, Darin D. and Rowell, David and Gerhardt, Greg A. and Smith, Gwenn S. and Ponce, Francisco A. and Walker, Harrison C. and Bronte-Stewart, Helen M. and Mayberg, Helen S. and Chizeck, Howard J. and Langevin, Jean-Philippe and Volkmann, Jens and Ostrem, Jill L. and Shute, Jonathan B. and Jimenez-Shahed, Joohi and Foote, Kelly D. and Wagle Shukla, Aparna and Rossi, Marvin A. and Oh, Michael and Pourfar, Michael and Rosenberg, Paul B. and Silburn, Peter A. and de Hemptine, Coralie and Starr, Philip A. and Denison, Timothy and Akbar, Umer and Grill, Warren M. and Okun, Michael S.},
  title     = {Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies},
  series = {Frontiers in Integrative Neuroscience},
  volume    = {10},
  journal   = {Frontiers in Integrative Neuroscience},
  number    = {38},
  doi       = {10.3389/fnint.2016.00038},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-168493},
  year      = {2016},
  abstract  = {This paper provides an overview of current progress in the technological advances and the use of deep brain stimulation (DBS) to treat neurological and neuropsychiatric disorders, as presented by participants of the Fourth Annual DBS Think Tank, which was convened in March 2016 in conjunction with the Center for Movement Disorders and Neurorestoration at the University of Florida, Gainesveille FL, USA. The Think Tank discussions first focused on policy and advocacy in DBS research and clinical practice, formation of registries, and issues involving the use of DBS in the treatment of Tourette Syndrome. Next, advances in the use of neuroimaging and electrochemical markers to enhance DBS specificity were addressed. Updates on ongoing use and developments of DBS for the treatment of Parkinson's disease, essential tremor, Alzheimer's disease, depression, post-traumatic stress disorder, obesity, addiction were presented, and progress toward innovation(s) in closed-loop applications were discussed. Each section of these proceedings provides updates and highlights of new information as presented at this year's international Think Tank, with a view toward current and near future advancement of the field.},
  language  = {en}
}
@phdthesis{Cholewa2005,
  author    = {Cholewa, Ute},
  title     = {Procalcitonin in der Fr{\"u}hdiagnose der bakteriellen Meningitis},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-16490},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {Die Prognose einer lebensbedrohlichen Meningitis wird bestimmt durch m{\"o}glichst erregergerechte und m{\"o}glichst fr{\"u}hzeitige Therapie. Dabei spielt die Unterscheidung zwischen eitriger Meningitis durch typische oder schwer anz{\"u}chtbare Bakterien und abakterieller Meningitis eine Rolle, um die potentiellen Komplikationen unn{\"o}tiger Polypragmasie zu vermeiden. Daher sind m{\"o}glichst einfach und rasch zu bestimmende Laborparameter zur Untersuchung w{\"u}nschenswert. Als relativ neuer Parameter zur Differenzierung bakterieller von nicht bakteriellen Infekten ist Procalcitonin (PCT) eingef{\"u}hrt, dessen Bestimmung jetzt auch am Krankenbett m{\"o}glich ist. PCT hat bisher seine N{\"u}tzlichkeit v. a. in der Sepsiserkennung und -therapie gezeigt. Erste Fragestellung dieser retrospektiven Analyse von Meningoencephalitispatienten war, ob bei Erwachsenen durch Messung des PCT-Spiegels eine Differenzierung zwischen bakterieller oder viraler Genese gelingt, und ob der Bedsidetest so zuverl{\"a}ssig ist wie der aufw{\"a}ndigere LUMItest®. Dazu wurden retrospektiv die Daten von 141 Patienten erhoben, die 1992-2001 an der Neurologischen Universit{\"a}tsklinik W{\"u}rzburg mit gesicherter Meningitis behandelt wurden, von denen sowohl Akten als auch Liquor- und Serumasservate vorlagen, in denen die PCT-Messungen durchgef{\"u}hrt wurden. In den Untersuchungen von Schwarz et al. [102], Gendrel et al. [100] und Jereb et al. [104] wurde bei einem PCT-Grenzwert von 0,5 ng/ml eine Spezifit{\"a}t von 100 \% f{\"u}r die Differenzierung bakterielle verusus abakterielle Meninigitis gefunden. Dagegen w{\"a}ren bei gleicher Messmethodik im hier vorliegendem gr{\"o}ßeren Patientengut 35 \% der gesicherten bakteriellen Meningitiden bei einem „cut-off" von 0,5 ng/ml nicht als solche erkannt worden. 5 \% der nicht-bakteriellen Meningitiden w{\"a}ren mittels PCT-Messung als bakteriell eingestuft worden. Im hier untersuchten Patientenkollektiv hatte PCT als diagnostischer Parameter f{\"u}r diese Fragestellung bei einem Grenzwert von 0,5 ng/ml eine Sensitivit{\"a}t von 65 \% und eine Spezifit{\"a}t von 96 \%. Eine 100 \% Spezifit{\"a}t w{\"a}re in unserer Untersuchung bei einem „cut-off" von 1 ng/ml erreicht worden. Diese Grenze wird jedoch auf dem Schnelltest nicht angegeben. Es stellte sich hier heraus, dass der PCT®-Q Schnelltest im Bereich > 0,5 ng/ml bzw. <0,5 ng/ml dem LUMItest® vergleichbare Ergebnisse lieferte. Das bedeutet zwar, dass alle bakteriellen Meningitiden durch typische Erreger (Meningokokken und Pneumokokken) rasch und sicher bettseitig mittels PCT-Schnelltest h{\"a}tten identifiziert werden k{\"o}nnen. Aber ein niedriger PCT-Wert schloss eine bakterielle Meningitis, insbesondere eine durch „atypische Erreger" wie Listerien und Mycobakterien, nicht sicher aus. Denkbare St{\"o}rgr{\"o}ßen f{\"u}r das vorliegende Ergebnis sind Antibiotikagabe und Immunschw{\"a}che. Ein statistisch auffallender Einfluss einer Antibiotikatherapie auf den PCT-Spiegel konnte in unserem Patientengut nicht festgestellt werden. F{\"u}r die wenigen F{\"a}lle mit anzunehmender verminderter Immunleistung ließ sich keine Regel bez{\"u}glich der PCT-Reaktion ableiten. Damit erscheint der Schnelltest im klinischen Alltag f{\"u}r eine 100\% spezifische, sichere Unterscheidung bakterielle vs. nicht-bakterielle Meniongoencephalitis nicht geeignet; das bisher gr{\"o}ßte untersuchte Kollektiv hat den in der Literatur angegebenen „cut-off" von 0,5 ng/ml f{\"u}r eine sichere Differenzierung nicht best{\"a}tigen k{\"o}nnen. Die zweite Frage ist, ob die Messung des PCT den traditionellen Parametern Liquorzellzahl, Liquoreiweiß, Liquor/Serum-Glucosequotient, BSG, Serumleukozytenzahl oder CRP bez{\"u}glich Spezifit{\"a}t und Sensitivit{\"a}t in der Differentialdiagnose {\"u}berlegen ist. Es zeigte sich, dass CRP bei einem Grenzwert von 5-6 mg/dl mit einer Sensitivit{\"a}t und Spezifit{\"a}t von 95 \% und 98 \% die sicherste Differenzierung zwischen bakterieller und abakterieller Meningitis bei diesem Patientenkollektiv leistete. Mithin kann die PCT-Bestimmung am Krankenbett in der Akutaufnahmesituation eines Patienten mit Meningoencephalitis bei Werten > 10 ng/ml zwar treffsicher die Diagnose einer Meningokokken- oder Pneumokokken-Infektion st{\"u}tzen. F{\"u}r jede dar{\"u}ber hinaus gehende Schlussfolgerung erscheint die PCT-Messung aber entbehrlich wegen mangelhafter Spezifit{\"a}t und Sensitivit{\"a}t und v.a. der Unterlegenheit gegen{\"u}ber traditionell herangezogenen Laborparametern, insbesondere CRP. Folglich erwies sich die Bestimmung des PCT bei akuter Meningoencephalitis als entbehrlich.},
  language  = {de}
}
@article{SaudekCahovaHavrdovaetal.2018,
  author    = {Saudek, František and Cahov{\´a}, Monika and Havrdov{\´a}, Terezie and Zacharovov{\´a}, Kl{\´a}ra and Daňkov{\´a}, Helena and Voska, Luděk and L{\´a}nsk{\´a}, Věra and {\"U}{\c{c}}eyler, Nurcan and Sommer, Claudia},
  title     = {Preserved Expression of Skin Neurotrophic Factors in Advanced Diabetic Neuropathy Does Not Lead to Neural Regeneration despite Pancreas and Kidney Transplantation},
  series = {Journal of Diabetes Research},
  volume    = {2018},
  journal   = {Journal of Diabetes Research},
  number    = {2309108},
  doi       = {10.1155/2018/2309108},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227469},
  pages     = {1-11},
  year      = {2018},
  abstract  = {Diabetic peripheral neuropathy (DPN) is a common complication of diabetes with potential severe consequences. Its pathogenesis involves hyperglycemia-linked mechanisms, which may include changes in the expression of neurotrophic growth factors. We analyzed the expression of 29 factors potentially related to nerve degeneration and regeneration in skin biopsies from 13 type 1 diabetic pancreas and kidney recipients with severe DPN including severe depletion of intraepidermal nerve fibers (IENF) in lower limb skin biopsies (group Tx1 1st examination). The investigation was repeated after a median 28-month period of normoglycemia achieved by pancreas transplantation (group Tx1 2nd examination). The same tests were performed in 13 stable normoglycemic pancreas and kidney recipients 6-12 years posttransplantation (group Tx2), in 12 matched healthy controls (group HC), and in 12 type 1 diabetic subjects without severe DPN (group DM). Compared to DM and HC groups, we found a significantly higher (p < 0.05-0.001) expression of NGF (nerve growth factor), NGFR (NGF receptor), NTRK1 (neurotrophic receptor tyrosine kinase 1), GDNF (glial cell-derived neurotrophic factor), GFRA1 (GDNF family receptor alpha 1), and GFAP (glial fibrillary acidic protein) in both transplant groups (Tx1 and Tx2). Enhanced expression of these factors was not normalized following the median 28-month period of normoglycemia (Tx1 2nd examination) and negatively correlated with IENF density and with electrophysiological indices of DPN (vibration perception threshold, electromyography, and autonomic tests). In contrast to our expectation, the expression of most of 29 selected factors related to neural regeneration was comparable in subjects with severe peripheral nerve fiber depletion and healthy controls and the expression of six factors was significantly upregulated. These findings may be important for better understanding the pathophysiology of nerve regeneration and for the development of intervention strategies.},
  language  = {en}
}
@article{GulbertiMollHameletal.2015,
  author    = {Gulberti, A. and Moll, C.K.E. and Hamel, W. and Buhmann, C. and Koeppen, J.A. and Boelmans, K. and Zittel, S. and Gerloff, C. and Westphal, M. and Schneider, T.R. and Engel, A.K.},
  title     = {Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus Impaired beta-band timing functions in PD},
  series = {NeuroImage: Clinical},
  volume    = {9},
  journal   = {NeuroImage: Clinical},
  doi       = {10.1016/j.nicl.2015.09.013},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-150049},
  pages     = {436-449},
  year      = {2015},
  abstract  = {Cortex-basal ganglia circuits participate in motor timing and temporal perception, and are important for the dynamic configuration of sensorimotor networks in response to exogenous demands. In Parkinson's disease (PD) patients, rhythmic auditory stimulation (RAS) induces motor performance benefits. Hitherto, little is known concerning contributions of the basal ganglia to sensory facilitation and cortical responses to RAS in PD. Therefore, we conducted an EEG study in 12 PD patients before and after surgery for subthalamic nucleus deep brain stimulation (STN-DBS) and in 12 age-matched controls. Here we investigated the effects of levodopa and STN-DBS on resting-state EEG and on the cortical-response profile to slow and fast RAS in a passive-listening paradigm focusing on beta-band oscillations, which are important for auditory-motor coupling. The beta-modulation profile to RAS in healthy participants was characterized by local peaks preceding and following auditory stimuli. In PD patients RAS failed to induce pre-stimulus beta increases. The absence of pre-stimulus beta-band modulation may contribute to impaired rhythm perception in PD. Moreover, post-stimulus beta-band responses were highly abnormal during fast RAS in PD patients. Treatment with levodopa and STN-DBS reinstated a post-stimulus beta-modulation profile similar to controls, while STN-DBS reduced beta-band power in the resting-state. The treatment-sensitivity of beta oscillations suggests that STN-DBS may specifically improve timekeeping functions of cortical beta oscillations during fast auditory pacing.},
  language  = {en}
}
@article{FarinelliPalmisanoMarcheseetal.2020,
  author    = {Farinelli, Veronica and Palmisano, Chiara and Marchese, Silvia Maria and Strano, Camilla Mirella Maria and D'Arrigo, Stefano and Pantaleoni, Chiara and Ardissone, Anna and Nardocci, Nardo and Esposti, Roberto and Cavallari, Paolo},
  title     = {Postural control in children with cerebellar ataxia},
  series = {Applied Sciences},
  volume    = {10},
  journal   = {Applied Sciences},
  number    = {5},
  issn      = {2076-3417},
  doi       = {10.3390/app10051606},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-200692},
  year      = {2020},
  abstract  = {Controlling posture, i.e., governing the ensemble of involuntary muscular activities that manage body equilibrium, represents a demanding function in which the cerebellum plays a key role. Postural activities are particularly important during gait initiation when passing from quiet standing to locomotion. Indeed, several studies used such motor task for evaluating pathological conditions, including cerebellar disorders. The linkage between cerebellum maturation and the development of postural control has received less attention. Therefore, we evaluated postural control during quiet standing and gait initiation in children affected by a slow progressive generalized cerebellar atrophy (SlowP) or non-progressive vermian hypoplasia (Joubert syndrome, NonP), compared to that of healthy children (H). Despite the similar clinical evaluation of motor impairments in NonP and SlowP, only SlowP showed a less stable quiet standing and a shorter and slower first step than H. Moreover, a descriptive analysis of lower limb and back muscle activities suggested a more severe timing disruption in SlowP. Such differences might stem from the extent of cerebellar damage. However, literature reports that during childhood, neural plasticity of intact brain areas could compensate for cerebellar agenesis. We thus proposed that the difference might stem from disease progression, which contrasts the consolidation of compensatory strategies.},
  language  = {en}
}
@article{KleinschnitzGrundWingleretal.2010,
  author    = {Kleinschnitz, Christoph and Grund, Henrike and Wingler, Kirstin and Armitage, Melanie E. and Jones, Emma and Mittal, Manish and Barit, David and Schwarz, Tobias and Geis, Christian and Kraft, Peter and Barthel, Konstanze and Schuhmann, Michael K. and Herrmann, Alexander M. and Meuth, Sven G. and Stoll, Guido and Meurer, Sabine and Schrewe, Anja and Becker, Lore and Gailus-Durner, Valerie and Fuchs, Helmut and Klopstock, Thomas and de Angelis, Martin Hrabe and Jandeleit-Dahm, Karin and Shah, Ajay M. and Weissmann, Norbert and Schmidt, Harald H. H. W.},
  title     = {Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68416},
  year      = {2010},
  abstract  = {Ischemic stroke is the second leading cause of death worldwide. Only one moderately effective therapy exists, albeit with contraindications that exclude 90\% of the patients. This medical need contrasts with a high failure rate of more than 1,000 pre-clinical drug candidates for stroke therapies. Thus, there is a need for translatable mechanisms of neuroprotection and more rigid thresholds of relevance in pre-clinical stroke models. One such candidate mechanism is oxidative stress. However, antioxidant approaches have failed in clinical trials, and the significant sources of oxidative stress in stroke are unknown. We here identify NADPH oxidase type 4 (NOX4) as a major source of oxidative stress and an effective therapeutic target in acute stroke. Upon ischemia, NOX4 was induced in human and mouse brain. Mice deficient in NOX4 (Nox42/2) of either sex, but not those deficient for NOX1 or NOX2, were largely protected from oxidative stress, blood-brain-barrier leakage, and neuronal apoptosis, after both transient and permanent cerebral ischemia. This effect was independent of age, as elderly mice were equally protected. Restoration of oxidative stress reversed the stroke-protective phenotype in Nox42/2 mice. Application of the only validated low-molecular-weight pharmacological NADPH oxidase inhibitor, VAS2870, several hours after ischemia was as protective as deleting NOX4. The extent of neuroprotection was exceptional, resulting in significantly improved long-term neurological functions and reduced mortality. NOX4 therefore represents a major source of oxidative stress and novel class of drug target for stroke therapy.},
  subject      = {Schlaganfall},
  language  = {en}
}
@phdthesis{Kohl2009,
  author    = {Kohl, Bianca Dorothea},
  title     = {PMP22-overexpressing mice as a model for Charcot-Marie-Tooth 1A neuropathy implicate a role of immune-related cells},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-43066},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2009},
  abstract  = {Charcot-Marie-Tooth disease (CMT) is a cohort of human hereditary disorders of the peripheral nervous system (PNS) which exhibit symptoms like sensory dysfunction, muscle weakness and gait disturbances. Different mutations are described as causation for this neuropathy, such as a duplication of chromosome 17 comprising the gene for the peripheral myelin protein-22 (PMP22). Based on different animal models former studies identified immune cells, i.e. macrophages and T-lymphocytes, as crucial mediators of pathology in these neuropathies. In this study, PMP22-overexpressing mice (PMP22tg, C61), serving as a model for a specific type of CMT - CMT1A - were crossbred with immune-deficient mutant mice to examine the impact of the immune system on nerve pathology. Crossbreeding of PMP22tg mice with recombination activating gene-1 (RAG-1) deficient mice, lacking mature T- and B-lymphocytes, caused no striking alterations of pathogenesis in peripheral nerves of mutant mice. In contrast, crossbreeding of PMP22tg myelin mutants with mice deficient in the chemokine monocyte chemoattractant protein-1 (MCP-1, CCL2) caused an amelioration of the demyelinating phenotype of peripheral nerves when MCP-1 was either reduced or completely absent. Furthermore, functional investigations, i.e. neurographic recordings and examinations of the grip strength of the extremities, revealed an amelioration in PMP22tg/MCP-1-/- mice in regard to a symptomatic improvement in the compound action muscle potential (CMAP) and stronger grip strength of the hindlimbs. Interestingly, peripheral nerves of PMP22tg mice showed an irregular distribution of potassium channels in presence of MCP-1, whereas the absence of MCP-1 in the myelin mutants rescued the ion channel distribution and resulted in a more wild type-like phenotype. Having shown the impact of MCP-1 as an important mediator of nerve pathology in PMP22/MCP-1 double mutants, the regulation of this chemokine became an important target for potential treatment strategies. We found that the signaling cascade MEK1/2/ERK1/2 was more strongly activated in peripheral nerves of PMP22tg mice compared to nerves of wild type mice. This activation corresponded to an increase in MCP-1 mRNA expression in peripheral nerves at the same age. Furthermore, a MEK1/2-inhibitor was used in vivo to confirm the regulation of MCP-1 by the MEK1/2/ERK1/2 pathway. After a treatment period of three weeks, a clear reduction of ERK1/2-phosphorylation as well as a reduction of MCP-1 mRNA expression was observed, accompanied by a decline in macrophage number in peripheral nerves of PMP22tg mice. These observations suggest that the expression of MCP-1 is crucial for the neuropathological progression in a mouse model for CMT1A. Therefore, this chemokine could provide a basis for a putative treatment strategy of inherited neuropathies.},
  subject      = {Myelin},
  language  = {en}
}
@article{LueningschroerBinottiDombertetal.2017,
  author    = {L{\"u}ningschr{\"o}r, Patrick and Binotti, Beyenech and Dombert, Benjamin and Heimann, Peter and Perez-Lara, Angel and Slotta, Carsten and Thau-Habermann, Nadine and von Collenberg, Cora R. and Karl, Franziska and Damme, Markus and Horowitz, Arie and Maystadt, Isabelle and F{\"u}chtbauer, Annette and F{\"u}chtbauer, Ernst-Martin and Jablonka, Sibylle and Blum, Robert and {\"U}{\c{c}}eyler, Nurcan and Petri, Susanne and Kaltschmidt, Barbara and Jahn, Reinhard and Kaltschmidt, Christian and Sendtner, Michael},
  title     = {Plekhg5-regulated autophagy of synaptic vesicles reveals a pathogenic mechanism in motoneuron disease},
  series = {Nature Communications},
  volume    = {8},
  journal   = {Nature Communications},
  number    = {678},
  doi       = {10.1038/s41467-017-00689-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-170048},
  year      = {2017},
  abstract  = {Autophagy-mediated degradation of synaptic components maintains synaptic homeostasis but also constitutes a mechanism of neurodegeneration. It is unclear how autophagy of synaptic vesicles and components of presynaptic active zones is regulated. Here, we show that Pleckstrin homology containing family member 5 (Plekhg5) modulates autophagy of synaptic vesicles in axon terminals of motoneurons via its function as a guanine exchange factor for Rab26, a small GTPase that specifically directs synaptic vesicles to preautophagosomal structures. Plekhg5 gene inactivation in mice results in a late-onset motoneuron disease, characterized by degeneration of axon terminals. Plekhg5-depleted cultured motoneurons show defective axon growth and impaired autophagy of synaptic vesicles, which can be rescued by constitutively active Rab26. These findings define a mechanism for regulating autophagy in neurons that specifically targets synaptic vesicles. Disruption of this mechanism may contribute to the pathophysiology of several forms of motoneuron disease.},
  language  = {en}
}
@phdthesis{ZimmermannneePapp2024,
  author    = {Zimmermann [n{\´e}e Papp], Lena},
  title     = {Platelets as modulators of blood-brain barrier disruption and inflammation in the pathophysiology of ischemic stroke},
  doi       = {10.25972/OPUS-30285},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-302850},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Ischemia-reperfusion injury (I/R injury) is a common complication in ischemic stroke (IS) treatment, which is characterized by a paradoxical perpetuation of tissue damage despite the successful re-establishment of vascular perfusion. This phenomenon is known to be facilitated by the detrimental interplay of platelets and inflammatory cells at the vascular interface. However, the spatio-temporal and molecular mechanisms underlying these cellular interactions and their contribution to infarct progression are still incompletely understood. Therefore, this study intended to clarify the temporal mechanisms of infarct growth after cerebral vessel recanalization. The data presented here could show that infarct progression is driven by early blood-brain-barrier perturbation and is independent of secondary thrombus formation. Since previous studies unravelled the secretion of platelet granules as a molecular mechanism of how platelets contribute to I/R injury, special emphasis was placed on the role of platelet granule secretion in the process of barrier dysfunction. By combining an in vitro approach with a murine IS model, it could be shown that platelet α-granules exerted endothelial-damaging properties, whereas their absence (NBEAL2-deficiency) translated into improved microvascular integrity. Hence, targeting platelet α-granules might serve as a novel treatment option to reduce vascular integrity loss and diminish infarct growth despite recanalization. Recent evidence revealed that pathomechanisms underlying I/R injury are already instrumental during large vessel occlusion. This indicates that penumbral tissue loss under occlusion and I/R injury during reperfusion share an intertwined relationship. In accordance with this notion, human observational data disclosed the presence of a neutrophil dominated immune response and local platelet activation and secretion, by the detection of the main components of platelet α-granules, within the secluded vasculature of IS patients. These initial observations of immune cells and platelets could be further expanded within this thesis by flow cytometric analysis of local ischemic blood samples. Phenotyping of immune cells disclosed a yet unknown shift in the lymphocyte population towards CD4+ T cells and additionally corroborated the concept of an immediate intravascular immune response that is dominated by granulocytes. Furthermore, this thesis provides first-time evidence for the increased appearance of platelet-leukocyte-aggregates within the secluded human vasculature. Thus, interfering with immune cells and/or platelets already under occlusion might serve as a potential strategy to diminish infarct expansion and ameliorate clinical outcome after IS.},
  subject      = {Schlaganfall},
  language  = {en}
}
@article{SchuhmannBieberFrankeetal.2021,
  author    = {Schuhmann, Michael K. and Bieber, Michael and Franke, Maximilian and Kollikowski, Alexander M. and Stegner, David and Heinze, Katrin G. and Nieswandt, Bernhard and Pham, Mirko and Stoll, Guido},
  title     = {Platelets and lymphocytes drive progressive penumbral tissue loss during middle cerebral artery occlusion in mice},
  series = {Journal of Neuroinflammation},
  volume    = {18},
  journal   = {Journal of Neuroinflammation},
  number    = {1},
  doi       = {10.1186/s12974-021-02095-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259172},
  pages     = {46},
  year      = {2021},
  abstract  = {Background In acute ischemic stroke, cessation of blood flow causes immediate tissue necrosis within the center of the ischemic brain region accompanied by functional failure in the surrounding brain tissue designated the penumbra. The penumbra can be salvaged by timely thrombolysis/thrombectomy, the only available acute stroke treatment to date, but is progressively destroyed by the expansion of infarction. The underlying mechanisms of progressive infarction are not fully understood. Methods To address mechanisms, mice underwent filament occlusion of the middle cerebral artery (MCAO) for up to 4 h. Infarct development was compared between mice treated with antigen-binding fragments (Fab) against the platelet surface molecules GPIb (p0p/B Fab) or rat immunoglobulin G (IgG) Fab as control treatment. Moreover, Rag1\(^{-/-}\) mice lacking T-cells underwent the same procedures. Infarct volumes as well as the local inflammatory response were determined during vessel occlusion. Results We show that blocking of the platelet adhesion receptor, glycoprotein (GP) Ibα in mice, delays cerebral infarct progression already during occlusion and thus before recanalization/reperfusion. This therapeutic effect was accompanied by decreased T-cell infiltration, particularly at the infarct border zone, which during occlusion is supplied by collateral blood flow. Accordingly, mice lacking T-cells were likewise protected from infarct progression under occlusion. Conclusions Progressive brain infarction can be delayed by blocking detrimental lymphocyte/platelet responses already during occlusion paving the way for ultra-early treatment strategies in hyper-acute stroke before recanalization.},
  language  = {en}
}
@article{KollikowskiPhamMaerzetal.2022,
  author    = {Kollikowski, Alexander M. and Pham, Mirko and M{\"a}rz, Alexander G. and Papp, Lena and Nieswandt, Bernhard and Stoll, Guido and Schuhmann, Michael K.},
  title     = {Platelet Activation and Chemokine Release Are Related to Local Neutrophil-Dominant Inflammation During Hyperacute Human Stroke},
  series = {Translational Stroke Research},
  volume    = {13},
  journal   = {Translational Stroke Research},
  number    = {3},
  issn      = {1868-601X},
  doi       = {10.1007/s12975-021-00938-w},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-270194},
  pages     = {364-369},
  year      = {2022},
  abstract  = {Experimental evidence has emerged that local platelet activation contributes to inflammation and infarct formation in acute ischemic stroke (AIS) which awaits confirmation in human studies. We conducted a prospective observational study on 258 consecutive patients undergoing mechanical thrombectomy (MT) due to large-vessel-occlusion stroke of the anterior circulation (08/2018-05/2020). Intraprocedural microcatheter aspiration of 1 ml of local (occlusion condition) and systemic arterial blood samples (self-control) was performed according to a prespecified protocol. The samples were analyzed for differential leukocyte counts, platelet counts, and plasma levels of the platelet-derived neutrophil-activating chemokine C-X-C-motif ligand (CXCL) 4 (PF-4), the neutrophil attractant CXCL7 (NAP-2), and myeloperoxidase (MPO). The clinical-biological relevance of these variables was corroborated by specific associations with molecular-cellular, structural-radiological, hemodynamic, and clinical-functional parameters. Seventy consecutive patients fulfilling all predefined criteria entered analysis. Mean local CXCL4 (+ 39\%: 571 vs 410 ng/ml, P = .0095) and CXCL7 (+ 9\%: 693 vs 636 ng/ml, P = .013) concentrations were higher compared with self-controls. Local platelet counts were lower (- 10\%: 347,582 vs 383,284/µl, P = .0052), whereas neutrophil counts were elevated (+ 10\%: 6022 vs 5485/µl, P = 0.0027). Correlation analyses revealed associations between local platelet and neutrophil counts (r = 0.27, P = .034), and between CXCL7 and MPO (r = 0.24, P = .048). Local CXCL4 was associated with the angiographic degree of reperfusion following recanalization (r =  - 0.2523, P = .0479). Functional outcome at discharge correlated with local MPO concentrations (r = 0.3832, P = .0014) and platelet counts (r = 0.288, P = .0181). This study provides human evidence of cerebral platelet activation and platelet-neutrophil interactions during AIS and points to the relevance of per-ischemic thrombo-inflammatory mechanisms to impaired reperfusion and worse functional outcome following recanalization.},
  language  = {en}
}
@article{GschmackMonoranuMaroufetal.2022,
  author    = {Gschmack, Eva and Monoranu, Camelia-Maria and Marouf, Hecham and Meyer, Sarah and Lessel, Lena and Idris, Raja and Berg, Daniela and Maetzler, Walter and Steigerwald, Frank and Volkmann, Jens and Gerlach, Manfred and Riederer, Peter and Koutsilieri, Eleni and Scheller, Carsten},
  title     = {Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease},
  series = {Journal of Neural Transmission},
  volume    = {129},
  journal   = {Journal of Neural Transmission},
  number    = {5-6},
  doi       = {10.1007/s00702-022-02495-4},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325161},
  pages     = {545-555},
  year      = {2022},
  abstract  = {Idiopathic Parkinson's disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus-subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood-brain barrier.},
  language  = {en}
}
@article{BellingerAltenmuellerVolkmann2017,
  author    = {Bellinger, Daniel and Altenm{\"u}ller, Eckart and Volkmann, Jens},
  title     = {Perception of time in music in patients with Parkinson's disease - The processing of musical syntax compensates for rhythmic deficits},
  series = {Frontiers in Neuroscience},
  volume    = {11},
  journal   = {Frontiers in Neuroscience},
  doi       = {10.3389/fnins.2017.00068},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171805},
  year      = {2017},
  abstract  = {Objective: Perception of time as well as rhythm in musical structures rely on complex brain mechanisms and require an extended network of multiple neural sources. They are therefore sensitive to impairment. Several psychophysical studies have shown that patients with Parkinson's disease (PD) have deficits in perceiving time and rhythms due to a malfunction of the basal ganglia (BG) network. Method: In this study we investigated the time perception of PD patients during music perception by assessing their just noticeable difference (JND) in the time perception of a complex musical Gestalt. We applied a temporal discrimination task using a short melody with a clear beat-based rhythm. Among the subjects, 26 patients under L-Dopa administration and 21 age-matched controls had to detect an artificially delayed time interval in the range between 80 and 300 ms in the middle of the musical period. We analyzed the data by (a) calculating the detection threshold directly, (b) by extrapolating the JNDs, (c) relating it to musical expertise. Results: Patients differed from controls in the detection of time-intervals between 220 and 300 ms (*p = 0.0200, n = 47). Furthermore, this deficit depended on the severity of the disease (*p = 0.0452; n = 47). Surprisingly, PD patients did not show any deficit of their JND compared to healthy controls, although the results showed a trend (*p = 0.0565, n = 40). Furthermore, no significant difference of the JND was found according to the severity of the disease. Additionally, musically trained persons seemed to have lower thresholds in detecting deviations in time and syntactic structures of music (*p = 0.0343, n = 39). Conclusion: As an explanation of these results, we would like to propose the hypothesis of a time-syntax-congruency in music perception suggesting that processing of time and rhythm is a Gestalt process and that cortical areas involved in processing of musical syntax may compensate for impaired BG circuits that are responsible for time processing and rhythm perception. This mechanism may emerge more strongly as the deficits in time processing and rhythm perception progress. Furthermore, we presume that top-down-bottom-up-processes interfere additionally and interact in this context of compensation.},
  language  = {en}
}
@article{BieniussaKahramanSkornickaetal.2022,
  author    = {Bieniussa, Linda and Kahraman, Baran and Skornicka, Johannes and Schulte, Annemarie and Voelker, Johannes and Jablonka, Sibylle and Hagen, Rudolf and Rak, Kristen},
  title     = {Pegylated insulin-like growth factor 1 attenuates hair cell loss and promotes presynaptic maintenance of medial olivocochlear cholinergic fibers in the cochlea of the progressive motor neuropathy mouse},
  series = {Frontiers in Neurology},
  volume    = {13},
  journal   = {Frontiers in Neurology},
  issn      = {1664-2295},
  doi       = {10.3389/fneur.2022.885026},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-276669},
  year      = {2022},
  abstract  = {The progressive motor neuropathy (PMN) mouse is a model of an inherited motor neuropathy disease with progressive neurodegeneration. Axon degeneration associates with homozygous mutations of the TBCE gene encoding the tubulin chaperone E protein. TBCE is responsible for the correct dimerization of alpha and beta-tubulin. Strikingly, the PMN mouse also develops a progressive hearing loss after normal hearing onset, characterized by degeneration of the auditory nerve and outer hair cell (OHC) loss. However, the development of this neuronal and cochlear pathology is not fully understood yet. Previous studies with pegylated insulin-like growth factor 1 (peg-IGF-1) treatment in this mouse model have been shown to expand lifespan, weight, muscle strength, and motor coordination. Accordingly, peg-IGF-1 was evaluated for an otoprotective effect. We investigated the effect of peg-IGF-1 on the auditory system by treatment starting at postnatal day 15 (p15). Histological analysis revealed positive effects on OHC synapses of medial olivocochlear (MOC) neuronal fibers and a short-term attenuation of OHC loss. Peg-IGF-1 was able to conditionally restore the disorganization of OHC synapses and maintain the provision of cholinergic acetyltransferase in presynapses. To assess auditory function, frequency-specific auditory brainstem responses and distortion product otoacoustic emissions were recorded in animals on p21 and p28. However, despite the positive effect on MOC fibers and OHC, no restoration of hearing could be achieved. The present work demonstrates that the synaptic pathology of efferent MOC fibers in PMN mice represents a particular form of "efferent auditory neuropathy." Peg-IGF-1 showed an otoprotective effect by preventing the degeneration of OHCs and efferent synapses. However, enhanced efforts are needed to optimize the treatment to obtain detectable improvements in hearing performances.},
  language  = {en}
}
@article{BrandtZimmermannKaufholdetal.2012,
  author    = {Brandt, Alexander U. and Zimmermann, Hanna and Kaufhold, Falko and Promesberger, Julia and Schippling, Sven and Finis, David and Aktas, Orhan and Geis, Christian and Ringelstein, Marius and Ringelstein, E. Bernd and Hartung, Hans-Peter and Paul, Friedemann and Kleffner, Ilka and D{\"o}rr, Jan},
  title     = {Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS},
  series = {PLoS One},
  volume    = {7},
  journal   = {PLoS One},
  number    = {6},
  doi       = {10.1371/journal.pone.0038741},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134013},
  pages     = {e38741},
  year      = {2012},
  abstract  = {Susac syndrome, a rare but probably underdiagnosed combination of encephalopathy, hearing loss, and visual deficits due to branch retinal artery occlusion of unknown aetiology has to be considered as differential diagnosis in various conditions. Particularly, differentiation from multiple sclerosis is often challenging since both clinical presentation and diagnostic findings may overlap. Optical coherence tomography is a powerful and easy to perform diagnostic tool to analyse the morphological integrity of retinal structures and is increasingly established to depict characteristic patterns of retinal pathology in multiple sclerosis. Against this background we hypothesised that differential patterns of retinal pathology facilitate a reliable differentiation between Susac syndrome and multiple sclerosis. In this multicenter cross-sectional observational study optical coherence tomography was performed in nine patients with a definite diagnosis of Susac syndrome. Data were compared with age-, sex-, and disease duration-matched relapsing remitting multiple sclerosis patients with and without a history of optic neuritis, and with healthy controls. Using generalised estimating equation models, Susac patients showed a significant reduction in either or both retinal nerve fibre layer thickness and total macular volume in comparison to both healthy controls and relapsing remitting multiple sclerosis patients. However, in contrast to the multiple sclerosis patients this reduction was not distributed over the entire scanning area but showed a distinct sectorial loss especially in the macular measurements. We therefore conclude that patients with Susac syndrome show distinct abnormalities in optical coherence tomography in comparison to multiple sclerosis patients. These findings recommend optical coherence tomography as a promising tool for differentiating Susac syndrome from MS.},
  language  = {en}
}
@article{KarlWussmannKressetal.2019,
  author    = {Karl, Franziska and Wußmann, Maximiliane and Kreß, Luisa and Malzacher, Tobias and Fey, Phillip and Groeber-Becker, Florian and {\"U}{\c{c}}eyler, Nurcan},
  title     = {Patient-derived in vitro skin models for investigation of small fiber pathology},
  series = {Annals of Clinical and Translational Neurology},
  volume    = {6},
  journal   = {Annals of Clinical and Translational Neurology},
  number    = {9},
  doi       = {10.1002/acn3.50871},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201649},
  pages     = {1797-1806},
  year      = {2019},
  abstract  = {Objective To establish individually expandable primary fibroblast and keratinocyte cultures from 3-mm skin punch biopsies for patient-derived in vitro skin models to investigate of small fiber pathology. Methods We obtained 6-mm skin punch biopsies from the calf of two patients with small fiber neuropathy (SFN) and two healthy controls. One half (3 mm) was used for diagnostic intraepidermal nerve fiber density (IENFD). From the second half, we isolated and cultured fibroblasts and keratinocytes. Cells were used to generate patient-derived full-thickness three-dimensional (3D) skin models containing a dermal and epidermal component. Cells and skin models were characterized morphologically, immunocyto- and -histochemically (vimentin, cytokeratin (CK)-10, CK 14, ki67, collagen1, and procollagen), and by electrical impedance. Results Distal IENFD was reduced in the SFN patients (2 fibers/mm each), while IENFD was normal in the controls (8 fibers/mm, 7 fibers/mm). Two-dimensional (2D) cultured skin cells showed normal morphology, adequate viability, and proliferation, and expressed cell-specific markers without relevant difference between SFN patient and healthy control. Using 2D cultured fibroblasts and keratinocytes, we obtained subject-derived 3D skin models. Morphology of the 3D model was analogous to the respective skin biopsy specimens. Both, the dermal and the epidermal layer carried cell-specific markers and showed a homogenous expression of extracellular matrix proteins. Interpretation Our protocol allows the generation of disease-specific 2D and 3D skin models, which can be used to investigate the cross-talk between skin cells and sensory neurons in small fiber pathology.},
  language  = {en}
}
@phdthesis{Knorr2024,
  author    = {Knorr, Susanne},
  title     = {Pathophysiology of early-onset isolated dystonia in a DYT-TOR1A rat model with trauma-induced dystonia-like movements},
  doi       = {10.25972/OPUS-20609},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-206096},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Early-onset torsion dystonia (DYT-TOR1A, DYT1) is an inherited hyperkinetic movement disorder caused by a mutation of the TOR1A gene encoding the torsinA protein. DYT-TOR1A is characterized as a network disorder of the central nervous system (CNS), including predominantly the cortico-basal ganglia-thalamo-cortical loop resulting in a severe generalized dystonic phenotype. The pathophysiology of DYTTOR1A is not fully understood. Molecular levels up to large-scale network levels of the CNS are suggested to be affected in the pathophysiology of DYT-TOR1A. The reduced penetrance of 30\% - 40\% indicates a gene-environmental interaction, hypothesized as "second hit". The lack of appropriate and phenotypic DYT-TOR1A animal models encouraged us to verify the "second hit" hypothesis through a unilateral peripheral nerve trauma of the sciatic nerve in a transgenic asymptomatic DYT-TOR1A rat model (∆ETorA), overexpressing the human mutated torsinA protein. In a multiscale approach, this animal model was characterized phenotypically and pathophysiologically. Nerve-injured ∆ETorA rats revealed dystonia-like movements (DLM) with a partially generalized phenotype. A physiomarker of human dystonia, describing increased theta oscillation in the globus pallidus internus (GPi), was found in the entopeduncular nucleus (EP), the rodent equivalent to the human GPi, of nerve-injured ∆ETorA rats. Altered oscillation patterns were also observed in the primary motor cortex. Highfrequency stimulation (HFS) of the EP reduced DLM and modulated altered oscillatory activity in the EP and primary motor cortex in nerve-injured ∆ETorA rats. Moreover, the dopaminergic system in ∆ETorA rats demonstrated a significant increased striatal dopamine release and dopamine turnover. Whole transcriptome analysis revealed differentially expressed genes of the circadian clock and the energy metabolism, thereby pointing towards novel, putative pathways in the pathophysiology of DYTTOR1A dystonia. In summary, peripheral nerve trauma can trigger DLM in genetically predisposed asymptomatic ΔETorA rats leading to neurobiological alteration in the central motor network on multiple levels and thereby supporting the "second hit" hypothesis. This novel symptomatic DYT-TOR1A rat model, based on a DYT-TOR1A genetic background, may prove as a valuable chance for DYT-TOR1A dystonia, to further investigate the pathomechanism in more detail and to establish new treatment strategies.},
  subject      = {Dystonie},
  language  = {en}
}
@phdthesis{Reymann2016,
  author    = {Reymann, Stephan Andreas},
  title     = {Pathophysiologische Rolle und therapeutische Relevanz von Plasmakallikrein beim experimentellen Schlaganfall},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135834},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2016},
  abstract  = {Die Rolle thromboinflammatorischer Vorg{\"a}nge in der Pathogenese des isch{\"a}mischen Schlaganfalls ist in den letzten Jahren immer mehr in den wissenschaftlichen Fokus ger{\"u}ckt. Plasmakallikrein (PK) spaltet von hochmolekularem Kininogen (KNG) Bradykinin (BK) ab und ist dadurch Ausgangspunkt des proinflammatorischen Kallikrein-Kinin-Systems (KKS). Zum anderen kann es den Gerinnungsfaktor XII (FXII) aktivieren, den Ausgangspunkt der intrinsischen Gerinnungskaskade. Es initiiert also sowohl inflammatorische als auch thrombotische Vorg{\"a}nge. Daher wurde in dieser Arbeit der Effekt einer Blockade PKs in einem Mausmodell der fokalen zerebralen Isch{\"a}mie untersucht - und zwar sowohl durch genetische Depletion als auch durch pharmakologische Blockade. Beide Ans{\"a}tze brachten einen nachhaltigen protektiven Effekt in Bezug auf Infarktgr{\"o}ßen und funktionelles Outcome, ohne die Blutungsgefahr zu erh{\"o}hen.},
  subject      = {Plasmakallikrein},
  language  = {de}
}
@phdthesis{Ritter2013,
  author    = {Ritter, Christian},
  title     = {Pathomechanismen von Antik{\"o}rpern gegen Aquaporin 4 in einem Tiermodell f{\"u}r die Neuromyelitis Optica},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-85526},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Die Neuromyelitis Optica (NMO) ist eine schwerwiegende autoimmune Erkrankung des zentralen Nervensystems (ZNS), die mit rezidivierenden Optikusneuritiden und Querschnittsmyelitiden einhergeht. Als serologischer Biomarker wurden Autoantik{\"o}rper gegen Aquaporin 4 (anti-AQP4-AK) identifiziert. Mit Hilfe eines passiv-Transfer Rattenmodelles mit implantierten intrathekalen Kathetern wurden aufgereinigte IgG Fraktionen (NMO-IgG) von Plasmapheresematerial anti-AQP4-AK positiver NMO Patienten verabreicht. Zum Nachweis der Antigen-Spezifit{\"a}t wurden in weiteren Versuchsgruppen rekombinante IgG-AK gegen AQP4 appliziert. Die repetitive Injektion von NMO-IgG oder anti-AQP4-AK f{\"u}hrte zu einer signifikanten klinischen Verschlechterung und einer reduzierten motorischen Leistungsf{\"a}higkeit der Versuchstiere im Vergleich zu Kontrollen. Mittels Magnetresonanztomographie konnten exemplarisch Kontrastmittel-aufnehmende L{\"a}sionsareale im R{\"u}ckenmark der Versuchstiere im Bereich der Katheterspitze detektiert werden. Histopathologisch zeigte sich in diesen L{\"a}sionsbereichen eine Anreicherung von intrathekal applizierten humanen IgG, ein Verlust der Expression von AQP4 und des Glutamattransporters EAAT2. Im Gegensatz zu der bisher bekannten, Komplement-induzierten Gewebedestruktion bei NMO-Patienten mit entz{\"u}ndlichen L{\"a}sionen wurde hier keine Depletion von Astrozyten oder Komplementaktivierung beobachtet. Stattdessen kam es in den hier beschriebenen Arealen mit IgG-Ablagerung zu einer Hypertrophie und Vermehrung der GFAP-positiven Astrozyten. Die Ergebnisse lassen auf eine pathophysiologisch relevante, intrinsische und komplement-unabh{\"a}ngige Wirkung von anti-AQP4-AK schließen.},
  subject      = {Autoantik{\"o}rper},
  language  = {de}
}
@phdthesis{Groh2013,
  author    = {Groh, Janos Michael},
  title     = {Pathogenic impact of immune cells in mouse models of neuronal ceroid lipofuscinosis},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-77684},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {The neuronal ceroid lipofuscinoses (NCLs) are fatal neurodegenerative disorders in which the visual system is affected in early stages of disease. A typical accompanying feature is neuroinflammation, the pathogenic impact of which is presently unknown. In this study, the role of inflammatory cells in the pathogenesis was investigated in Palmitoyl-protein thioesterase 1-deficient (Ppt1-/-) and Ceroidlipofuscinosis, neuronal 3-deficient (Cln3-/-) mice, models of the infantile and juvenile forms of NCL, respectively. Focusing predominantly on the visual system, an infiltration of CD8+ cytotoxic Tlymphocytes and an activation of microglia/macrophage-like cells was observed early in disease. To analyze the pathogenic impact of lymphocytes, Ppt1-/- mice were crossbred with mice lacking lymphocytes (Rag1-/-) and axonal transport, perturbation and neuronal survival were scored. Lack of lymphocytes led to a significant amelioration of neuronal disease and reconstitution experiments revealed a crucial role of CD8+ cytotoxic T-lymphocytes. Lack of lymphocytes also caused an improved clinical phenotype and extended longevity. To investigate the impact of microglia/macrophage-like cells, Ppt1-/- and Cln3-/- mice were crossbred with mice lacking sialoadhesin (Sn-/-), a monocyte lineage-restricted cell adhesion molecule important for interactions between macrophage-like cells and lymphocytes. Similar to the lack of lymphocytes, absence of sialoadhesin significantly ameliorated the disease in Ppt1-/- and Cln3-/- mice. Taken together, both T-lymphocytes and microglia/macrophage-like cells were identified as pathogenic mediators in two distinct forms of fatal inherited neurodegenerative storage disorders. These studies expand the concept of secondary inflammation as a common pathomechanistic feature in some neurological diseases and provide novel insights that may be crucial for developing treatment strategies for different forms of NCL.},
  subject      = {Nervendegeneration},
  language  = {en}
}
@article{WolfBraunHainingetal.2016,
  author    = {Wolf, Karen and Braun, Attila and Haining, Elizabeth J. and Tseng, Yu-Lun and Kraft, Peter and Schuhmann, Michael K. and Gotru, Sanjeev K. and Chen, Wenchun and Hermanns, Heike M. and Stoll, Guido and Lesch, Klaus-Peter and Nieswandt, Bernhard},
  title     = {Partially Defective Store Operated Calcium Entry and Hem(ITAM) Signaling in Platelets of Serotonin Transporter Deficient Mice},
  series = {PLoS One},
  volume    = {11},
  journal   = {PLoS One},
  number    = {1},
  doi       = {10.1371/journal.pone.0147664},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146399},
  pages     = {e0147664},
  year      = {2016},
  abstract  = {Background Serotonin (5-hydroxytryptamin, 5-HT) is an indolamine platelet agonist, biochemically derived from tryptophan. 5-HT is secreted from the enterochromaffin cells into the gastrointestinal tract and blood. Blood 5-HT has been proposed to regulate hemostasis by acting as a vasoconstrictor and by triggering platelet signaling through 5-HT receptor 2A (5HTR2A). Although platelets do not synthetize 5-HT, they take 5-HT up from the blood and store it in their dense granules which are secreted upon platelet activation. Objective To identify the molecular composite of the 5-HT uptake system in platelets and elucidate the role of platelet released 5-HT in thrombosis and ischemic stroke. Methods: 5-HT transporter knockout mice (5Htt\(^{-/-}\)) were analyzed in different in vitro and in vivo assays and in a model of ischemic stroke. Results In 5Htt\(^{-/-}\) platelets, 5-HT uptake from the blood was completely abolished and agonist-induced Ca2+ influx through store operated Ca\(^{2+}\) entry (SOCE), integrin activation, degranulation and aggregation responses to glycoprotein VI (GPVI) and C-type lectin-like receptor 2 (CLEC-2) were reduced. These observed in vitro defects in 5Htt\(^{-/-}\) platelets could be normalized by the addition of exogenous 5-HT. Moreover, reduced 5-HT levels in the plasma, an increased bleeding time and the formation of unstable thrombi were observed ex vivo under flow and in vivo in the abdominal aorta and carotid artery of 5Htt\(^{-/-}\) mice. Surprisingly, in the transient middle cerebral artery occlusion (tMCAO) model of ischemic stroke 5Htt\(^{-/-}\) mice showed nearly normal infarct volume and the neurological outcome was comparable to control mice. Conclusion Although secreted platelet 5-HT does not appear to play a crucial role in the development of reperfusion injury after stroke, it is essential to amplify the second phase of platelet activation through SOCE and plays an important role in thrombus stabilization.},
  language  = {en}
}
@phdthesis{Pozzi2020,
  author    = {Pozzi, Nicol{\´o} Gabriele},
  title     = {Parkinson's disease revisited: multiple circuitopathies},
  doi       = {10.25972/OPUS-21671},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-216715},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Parkinson's disease (PD) is among the most common neurodegenerative conditions, and it is characterized by the progressive loss of dopaminergic neurons and a great variability in clinical expression. Despite several effective medications, it still causes disability as all patients show treatment-resistant symptoms and complications. A possible reason for this therapeutic-burden and great clinical variability lies in a probable misconception about its pathophysiology, one that focuses on neurodegeneration, while largely neglecting its functional consequences and the related compensatory changes. In this thesis, I expand on the hypothesis that some PD symptoms have a dysfunctional origin and reflect derangements of neural network dynamics, the means by which brain coordination supports any motor behaviour. In particular, I have investigated resting tremor and freezing of gait, two common symptoms with an enigmatic mechanism and suboptimal management. In the case of tremor, I predicted a pathological change in response to dopamine loss, which included the activation of noradrenergic (NA) neurons of the locus coeruleus (LC) projecting to the cerebellum. This compensatory LC activation that supports dopaminergic neurons might indeed come at the expense of tremor development. To assess the role of LC-NA in tremor development, I recorded tremor occurrence in the reserpinized rat model of PD, one of very few showing tremor, after selective lesioning (with the neurotoxin DSP-4) of the LC-NA terminal axons. DSP-4 induced a severe reduction of LC-NA terminal axons in the cerebellar cortex and this was associated with a significant reduction in tremor development. Unlike its development, tremor frequency and the akinetic rigid signs did not differ between the groups, thus suggesting a dopaminergic dependency. These findings suggest that the LC-NA innervation of the cerebellum has a critical role for PD tremor, possibly by exerting a network effect, which gates the cerebello-thalamic-cortical circuit into pathological oscillations upon a dopaminergic loss in the basal ganglia. In contrast, for the study of freezing of gait, I worked with human PD subjects and deep brain stimulation, a therapeutic neuromodulation device that in some prototypes also allows the recording of neural activity in freely-moving subjects. Gait freezing is a disabling PD symptom that suddenly impairs effective stepping, thus causing falls and disability. Also in this study, I hypothesized that the underlying pathophysiology may be represented by dysfunctional neural network dynamics that abruptly impair locomotor control by affecting the communication in the supraspinal locomotor network. To test this hypothesis, I investigated the coupling between the cortex and the subthalamic nucleus, two main nodes of the supraspinal locomotor network, in freely-moving subjects PD patients and also performed molecular brain imaging of striatal dopamine receptor density and kinematic measurements. I found that in PD patients, walking is associated with cortical-subthalamic stable coupling in a low-frequency band (i.e. θ-α rhythms). In contrast, these structures decoupled when gait freezing occurred in the brain hemisphere with less dopaminergic innervation. These findings suggest that freezing of gait is a "circuitopathy", with dysfunctional cortical-subcortical communication. Altogether the results of my experiments support the hypothesis that the pathophysiology of PD goes beyond neurodegenerative (loss-of-function) processes and that derangement of neural network dynamics coincides with some disabling PD symptoms, thus suggesting that PD can be interpreted as the combination of multiple circuitopathies.},
  subject      = {Parkinson-Krankheit},
  language  = {en}
}
@article{MencacciIsaiasReichetal.2014,
  author    = {Mencacci, Niccol{\´o} E. and Isaias, Ioannis U. and Reich, Martin M. and Ganos, Christos and Plagnol, Vincent and Polke, James M. and Bras, Jose and Hersheson, Joshua and Stamelou, Maria and Pittman, Alan M. and Noyce, Alastair J. and Mok, Kin Y. and Opladen, Thomas and Kunstmann, Erdmute and Hodecker, Sybille and M{\"u}nchau, Alexander and Volkmann, Jens and Samnick, Samuel and Sidle, Katie and Nanji, Tina and Sweeney, Mary G. and Houlden, Henry and Batla, Amit and Zecchinelli, Anna L. and Pezzoli, Gianni and Marotta, Giorgio and Lees, Andrew and Alegria, Paulo and Krack, Paul and Cormier-Dequaire, Florence and Lesage, Suzanne and Brice, Alexis and Heutink, Peter and Gasser, Thomas and Lubbe, Steven J. and Morris, Huw R. and Taba, Pille and Koks, Sulev and Majounie, Elisa and Gibbs, J. Raphael and Singleton, Andrew and Hardy, John and Klebe, Stephan and Bhatia, Kailash P. and Wood, Nicholas W.},
  title     = {Parkinson's disease in GTP cyclohydrolase 1 mutation carriers},
  series = {Brain},
  volume    = {137},
  journal   = {Brain},
  number    = {9},
  doi       = {10.1093/brain/awu179},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121268},
  pages     = {2480-92},
  year      = {2014},
  abstract  = {GTP cyclohydrolase 1, encoded by the GCH1 gene, is an essential enzyme for dopamine production in nigrostriatal cells. Loss-of-function mutations in GCH1 result in severe reduction of dopamine synthesis in nigrostriatal cells and are the most common cause of DOPA-responsive dystonia, a rare disease that classically presents in childhood with generalized dystonia and a dramatic long-lasting response to levodopa. We describe clinical, genetic and nigrostriatal dopaminergic imaging ([(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane single photon computed tomography) findings of four unrelated pedigrees with DOPA-responsive dystonia in which pathogenic GCH1 variants were identified in family members with adult-onset parkinsonism. Dopamine transporter imaging was abnormal in all parkinsonian patients, indicating Parkinson's disease-like nigrostriatal dopaminergic denervation. We subsequently explored the possibility that pathogenic GCH1 variants could contribute to the risk of developing Parkinson's disease, even in the absence of a family history for DOPA-responsive dystonia. The frequency of GCH1 variants was evaluated in whole-exome sequencing data of 1318 cases with Parkinson's disease and 5935 control subjects. Combining cases and controls, we identified a total of 11 different heterozygous GCH1 variants, all at low frequency. This list includes four pathogenic variants previously associated with DOPA-responsive dystonia (Q110X, V204I, K224R and M230I) and seven of undetermined clinical relevance (Q110E, T112A, A120S, D134G, I154V, R198Q and G217V). The frequency of GCH1 variants was significantly higher (Fisher's exact test P-value 0.0001) in cases (10/1318 = 0.75\%) than in controls (6/5935 = 0.1\%; odds ratio 7.5; 95\% confidence interval 2.4-25.3). Our results show that rare GCH1 variants are associated with an increased risk for Parkinson's disease. These findings expand the clinical and biological relevance of GTP cycloydrolase 1 deficiency, suggesting that it not only leads to biochemical striatal dopamine depletion and DOPA-responsive dystonia, but also predisposes to nigrostriatal cell loss. Further insight into GCH1-associated pathogenetic mechanisms will shed light on the role of dopamine metabolism in nigral degeneration and Parkinson's disease.},
  language  = {en}
}
@phdthesis{Stengel2022,
  author    = {Stengel, Helena Maria},
  title     = {Paranodale und nodale Autoantik{\"o}rper: Charakterisierung der Anti-Neurofascin-Autoantik{\"o}rper-assoziierten Neuropathie und Untersuchung des Effektes von Anti-Contactin-1-Autoantik{\"o}rpern im Zellkulturmodell},
  doi       = {10.25972/OPUS-25466},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-254662},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Die (Para-)nodopathie ist neben der prim{\"a}r axonalen und der prim{\"a}r demyelinisierenden Polyneuropathie eine neue Krankheitsentit{\"a}t, die sich durch eine Sch{\"a}digung der Funktion des Ranvierschen Schn{\"u}rringes auszeichnet. Die Forschung zu (para-)nodalen Autoantik{\"o}rpern fokussierte sich bislang haupts{\"a}chlich auf Neurofascin-155- und Contactin-1-Autoantik{\"o}rper der Subklasse IgG4. In dieser Studie wurden die Seren von insgesamt 264 PatientInnen mit CIDP, GBS oder anderen Formen von Polyneuropathien mittels Bindungsassays an murinen Ischiadicuszupfnerven und gegebenenfalls ELISA auf (para-)nodale Autoantik{\"o}rper gescrennt. Positive Autoantik{\"o}rperbefunde wurden bei IgG-Autoantik{\"o}rpern mittels Bindungsassays an transfizierten HEK-293-Zellen und bei IgM-Autoantik{\"o}rpern mittels Western Blot best{\"a}tigt. ELISA Untersuchungen dienten zur n{\"a}heren Spezifizierung. Weiterhin wurde die zeitabh{\"a}ngige Wirkung von Contactin-1-Autoantik{\"o}rpern im Zellkulturmodell untersucht. Die im folgenden dargestellten Ergebnisse zeigen, dass die (Para-)nodopathie nicht auf die bisher am h{\"a}ufigsten beschriebene Erkrankung mit IgG4-Autoantik{\"o}rpern beschr{\"a}nkt werden sollte. Bei dem extrem schwer betroffenen IgG-Patient 1 konnte ein Pan-Neurofascin-IgG3-Autoantik{\"o}rper nachgewiesen werden. Als charakteristische Symptome f{\"u}r diese Autoantik{\"o}rper konnten in {\"U}bereinstimmung mit weiteren Fallberichten Tetraplegie, Beatmungspflichtigkeit sowie eine schwere Hirnnervenbeteiligung bis zur Locked-In-Symptomatik identifiziert werden. Diese Patienten heben sich deutlich von den PatientInnen mit den bisher haupts{\"a}chlich beschriebenen Neurofascin-155-IgG4-Autoantik{\"o}rpern ab, die wie IgG-Patient 2 charakteristischerweise in jungem Alter an einer CIDP mit Tremor ohne Besserung unter IVIG-Therapie leiden. Es wurden f{\"u}nf PatientInnen mit Neurofascin-155-IgM-Autoantik{\"o}rpern identifiziert, die eine akut beginnende Erkrankung mit Tetraparese, Tremor und neuropathischen Schmerzen zeigten. Ob sich dieser Ph{\"a}notyp als charakteristisch f{\"u}r eine Neurofascin-155-IgM-(Para-)nodopathie best{\"a}tigt, sollte in weiteren Studien untersucht werden. Im murinen Zellkulturmodell an cerebell{\"a}ren Neuronen und Spinalganglienneuronen zeigte sich nach Inkubation mit Contactin-1-IgG-Patientenantik{\"o}rpern eine zeitabh{\"a}ngige, rasch reversible Verminderung der Contactin-1-Protein-Expression in immunhistochemischen F{\"a}rbungen sowie Western Blots, die durch eine Internalisierung des Contactin-1-Proteins erkl{\"a}rbar w{\"a}re. Der Angriff von Autoantik{\"o}rpern an Spinalganglienneuronen und cerebell{\"a}ren Neurone sollte in weitere pathophysiologische {\"U}berlegungen miteinbezogen werden, da hierdurch typische Symptome der (Para-)nodopathie wie eine sensible Ataxie oder ein cerebell{\"a}rer Tremor erkl{\"a}rt werden k{\"o}nnten.},
  subject      = {Ranvier-Schn{\"u}rring},
  language  = {de}
}
@article{DelVecchioHanafiPozzietal.2023,
  author    = {Del Vecchio, Jasmin and Hanafi, Ibrahem and Pozzi, Nicol{\´o} Gabriele and Capetian, Philipp and Isaias, Ioannis U. and Haufe, Stefan and Palmisano, Chiara},
  title     = {Pallidal recordings in chronically implanted dystonic patients: mitigation of tremor-related artifacts},
  series = {Bioengineering},
  volume    = {10},
  journal   = {Bioengineering},
  number    = {4},
  issn      = {2306-5354},
  doi       = {10.3390/bioengineering10040476},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-313498},
  year      = {2023},
  abstract  = {Low-frequency oscillatory patterns of pallidal local field potentials (LFPs) have been proposed as a physiomarker for dystonia and hold the promise for personalized adaptive deep brain stimulation. Head tremor, a low-frequency involuntary rhythmic movement typical of cervical dystonia, may cause movement artifacts in LFP signals, compromising the reliability of low-frequency oscillations as biomarkers for adaptive neurostimulation. We investigated chronic pallidal LFPs with the Percept\(^{TM}\) PC (Medtronic PLC) device in eight subjects with dystonia (five with head tremors). We applied a multiple regression approach to pallidal LFPs in patients with head tremors using kinematic information measured with an inertial measurement unit (IMU) and an electromyographic signal (EMG). With IMU regression, we found tremor contamination in all subjects, whereas EMG regression identified it in only three out of five. IMU regression was also superior to EMG regression in removing tremor-related artifacts and resulted in a significant power reduction, especially in the theta-alpha band. Pallido-muscular coherence was affected by a head tremor and disappeared after IMU regression. Our results show that the Percept PC can record low-frequency oscillations but also reveal spectral contamination due to movement artifacts. IMU regression can identify such artifact contamination and be a suitable tool for its removal.},
  language  = {en}
}
@article{PoliteiBouhassiraGermainetal.2016,
  author    = {Politei, Juan M. and Bouhassira, Didier and Germain, Dominique P. and Goizet, Cyril and Guerrero-Sola, Antonio and Hilz, Max J. and Hutton, Elspeth J. and Karaa, Amel and Liuori, Rocco and {\"U}ceyler, Nurcan and Zeltzer, Lonnie K. and Burlina, Alessandro},
  title     = {Pain in fabry disease: practical recommendations for diagnosis and treatment},
  series = {CNS Neuroscience \& Therapeutics},
  volume    = {22},
  journal   = {CNS Neuroscience \& Therapeutics},
  number    = {7},
  doi       = {10.1111/cns.12542},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-188127},
  pages     = {568-576},
  year      = {2016},
  abstract  = {Aims: Patients with Fabry disease (FD) characteristically develop peripheral neuropathy at an early age, with pain being a crucial symptom of underlying pathology. However, the diagnosis of pain is challenging due to the heterogeneous and nonspecific symptoms. Practical guidance on the diagnosis and management of pain in FD is needed. Methods: In 2014, experts met to discuss recent advances on this topic and update clinical guidance. Results: Emerging disease-specific tools, including FabryScan, Fabry-specific Pediatric Health and Pain Questionnaire, and Wurzburg Fabry Pain Questionnaire, and more general tools like the Total Symptom Score can aid diagnosis, characterization, and monitoring of pain in patients with FD. These tools can be complemented by more objective and quantifiable sensory testing. In male and female patients of any age, pain related to FD can be an early indication to start disease-specific enzyme replacement therapy before potentially irreversible organ damage to the kidneys, heart, or brain occurs. Conclusion: To improve treatment outcomes, pain should be diagnosed early in unrecognized or newly identified FD patients. Treatment should include: (a) enzyme replacement therapy controlling the progression of underlying pathology; (b) adjunctive, symptomatic pain management with analgesics for chronic neuropathic and acute nociceptive, and inflammatory or mixed pain; and (c) lifestyle modifications.},
  language  = {en}
}
@phdthesis{Visan2003,
  author    = {Visan, Ion Lucian},
  title     = {P0 specific T-cell repertoire in wild-type and P0 deficient mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-5734},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {Zusammenfassung Das Myelinprotein P0 stellt eine zentrale Komponente f{\"u}r die Stabilit{\"a}t und Funktionalit{\"a}t der Myelinscheiden des peripheren Nervensystems dar. Mutationen des P0-Proteins f{\"u}hren zu verschiedenen, schwer behindernden peripheren Neuropathien wie der Charcot-Marie-Tooth- oder der Dejerine-Sotas-Erkrankung. Wir haben das Tiermodell der P0-Knock-Out-M{\"a}use verwendet, um im Vergleich zu den C57BL/6-Wildtyp-Tieren Selektionsmechanismen des P0-spezifischen T-Zell-Repertoires zu untersuchen. Dazu wurde eine Reihe von {\"u}berlappenden 20-mer-Peptiden benutzt, die die gesamte Aminos{\"a}uresequenz von P0 abdeckten. Mit Hilfe dieser Peptide wurde ein sog. „Epitop-Mapping" der H2-Ab-restringierten T-Zell-Antwort durchgef{\"u}hrt. Auf diese Weise konnte das P0-Peptid 5 (Aminos{\"a}ure 41-60) in der extrazellul{\"a}ren P0-Dom{\"a}ne als immunogene Determinante identifiziert werden. Dieses immunogene Peptid wurde dann f{\"u}r Untersuchungen der Toleranzmechanismen verwendet und zeigte, dass in P0-Knock-Out-M{\"a}usen ein hochreaktives P0-spezifisches T-Zell-Repertoire vorliegt, w{\"a}hrend es in Wildtyp-Tieren inaktiviert ist und so Selbsttoleranz erzeugt wird. Die Toleranzerzeugung in Wildtyp- und heterozygoten P0 +/- M{\"a}usen h{\"a}ngt nicht von der Gen-Dosis ab. P0 ist ein gewebespezifisches Antigen, dessen Expression normalerweise auf myelinisierende Schwann-Zellen beschr{\"a}nkt ist. Die klassischen Vorstellungen zu Toleranzmechanismen gegen{\"u}ber gewebsspezifischen Antigenen schrieben diese vor allem peripheren Immunmechanismen zu. Durch den erstmaligen Nachweis von intrathymischer Expression gewebsspezifischer Antigene wie P0 konnten wir best{\"a}tigen, dass f{\"u}r P0 offensichtlich die Expression deutlich weiter verbreitet ist, insbesondere auch auf Thymus-Stroma-Zellen. Unter Verwendung von Knochenmarkschim{\"a}ren haben wir weitere Untersuchungen durchgef{\"u}hrt, wie Knochenmarks-abstammende Zellen im Vergleich zu nicht-h{\"a}matopoetischen Zellen Toleranz gegen{\"u}ber P0 erzeugen k{\"o}nnen. Unsere Befunde zeigen, dass Knochenmarks-abh{\"a}ngige Zellen nicht ausreichen, um v{\"o}llige Toleranz zu erzeugen. Zus{\"a}tzlich wurde eine P0-Expression auf anderen Geweben wie dem Thymus ben{\"o}tigt, um komplette Toleranz zu erhalten. Wir identifizierten ein kryptisches P0-Peptid 8 und zwei subdominante P0-Peptide 1 und 3. W{\"a}hrend das Peptid 8 sowohl in Wildtyp- als auch Knock-Out-M{\"a}usen erkannt wurde, wurden die Peptide 1 und 3 in Wildtyp-M{\"a}usen nicht als Immunogen erkannt. Die genannten Peptide wurden verwendet, um eine experimentelle autoimmune Neuritis (EAN) zu erzeugen. Mit keinem der experimentellen Ans{\"a}tze konnten wir klinische Zeichen einer EAN generieren, allerdings mit dem Peptid 3 doch Entz{\"u}ndung im peripheren Nerven beobachten. Es werden zuk{\"u}nftig weitere Untersuchungen ben{\"o}tigt, um P0-spezifische T-Zell-Linien zu etablieren und so mit h{\"o}herer Effizienz eine EAN zu erzeugen. Unsere Untersuchungen sprechen daf{\"u}r, dass bei gentherapeutischen Ans{\"a}tzen bei erblichen Neuropathien vorsichtig und schrittweise vorgegangen werden muss, da mit sekund{\"a}rer Autoimmunit{\"a}t und damit Inflammation im peripheren Nerven zu rechnen ist.},
  subject      = {Myelin},
  language  = {en}
}
@article{PhamHelluyBraeuningeretal.2010,
  author    = {Pham, Mirko and Helluy, X. and Braeuninger, S. and Jakob, P. and Stoll, G. and Kleinschnitz, Christoph and Bendszus, M.},
  title     = {Outcome of experimental stroke in C57Bl/6 and Sv/129 mice assessed by multimodal ultra-high field MRI},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68115},
  year      = {2010},
  abstract  = {Transgenic mice bred on C57Bl/6 or Sv/129 genetic background are frequently used in stroke research. It is well established that variations in cerebrovascular anatomy and hemodynamics can influence stroke outcome in different inbred mouse lines. We compared stroke development in C57Bl/6 and Sv/129 mice in the widely used model of transient middle cerebral artery occlusion (tMCAO) by multimodal ultra-high field magnetic resonance imaging (MRI). C57Bl/6 and Sv/129 mice underwent 60 min of tMCAO and were analyzed by MRI 2 h and 24 h afterwards. Structural and functional images were registered to a standard anatomical template. Probability maps of infarction were rendered by automated segmentation from quantitative T2-relaxometric images. Whole-brain segmentation of infarction was accomplished manually on high-resolution T2-weighted (T2-w) RARE images. Cerebral perfusion (cerebral blood flow, CBF) was measured quantitatively by modified continuous arterial-spin-labeling (CASL) and apparent diffusion coefficients (ADC) by spin-echo diffusion-weighted imaging (DWI). Probabilities of cortical (95.1\% ± 3.1 vs. 92.1\% ± 2.5; p > 0.05) and subcortical (100\% vs. 100\%; p > 0.05) infarctions at 24 h were similar in both groups as was the whole-brain volumetric extent of cerebral infarction. In addition, CBF and ADC values did not differ between C57Bl/6 and Sv/129 mice at any time point or region of interest. The C57Bl/6 and Sv/129 genetic background is no major confounding factor of infarct size and cerebral perfusion in the tMCAO model.},
  subject      = {NMR-Tomographie},
  language  = {en}
}
@article{OderUeceylerLiuetal.2016,
  author    = {Oder, Daniel and {\"U}ceyler, Nurcan and Liu, Dan and Hu, Kai and Petritsch, Bernhard and Sommer, Claudia and Ertl, Georg and Wanner, Christoph and Nordbeck, Peter},
  title     = {Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y},
  series = {BMJ Open},
  volume    = {6},
  journal   = {BMJ Open},
  doi       = {10.1136/bmjopen-2015-010422},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-161210},
  pages     = {e010422},
  year      = {2016},
  abstract  = {Objectives: The severity of Fabry disease is dependent on the type of mutation in the α-galactosidase A (AgalA) encoding gene (GLA). This study focused on the impact of the GLA haplotype D313Y on long-term organ involvement and function. Setting and participants: In this monocentric study, all participants presenting with the D313Y haplotype between 2001 and 2015 were comprehensively clinically investigated at baseline and during a 4-year follow-up if available. Five females and one male were included. Primary and secondary outcome measures: Cardiac, nephrological, neurological, laboratory and quality of life data. Results: AgalA enzyme activity in leucocytes (0.3±0.9 nmol/min/mg protein (mean±SD)) and serum lyso-Gb3 (0.6±0.3 ng/mL at baseline) were in normal range in all patients. Cardiac morphology and function were normal (left-ventricular (LV) ejection fraction 66±8\%; interventricular septum 7.7±1.4 mm; LV posterior wall 7.5±1.4 mm; normalised LV mass in MRI 52±9 g/m2; LV global longitudinal strain -21.6±1.9\%) and there were no signs of myocardial fibrosis in cardiac MRI. Cardiospecific biomarkers were also in normal range. Renal function was not impaired (estimated glomerular filtration rate MDRD 103±15 mL/min; serum-creatinine 0.75±0.07 mg/dL; cystatin-c 0.71±0.12 mg/L). One female patient (also carrying a Factor V Leiden mutation) had a transitory ischaemic attack. One patient showed white matter lesions in brain MRI, but none had Fabry-associated pain attacks, pain crises, evoked pain or permanent pain. Health-related quality of life analysis revealed a reduction in individual well-being. At long-term follow-up after 4 years, no significant change was seen in any parameter. Conclusions: The results of the current study suggest that the D313Y genotype does not lead to severe organ manifestations as seen in genotypes known to be causal for classical FD."},
  language  = {en}
}
@article{SommerKloseWelschetal.2020,
  author    = {Sommer, Claudia and Klose, Petra and Welsch, Patrick and Petzke, Frank and H{\"a}user, Winfried},
  title     = {Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration},
  series = {European Journal of Pain},
  volume    = {24},
  journal   = {European Journal of Pain},
  number    = {1},
  doi       = {10.1002/ejp.1494},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-218487},
  pages     = {3 -- 18},
  year      = {2020},
  abstract  = {Background and Objective This updated systematic review evaluated the efficacy, tolerability and safety of opioids compared to placebo in chronic non-cancer neuropathic pain. Databases and Data Treatment Clinicaltrials.gov, CENTRAL, PubMed and PsycINFO were searched from October 2013 to June 2019. Randomized controlled trials comparing opioids with placebo and at least 4 weeks double-blinded duration were analysed. Primary outcomes were pain relief of 50\% or greater, disability, tolerability and safety. Effects were summarized by a random effects model using risk differences (RD) or standardized mean differences (SMD). We added four new studies with 662 participants for a total of 16 included studies with 2,199 participants. Study duration ranged between 4 and 12 weeks. Studies with a parallel and cross-over design: Based on low to moderate quality evidence, opioids (buprenorphine, hydromorphone, morphine, oxycodone, tramadol) provided a clinically relevant pain relief of 50\% or greater and reduction of disability compared to placebo. There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by opioids compared to placebo. Enriched enrolment randomized withdrawal design: Based on low to moderate quality evidence, tapentadol provided a clinically relevant pain relief of 50\% or greater and reduction of disability compared to placebo in diabetic polyneuropathy. There was no clinically relevant harm with regards to the drop out rate due to adverse and serious adverse events by tapentadol compared to placebo. Conclusions Some opioids provided a short-term substantial pain relief in highly selected patients in some neuropathic pain syndromes. Significance Some opioids (buprenorphine, morphine, oxycodone, tramadol, tapentadol) provide substantial pain relief compared to placebo in postherpetic neuralgia and peripheral neuropathies of different aetiologies for 4-12 weeks. There is insufficient evidence to support or refute the suggestion that these drugs are effective in other neuropathic pain conditions. The safety of opioids with regards to abuse and deaths in the studies analysed cannot be extrapolated to routine clinical care.},
  language  = {en}
}
@article{PetzkeKloseWelschetal.2020,
  author    = {Petzke, Frank and Klose, Petra and Welsch, Patrick and Sommer, Claudia and H{\"a}user, Winfried},
  title     = {Opioids for chronic low back pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks of double-blind duration},
  series = {European Journal of Pain},
  volume    = {24},
  journal   = {European Journal of Pain},
  number    = {3},
  doi       = {10.1002/ejp.1519},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-218498},
  pages     = {497 -- 517},
  year      = {2020},
  abstract  = {Background and Objective This updated systematic review evaluated the efficacy, tolerability and safety of opioids compared to placebo in non-malignant chronic low back pain. Databases and Data Treatment Clinicaltrials.gov, CENTRAL, MEDLINE and PsycINFO were searched from October 2013 to May 2019. Randomized controlled trials comparing opioids with placebo and at least 4 weeks of double-blinded duration were analysed. Primary outcomes were pain relief of 50\% or greater, disability, tolerability and safety. Effects were summarized by a random effects model using risk differences or standardized mean differences. We added nine new studies with 2,980 participants for a total of 21 studies with 7,650 participants. Study duration ranged between 4 and 15 weeks. Studies with a parallel and cross-over design: Based on very low to low-quality evidence, opioids provided no clinically relevant pain relief of 50\% or greater, but a clinically relevant reduction of disability compared to placebo. Enriched enrolment randomized withdrawal (EERW) design: Based on very low to low-quality evidence, opioids provided a clinically relevant pain relief of 50\% or greater, but not a clinically relevant reduction of disability compared to placebo. There was no clinically relevant harm with regard to serious adverse events by opioids compared to placebo in studies with parallel/cross-over and EERW design. There was a relevant harm with regard to drop out rates due to adverse events in studies with parallel/cross-over, but not in studies with EERW design. Conclusions Opioids may provide a safe and clinically relevant pain relief for 4-15 weeks in highly selected patients. Significance Within the context of randomized controlled trials of 4-15 weeks, opioids provided a clinically relevant pain relief of 30\% or greater and a clinically relevant reduction of disability compared to placebo in non-malignant chronic low back pain. Number needed to treat for an additional drop out due to side effects was 11 (95\% confidence interval: 6-33). Assessment of abuse and addiction was incomplete. The frequency of serious adverse events including deaths did not differ from placebo.},
  language  = {en}
}
@article{TuetuencueOlmaKunzeetal.2022,
  author    = {T{\"u}t{\"u}nc{\"u}, Serdar and Olma, Manuel and Kunze, Claudia and Dietzel, Joanna and Schurig, Johannes and Fiessler, Cornelia and Malsch, Carolin and Haas, Tobias Eberhard and Dimitrijeski, Boris and Doehner, Wolfram and Hagemann, Georg and Hamilton, Frank and Honermann, Martin and Jungehulsing, Gerhard Jan and Kauert, Andreas and Koennecke, Hans-Christian and Mackert, Bruno-Marcel and Nabavi, Darius and Nolte, Christian H. and Reis, Joschua Mirko and Schmehl, Ingo and Sparenberg, Paul and Stingele, Robert and V{\"o}lzke, Enrico and Waldschmidt, Carolin and Zeise-Wehry, Daniel and Heuschmann, Peter U. and Endress, Matthias and Haeusler, Karl Georg},
  title     = {Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry},
  series = {Journal of Neurology},
  volume    = {269},
  journal   = {Journal of Neurology},
  number    = {1},
  issn      = {1432-1459},
  doi       = {10.1007/s00415-021-10866-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-266969},
  pages     = {470-480},
  year      = {2022},
  abstract  = {Aims We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke. Methods The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke. Results At stroke onset, an off-label daily dose was prescribed in 61 (25.5\%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8\%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95\% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95\% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2\%) of 61 patients. Overall, 79 (13.7\%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6\%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95\% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95\% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95\% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95\% CI 1.28-2.84, P < 0.01]. Conclusion At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge.},
  language  = {en}
}
@phdthesis{Hochheimer2022,
  author    = {Hochheimer, Vanessa Christine},
  title     = {Of cells and enzymes: How dermal fibroblasts can impact pain in Fabry Disease and Why looking at the 3D-structure of α-Galactosidase A may be worthwhile for clinical management of Fabry patients},
  doi       = {10.25972/OPUS-29660},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-296607},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Fabry Disease (FD) is a genetic lysosomal storage disorder based on mutations in the gene encoding α-Galactosidase A (α-GalA) leading to accumulation of globotriaosylceramide (Gb3). Missense mutations induce an amino acid exchange (AAE) in the α-GalA. Pain is a predominant symptom in FD and the pathophysiology is unclear. Skin punch biopsies were obtained from 40 adult FD patients and ten healthy controls and dermal fibroblast cultures were generated for cell culture experiments to investigate Gb3 load, gene and protein expression patterns and ion channel activity. The 3D-structure of α-GalA was downloaded into Pymol Graphics System and the AAE was depicted and located in order to investigate the correlation between the AAE location type in the α-GalA and the clinical FD phenotype. FD dermal fibroblasts showed high Gb3 load depending on treatment interval and expressed Kca1.1 channels. Activity was reduced in FD cells at baseline, but increased over-proportionately upon Gb3-cleavage by enzyme replacement therapy. Gene and protein expression of Kca1.1 was increased in FD cells. FD dermal fibroblasts showed higher gene expression of Notch1 and several cytokines. Further, it was shown that three different AAE location types can be differentiated: mutations in the active site ('active site'), those buried in the core of α-GalA ('buried') and those at another location, mostly on the protein surface ('other'). FD patients carrying active site or buried mutations showed a severe clinical phenotype with multi-organ manifestation and early disease onset. Patients with other mutations were less severely affected with oligo-organ manifestation sparing the nervous system and later disease onset. These results show that dermal fibroblasts may be involved in FD-associated pain and that stratification of FD patients carrying missense mutations by AAE location type may be an advantageous parameter that can help in the management of FD patients.},
  subject      = {Fabry-Krankheit},
  language  = {en}
}
@phdthesis{Weisensee2007,
  author    = {Weisensee, Tim Andr{\´e}},
  title     = {Nutzen von Stroke-Unit-Behandlung f{\"u}r die geriatrische Rehabilitationsprognose},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-24937},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2007},
  abstract  = {Die vorliegende Arbeit {\"u}berpr{\"u}ft an einem nach Alter, Geschlecht, Barthel-Index und Mini-Mental-State-Test gematchten geriatrischen Patientenkollektiv mit erstmaligem Schlaganfall die Wirksamkeit einer vorausgegangenen Akutbehandlung an einer Stroke Unit (n=59) gegen{\"u}ber einer allgemeinen (internistischen oder neurologischen) station{\"a}ren Akutbehandlung (n=59) f{\"u}r die Prognose im Laufe einer nachfolgenden geriatrischen Rehabilitationsbehandlung. Hintergrund dieser Frage ist der erh{\"o}hte {\"o}konomische Druck im Gesundheitswesen, der eine Effizienzpr{\"u}fung einer personell, technisch und logistisch aufw{\"a}ndigeren und damit teureren Behandlung auf einer Spezialstation verlangt. Bei Anwendung zahlreicher funktioneller Skalen und Erhebung einiger sozio{\"o}konomischer Faktoren zeigte sich auf Signifikanzniveau, dass die auf Stroke Unit Vorbehandelten bei Aufnahme in die Rehabilitation motorisch schwerer beeintr{\"a}chtigt waren (timed up and go-Test p=0,044, Lachs-Test p=0,34) und sich dann ausgepr{\"a}gter (Transferleistung p=0,024) auf ein bei Rehabilitationsende schließlich vergleichbares Leistungsniveau verbesserten. Die urspr{\"u}nglich geplante Langzeiteffizienzbetrachtung im Gruppenvergleich scheiterte an Datenschutzbedenken. Gesundheits{\"o}konomisch relevant ist, dass die Vorverweildauer im Akutkrankenhaus bei Stroke Unit-Patienten sechs Tage k{\"u}rzer war, die Rehabilitationsdauer allerdings vier Tage l{\"a}nger. Weitergehende Kostenbetrachtungen scheiterten am Unwillen zur Leistungsoffenlegung verschiedener Beteiligter im Gesundheitssystem. Eine plausible Erkl{\"a}rung f{\"u}r diese positive motorische Leistungsweiterentwicklung nach Stroke Unit-Vorbehandlung kann in einer fr{\"u}hzeitigeren und effektiveren Anstrengung durch Krankengymnastik, Ergotherapie, Logop{\"a}die, aktivierende Pflege, „enriched environment" gesucht werden, die sich positiv auf die Plastizit{\"a}t im Gehirn als wesentliche Bedingung zur Funktionswiedergewinnung auswirken k{\"o}nnte, was aber noch umstritten ist und Ziel weiterer Untersuchungen sein muss.},
  subject      = {Geriatrie},
  language  = {de}
}
@article{HopfnerSchormairKnaufetal.2011,
  author    = {Hopfner, Franziska and Schormair, Barbara and Knauf, Franziska and Berthele, Achim and T{\"o}lle, Thomas R. and Baron, Ralf and Maier, Christoph and Treede, Rolf-Detlef and Binder, Andreas and Sommer, Claudia and Maih{\"o}fner, Christian and Kunz, Wolfram and Zimprich, Friedrich and Heemann, Uwe and Pfeufer, Arne and N{\"a}bauer, Michael and K{\"a}{\"a}b, Stefan and Nowak, Barbara and Gieger, Christian and Lichtner, Peter and Trenkwalder, Claudia and Oexle, Konrad and Winkelmann, Juliane},
  title     = {Novel SCARB2 mutation in Action Myoclonus-Renal Failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features},
  series = {BMC Neurology},
  volume    = {11},
  journal   = {BMC Neurology},
  number    = {134},
  doi       = {10.1186/1471-2377-11-134},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-141209},
  pages     = {1-8},
  year      = {2011},
  abstract  = {Background: Action myoclonus-renal failure syndrome is a hereditary form of progressive myoclonus epilepsy associated with renal failure. It is considered to be an autosomal-recessive disease related to loss-of-function mutations in SCARB2. We studied a German AMRF family, additionally showing signs of demyelinating polyneuropathy and dilated cardiomyopathy. To test the hypothesis whether isolated appearance of individual AMRF syndrome features could be related to heterozygote SCARB2 mutations, we screened for SCARB2 mutations in unrelated patients showing isolated AMRF features. Methods: In the AMRF family all exons of SCARB2 were analyzed by Sanger sequencing. The mutation screening of unrelated patients with isolated AMRF features affected by either epilepsy (n = 103, progressive myoclonus epilepsy or generalized epilepsy), demyelinating polyneuropathy (n = 103), renal failure (n = 192) or dilated cardiomyopathy (n = 85) was performed as high resolution melting curve analysis of the SCARB2 exons. Results: A novel homozygous 1 bp deletion (c.111delC) in SCARB2 was found by sequencing three affected homozygous siblings of the affected family. A heterozygous sister showed generalized seizures and reduction of nerve conduction velocity in her legs. No mutations were found in the epilepsy, renal failure or dilated cardiomyopathy samples. In the polyneuropathy sample two individuals with demyelinating disease were found to be carriers of a SCARB2 frameshift mutation (c.666delCCTTA). Conclusions: Our findings indicate that demyelinating polyneuropathy and dilated cardiomyopathy are part of the action myoclonus-renal failure syndrome. Moreover, they raise the possibility that in rare cases heterozygous SCARB2 mutations may be associated with PNP features.},
  language  = {en}
}
@article{SilwedelSpeerHaarmannetal.2018,
  author    = {Silwedel, Christine and Speer, Christian P. and Haarmann, Axel and Fehrholz, Markus and Claus, Heike and Buttmann, Mathias and Glaser, Kirsten},
  title     = {Novel insights into neuroinflammation: bacterial lipopolysaccharide, tumor necrosis factor α, and Ureaplasma species differentially modulate atypical chemokine receptor 3 responses in human brain microvascular endothelial cells},
  series = {Journal of Neuroinflammation},
  volume    = {15},
  journal   = {Journal of Neuroinflammation},
  number    = {156},
  doi       = {10.1186/s12974-018-1170-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-175952},
  year      = {2018},
  abstract  = {Background: Atypical chemokine receptor 3 (ACKR3, synonym CXCR7) is increasingly considered relevant in neuroinflammatory conditions, in which its upregulation contributes to compromised endothelial barrier function and may ultimately allow inflammatory brain injury. While an impact of ACKR3 has been recognized in several neurological autoimmune diseases, neuroinflammation may also result from infectious agents, including Ureaplasma species (spp.). Although commonly regarded as commensals of the adult urogenital tract, Ureaplasma spp. may cause invasive infections in immunocompromised adults as well as in neonates and appear to be relevant pathogens in neonatal meningitis. Nonetheless, clinical and in vitro data on Ureaplasma-induced inflammation are scarce. Methods: We established a cell culture model of Ureaplasma meningitis, aiming to analyze ACKR3 variances as a possible pathomechanism in Ureaplasma-associated neuroinflammation. Non-immortalized human brain microvascular endothelial cells (HBMEC) were exposed to bacterial lipopolysaccharide (LPS) or tumor necrosis factor-α (TNF-α), and native as well as LPS-primed HBMEC were cultured with Ureaplasma urealyticum serovar 8 (Uu8) and U. parvum serovar 3 (Up3). ACKR3 responses were assessed via qRT-PCR, RNA sequencing, flow cytometry, and immunocytochemistry. Results: LPS, TNF-α, and Ureaplasma spp. influenced ACKR3 expression in HBMEC. LPS and TNF-α significantly induced ACKR3 mRNA expression (p < 0.001, vs. control), whereas Ureaplasma spp. enhanced ACKR3 protein expression in HBMEC (p < 0.01, vs. broth control). Co-stimulation with LPS and either Ureaplasma isolate intensified ACKR3 responses (p < 0.05, vs. LPS). Furthermore, stimulation wielded a differential influence on the receptor's ligands. Conclusions: We introduce an in vitro model of Ureaplasma meningitis. We are able to demonstrate a pro-inflammatory capacity of Ureaplasma spp. in native and, even more so, in LPS-primed HBMEC, underlining their clinical relevance particularly in a setting of co-infection. Furthermore, our data may indicate a novel role for ACKR3, with an impact not limited to auto-inflammatory diseases, but extending to infection-related neuroinflammation as well. AKCR3-induced blood-brain barrier breakdown might constitute a potential common pathomechanism.},
  language  = {en}
}
@article{PiroEckesKasaragodetal.2021,
  author    = {Piro, Inken and Eckes, Anna-Lena and Kasaragod, Vikram Babu and Sommer, Claudia and Harvey, Robert J. and Schaefer, Natascha and Villmann, Carmen},
  title     = {Novel Functional Properties of Missense Mutations in the Glycine Receptor β Subunit in Startle Disease},
  series = {Frontiers in Molecular Neuroscience},
  volume    = {14},
  journal   = {Frontiers in Molecular Neuroscience},
  issn      = {1662-5099},
  doi       = {10.3389/fnmol.2021.745275},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-246676},
  year      = {2021},
  abstract  = {Startle disease is a rare disorder associated with mutations in GLRA1 and GLRB, encoding glycine receptor (GlyR) α1 and β subunits, which enable fast synaptic inhibitory transmission in the spinal cord and brainstem. The GlyR β subunit is important for synaptic localization via interactions with gephyrin and contributes to agonist binding and ion channel conductance. Here, we have studied three GLRB missense mutations, Y252S, S321F, and A455P, identified in startle disease patients. For Y252S in M1 a disrupted stacking interaction with surrounding aromatic residues in M3 and M4 is suggested which is accompanied by an increased EC\(_{50}\) value. By contrast, S321F in M3 might stabilize stacking interactions with aromatic residues in M1 and M4. No significant differences in glycine potency or efficacy were observed for S321F. The A455P variant was not predicted to impact on subunit folding but surprisingly displayed increased maximal currents which were not accompanied by enhanced surface expression, suggesting that A455P is a gain-of-function mutation. All three GlyR β variants are trafficked effectively with the α1 subunit through intracellular compartments and inserted into the cellular membrane. In vivo, the GlyR β subunit is transported together with α1 and the scaffolding protein gephyrin to synaptic sites. The interaction of these proteins was studied using eGFP-gephyrin, forming cytosolic aggregates in non-neuronal cells. eGFP-gephyrin and β subunit co-expression resulted in the recruitment of both wild-type and mutant GlyR β subunits to gephyrin aggregates. However, a significantly lower number of GlyR β aggregates was observed for Y252S, while for mutants S321F and A455P, the area and the perimeter of GlyR β subunit aggregates was increased in comparison to wild-type β. Transfection of hippocampal neurons confirmed differences in GlyR-gephyrin clustering with Y252S and A455P, leading to a significant reduction in GlyR β-positive synapses. Although none of the mutations studied is directly located within the gephyrin-binding motif in the GlyR β M3-M4 loop, we suggest that structural changes within the GlyR β subunit result in differences in GlyR β-gephyrin interactions. Hence, we conclude that loss- or gain-of-function, or alterations in synaptic GlyR clustering may underlie disease pathology in startle disease patients carrying GLRB mutations.},
  language  = {en}
}
@article{GrohStadlerButtmannetal.2014,
  author    = {Groh, Janos and Stadler, David and Buttmann, Mathias and Martini, Rudolf},
  title     = {Non-invasive assessment of retinal alterations in mouse models of infantile and juvenile neuronal ceroid lipofuscinosis by spectral domain optical coherence tomography},
  doi       = {10.1186/2051-5960-2-54},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110566},
  year      = {2014},
  abstract  = {Introduction The neuronal ceroid lipofuscinoses constitute a group of fatal inherited lysosomal storage diseases that manifest in profound neurodegeneration in the CNS. Visual impairment usually is an early symptom and selective degeneration of retinal neurons has been described in patients suffering from distinct disease subtypes. We have previously demonstrated that palmitoyl protein thioesterase 1 deficient (Ppt1-/-) mice, a model of the infantile disease subtype, exhibit progressive axonal degeneration in the optic nerve and loss of retinal ganglion cells, faithfully reflecting disease severity in the CNS. Here we performed spectral domain optical coherence tomography (OCT) in Ppt1-/- and ceroid lipofuscinosis neuronal 3 deficient (Cln3-/-) mice, which are models of infantile and juvenile neuronal ceroid lipofuscinosis, respectively, in order to establish a non-invasive method to assess retinal alterations and monitor disease severity in vivo. Results Blue laser autofluorescence imaging revealed increased accumulation of autofluorescent storage material in the inner retinae of 7-month-old Ppt1-/- and of 16-month-old Cln3-/- mice in comparison with age-matched control littermates. Additionally, optical coherence tomography demonstrated reduced thickness of retinae in knockout mice in comparison with age-matched control littermates. High resolution scans and manual measurements allowed for separation of different retinal composite layers and revealed a thinning of layers in the inner retinae of both mouse models at distinct ages. OCT measurements correlated well with subsequent histological analysis of the same retinae. Conclusions These results demonstrate the feasibility of OCT to assess neurodegenerative disease severity in mouse models of neuronal ceroid lipofuscinosis and might have important implications for diagnostic evaluation of disease progression and therapeutic efficacy in patients. Moreover, the non-invasive method allows for longitudinal studies in experimental models, reducing the number of animals used for research.},
  language  = {en}
}
@phdthesis{Brunder2022,
  author    = {Brunder, Anna-Michelle},
  title     = {Nodale und paranodale Autoantik{\"o}rper bei inflammatorischen Polyneuropathien: Nachweis, Charakterisierung und Assoziation zu klinischen Verlaufsformen},
  doi       = {10.25972/OPUS-28218},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-282185},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {In den letzten Jahren gewann das Konzept der Paranodopathien als eigene Krankheitsentit{\"a}t der inflammatorischen Polyneuropathien zunehmend an Bedeutung. Die Forschung konzentrierte sich dabei {\"u}berwiegend auf die chronisch inflammatorische Polyradikuloneuropathie (CIDP). In dieser Arbeit werden (para-)nodale Antik{\"o}rper gegen Neurofascin-155, panNeurofascin, Contactin-1 und Caspr-1 in einer großen Kohorte von Patienten mit Guillain-Barr{\´e}-Syndrom (GBS) und CIDP nachgewiesen. Patienten mit Anti-panNeurofascin-Antik{\"o}rpern zeigten besonders schwere Verlaufsformen. Patienten mit anderen (para-)nodalen Antik{\"o}rpern zeigten je nach IgG-Subklasse der Antik{\"o}rper spezifische klinische Merkmale und ein unterschiedliches Ansprechen auf die Therapie. Die Arbeit zeigt, dass die Bestimmung (para-)nodaler Antik{\"o}rper bei Patienten mit GBS und CIDP im klinischen Alltag zur Einordung der Prognose und Therapieplanung sinnvoll sein kann.},
  subject      = {Polyneuropathie},
  language  = {de}
}
@article{NguemeniStiehlHiewetal.2021,
  author    = {Nguemeni, Carine and Stiehl, Annika and Hiew, Shawn and Zeller, Daniel},
  title     = {No Impact of Cerebellar Anodal Transcranial Direct Current Stimulation at Three Different Timings on Motor Learning in a Sequential Finger-Tapping Task},
  series = {Frontiers in Human Neuroscience},
  volume    = {15},
  journal   = {Frontiers in Human Neuroscience},
  issn      = {1662-5161},
  doi       = {10.3389/fnhum.2021.631517},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-225477},
  year      = {2021},
  abstract  = {Background: Recently, attention has grown toward cerebellar neuromodulation in motor learning using transcranial direct current stimulation (tDCS). An important point of discussion regarding this modulation is the optimal timing of tDCS, as this parameter could significantly influence the outcome. Hence, this study aimed to investigate the effects of the timing of cerebellar anodal tDCS (ca-tDCS) on motor learning using a sequential finger-tapping task (FTT). Methods: One hundred and twenty two healthy young, right-handed subjects (96 females) were randomized into four groups (During\(_{sham}\), Before, During\(_{real}\), After). They performed 2 days of FTT with their non-dominant hand on a custom keyboard. The task consisted of 40 s of typing followed by 20 s rest. Each participant received ca-tDCS (2 mA, sponge electrodes of 25 cm\(^{2}\), 20 min) at the appropriate timing and performed 20 trials on the first day (T1, 20 min). On the following day, only 10 trials of FTT were performed without tDCS (T2, 10 min). Motor skill performance and retention were assessed. Results: All participants showed a time-dependent increase in learning. Motor performance was not different between groups at the end of T1 (p = 0.59). ca-tDCS did not facilitate the retention of the motor skill in the FTT at T2 (p = 0.27). Thus, our findings indicate an absence of the effect of ca-tDCS on motor performance or retention of the FTT independently from the timing of stimulation. Conclusion: The present results suggest that the outcome of ca-tDCS is highly dependent on the task and stimulation parameters. Future studies need to establish a clear basis for the successful and reproducible clinical application of ca-tDCS.},
  language  = {en}
}
@article{BellutRaimondiHaarmannetal.2022,
  author    = {Bellut, Maximilian and Raimondi, Anthony T. and Haarmann, Axel and Zimmermann, Lena and Stoll, Guido and Schuhmann, Michael K.},
  title     = {NLRP3 inhibition reduces rt-PA induced endothelial dysfunction under ischemic conditions},
  series = {Biomedicines},
  volume    = {10},
  journal   = {Biomedicines},
  number    = {4},
  issn      = {2227-9059},
  doi       = {10.3390/biomedicines10040762},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-267261},
  year      = {2022},
  abstract  = {Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is a mainstay of acute ischemic stroke treatment but is associated with bleeding complications, especially after prolonged large vessel occlusion. Recently, inhibition of the NLRP3 inflammasome led to preserved blood-brain barrier (BBB) integrity in experimental stroke in vivo. To further address the potential of NLRP3 inflammasome inhibition as adjunct stroke treatment we used immortalized brain derived endothelial cells (bEnd5) as an in vitro model of the BBB. We treated bEnd5 with rt-PA in combination with the NLRP3 specific inhibitor MCC950 or vehicle under normoxic as well as ischemic (OGD) conditions. We found that rt-PA exerted a cytotoxic effect on bEnd5 cells under OGD confirming that rt-PA is harmful to the BBB. This detrimental effect could be significantly reduced by MCC950 treatment. Moreover, under ischemic conditions, the Cell Index — a sensible indicator for a patent BBB — and the protein expression of Zonula occludens 1 stabilized after MCC950 treatment. At the same time, the extent of endothelial cell death and NLRP3 expression decreased. In conclusion, NLRP3 inhibition can protect the BBB from rt-PA-induced damage and thereby potentially increase the narrow time window for safe thrombolysis in stroke.},
  language  = {en}
}
@article{BellutPappBieberetal.2022,
  author    = {Bellut, Maximilian and Papp, Lena and Bieber, Michael and Kraft, Peter and Stoll, Guido and Schuhmann, Michael K.},
  title     = {NLPR3 inflammasome inhibition alleviates hypoxic endothelial cell death in-vitro and protects blood-brain barrier integrity in murine stroke},
  series = {Cell Death \& Disease},
  volume    = {13},
  journal   = {Cell Death \& Disease},
  doi       = {10.1038/s41419-021-04379-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265693},
  year      = {2022},
  abstract  = {In ischemic stroke (IS) impairment of the blood-brain barrier (BBB) has an important role in the secondary deterioration of neurological function. BBB disruption is associated with ischemia-induced inflammation, brain edema formation, and hemorrhagic infarct transformation, but the underlying mechanisms are incompletely understood. Dysfunction of endothelial cells (EC) may play a central role in this process. Although neuronal NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome upregulation is an established trigger of inflammation in IS, the contribution of its expression in EC is unclear. We here used brain EC, exposed them to oxygen and glucose deprivation (OGD) in vitro, and analyzed their survival depending on inflammasome inhibition with the NLRP3-specific drug MCC950. During OGD, EC death could significantly be reduced when targeting NLRP3, concomitant with diminished endothelial NLRP3 expression. Furthermore, MCC950 led to reduced levels of Caspase 1 (p20) and activated Gasdermin D as markers for pyroptosis. Moreover, inflammasome inhibition reduced the secretion of pro-inflammatory chemokines, cytokines, and matrix metalloproteinase-9 (MMP9) in EC. In a translational approach, IS was induced in C57Bl/6 mice by 60 mins transient middle cerebral artery occlusion and 23 hours of reperfusion. Stroke volume, functional outcome, the BBB integrity, and-in good agreement with the in vitro results-MMP9 secretion as well as EC survival improved significantly in MCC950-treated mice. In conclusion, our results establish the NLRP3 inflammasome as a critical pathogenic effector of stroke-induced BBB disruption by activating inflammatory signaling cascades and pyroptosis in brain EC.},
  language  = {en}
}
@article{ChenBoettgerReifetal.2010,
  author    = {Chen, Yong and Boettger, Michael K. and Reif, Andreas and Schmitt, Angelika and Ueceyler, Nurcan and Sommer, Claudia},
  title     = {Nitric oxide synthase modulates CFA-induced thermal hyperalgesia through cytokine regulation in mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68349},
  year      = {2010},
  abstract  = {Background: Although it has been largely demonstrated that nitric oxide synthase (NOS), a key enzyme for nitric oxide (NO) production, modulates inflammatory pain, the molecular mechanisms underlying these effects remain to be clarified. Here we asked whether cytokines, which have well-described roles in inflammatory pain, are downstream targets of NO in inflammatory pain and which of the isoforms of NOS are involved in this process. Results: Intraperitoneal (i.p.) pretreatment with 7-nitroindazole sodium salt (7-NINA, a selective neuronal NOS inhibitor), aminoguanidine hydrochloride (AG, a selective inducible NOS inhibitor), L-N(G)-nitroarginine methyl ester (L-NAME, a non-selective NOS inhibitor), but not L-N(5)-(1-iminoethyl)-ornithine (L-NIO, a selective endothelial NOS inhibitor), significantly attenuated thermal hyperalgesia induced by intraplantar (i.pl.) injection of complete Freund's adjuvant (CFA). Real-time reverse transcription-polymerase chain reaction (RT-PCR) revealed a significant increase of nNOS, iNOS, and eNOS gene expression, as well as tumor necrosis factor-alpha (TNF), interleukin-1 beta (IL-1b), and interleukin-10 (IL-10) gene expression in plantar skin, following CFA. Pretreatment with the NOS inhibitors prevented the CFA-induced increase of the pro-inflammatory cytokines TNF and IL-1b. The increase of the antiinflammatory cytokine IL-10 was augmented in mice pretreated with 7-NINA or L-NAME, but reduced in mice receiving AG or L-NIO. NNOS-, iNOS- or eNOS-knockout (KO) mice had lower gene expression of TNF, IL-1b, and IL-10 following CFA, overall corroborating the inhibitor data. Conclusion: These findings lead us to propose that inhibition of NOS modulates inflammatory thermal hyperalgesia by regulating cytokine expression.},
  subject      = {Medizin},
  language  = {en}
}
@phdthesis{Nuth2017,
  author    = {Nuth, Linda},
  title     = {Niederfrequente, Tiefe Hirnstimulation bei Parkinson-Patienten mit ON-Freezing. Identifikation von Respondern anhand kinematischer Gangparameter},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-150317},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {Das ON-Freezing ist ein seltenes, aber generell extrem schwer zu therapierendes Ph{\"a}nomen. Es betrifft Parkinson-Patienten mit und ohne THS. Die derzeitige Literaturlage spiegelt wider, dass es unterschiedliche Strategien gibt, diesem Ph{\"a}nomen zu begegnen. Ein allgemeing{\"u}ltiges Therapiekonzept existiert dabei nicht. F{\"u}r einige Patienten mit STN-THS konnte durch eine Reduktion der Stimulationsfrequenz eine Besserung der Gangst{\"o}rung erzielt werden. Andere profitierten vom Einsatz sogenannter Interleaving-Protokolle mit gleichzeitiger Stimulation der Substantia nigra (Sn). Im Vergleich zu anderen Arbeiten, die keine vorhersagbaren Parameter gefunden oder sich auf Symptome, Auspr{\"a}gung der Subtypen und Erkrankungsdauer oder den Zeitpunkt der Erkrankung konzentriert haben, verfolgten wir die Absicht, die Effekte der LF-Stim des STN auf Parkinson-Patienten mit Gangst{\"o}rung und Freezing-Ph{\"a}nomen zu untersuchen und herauszufinden, ob man Gangparameter identifizieren kann, an Hand derer man das Ansprechen auf eine LF-Stim vorhersagen kann. Unter der Einschr{\"a}nkung, dass die Zahl der Probanden unserer Studie sehr gering ist, haben wir herausgefunden, dass diejenigen Patienten besser auf eine LF-Stim ansprechen, die unter der Standard-HF-Stim eine signifikant h{\"o}here Ganggeschwindigkeit und eine gr{\"o}ßere Schrittl{\"a}nge aufzeigen und nur ein intermittierendes Freezing haben. Dar{\"u}ber hinaus zeigte sich ein besseres Ansprechen der LF-Stim bei Parkinson-Patienten mit akinetisch-rigidem Parkinson-Ph{\"a}notyp. Unsere Ergebnisse best{\"a}tigen die Annahme, dass sich L-Dopa additiv zur Stimulationstherapie bei manchen Parkinson-Patienten zus{\"a}tzlich positiv auf die motorischen PD-Symptome auswirken kann. In Bezug auf die Verbesserung der Gangparameter zeigte sich in unseren Ergebnissen allerdings, dass L-Dopa eher eine untergeordnete Rolle spielt. Aufgrund der niedrigen Anzahl von Respondern in unserer Studie l{\"a}sst sich daher sicherlich noch keine allgemeing{\"u}ltige Regel ableiten. Es bedarf letztlich weiterer Studien mit gr{\"o}ßeren Untersuchungszahlen, um unsere Thesen zu st{\"u}tzen und abzusichern. In jedem Fall wird aber das ON-Freezing auch weiterhin eine therapeutische Herausforderung bleiben.},
  subject      = {Parkinson},
  language  = {de}
}
@article{IsaiasSpiegelBrumbergetal.2014,
  author    = {Isaias, Ioannis Ugo and Spiegel, J{\"o}rg and Brumberg, Joachim and Cosgrove, Kelly P. and Marotta, Giorgio and Oishi, Naoya and Higuchi, Takahiro and K{\"u}sters, Sebastian and Schiller, Markus and Dillmann, Ulrich and van Dyck, Christopher H. and Buck, Andreas and Herrmann, Ken and Schloegl, Susanne and Volkmann, Jens and Lassmann, Michael and Fassbender, Klaus and Lorenz, Reinhard and Samnick, Samuel},
  title     = {Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease},
  series = {Frontiers in Aging Neuroscience},
  volume    = {6},
  journal   = {Frontiers in Aging Neuroscience},
  doi       = {10.3389/fnagi.2014.00213},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-119351},
  pages     = {213},
  year      = {2014},
  abstract  = {We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson's disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease.},
  language  = {en}
}
@phdthesis{Purrer2020,
  author    = {Purrer, Veronika},
  title     = {Nicht-motorische Begleitsymptome bei Patienten mit Essentiellen Tremor},
  doi       = {10.25972/OPUS-19366},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-193665},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Der essentielle Tremor (ET) ist eine der h{\"a}ufigsten Bewegungsst{\"o}rungen, welcher lange Zeit als rein motorische St{\"o}rung angesehen wurde. Aufgrund zunehmender Belege {\"u}ber nicht-motorisch Begleitsymptome wandelte sich dieses Bild jedoch in den letzten Jahren zunehmend. In der vorliegenden Arbeit untersuchten wir 113 Probanden aus der Allgemeinbev{\"o}lkerung mit klinisch definitiven oder wahrscheinlichen ET anhand einer breiten Batterie neuro-psychologischer Testverfahren. Es gelang hierbei signifikante Unterschiede im Vergleich zu gesunden Eichstichproben im Hinblick auf neuro-psychologische Charakteristika, wie Apathie, {\"A}ngstlichkeit und exekutive Dysfunktion, sowie deren negativen Einfluss auf die Lebensqualit{\"a}t der Probanden darzustellen. Bisher werden im klinischen Alltag nicht-motorische Begleitph{\"a}nomene beim ET nicht regelhaft erfasst; aufgrund unserer Ergebnisse und der Relevanz vor allem im Hinblick auf die Lebensqualit{\"a}t des Einzelnen halten wir jedoch die Erfassung und gegebenenfalls Behandlung dieser Symptome f{\"u}r ebenso relevant.},
  subject      = {Essentieller Tremor},
  language  = {de}
}